feel better live longer grow deliver simplify annual report find gsk online wwwgskcom website glaxosmithklines website wwwgskcom gives additional information group information made available website constitute part annual report notice regarding limitations director liability english law uk companies act safe harbour limits liability directors respect statements omissions report directors contained pages english law directors would liable company third party report directors contains errors result recklessness knowing misstatement dishonest concealment material fact would otherwise liable report directors pages inclusive consist report directors drawn presented accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions provided law cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events shareholder identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual reportgsk annual report grow contents diversified global business chairman ceo summary strategy deliver products value report directors business review corporate governance remuneration report simplify financial statements operating model directors statement responsibilities independent auditors report consolidated income statement consolidated balance sheet consolidated cash flow statement consolidated statement recognised income expense notes financial statements financial statements glaxosmithkline plc set three new strategic shareholder information financial record priorities aim improve longterm product development pipeline financial performance shareholder information taxation information shareholders glossary terms believe priorities enable us index navigate coming years successfully retain leadingedge company able meet patients payers needs future find priorities following pages gsk annual report mission challenging inspiring mission improve quality human life enabling people feel better live longer focusing business around strategic priorities confident fulfil promise sir christopher gent andrew witty chairman chief executive officergsk annual report chairman ceo summary marked turning point gsk pivotal strategic priorities period change redefine business model increase established three strategic priorities grow sales growth reduce risk deliver longterm sustainable financial diversified global business deliver products value performance shareholders simplify operating model financial performance priorities designed radically transform business pleased response business always reducing relative dependence small molecule pharmaceuticals knew would challenging months due adverse impact developed western markets expect see increase significant us patent expiries decline avandia sales relative importance emerging markets japanese anticipated factors led decline earnings per share businesses increasingly greater contribution business eps year compounded unexpected legal vaccines consumer products also anticipate charge fourth quarter growing capability deliver products value rd deliver benefits patients also total sales year billion constant readily meet payers needs therefore enable us achieve exchange rate cer terms eps excluding major restructuring rapid reimbursed product approvals expanded restructuring p decrease cer terms cash programme expected deliver annual savings generation remains strong net cash inflow operating billion vital catalyst change activities billion sterling terms priorities progress made implement board declared dividend year p p explained following pages find year completed share repurchases billion information including regular updates progress expect make significant repurchases move visiting website wwwgskcom financial strategy remains maintain efficient balance sheet using cash resources invest strategic priorities increase changes board returns shareholders progressive dividend policy sir ian prosser dr ronaldo schmitz retire board annual general meeting thank performance core pharmaceuticals business dedicated service boards gsk heritage companies increasing diversification sales base important indicators valuable contributions made business gsks progress pharmaceutical turnover declined cer terms reflecting adverse impact generic competition may welcome james murdoch board non patented products lower avandia pandemic product sales executive director chairman chief executive news excluding genericised products avandia pandemic products corporation europe asia james brings great experience significant sales volatility remaining pharmaceuticals expertise boardroom particularly evident business delivered billion sales grew cer role member gsks corporate responsibility committee terms within vaccines sales rose billion outlook sales emerging markets grew billion sales asia enter confidence expect make good pacific japan totalled billion moving phase progress implementing strategic priorities enable converting extensive pipeline japan approved medicines us meet longterm objective reducing risk delivering sustainable growth shareholders continued good work previous year launched pharmaceutical products including vaccines finally would especially like recognise enormous also starting see good traction new pharmaceutical contribution employees wide network partners products launched last two years contributed sales willingness energy enthusiasm change strong almost billion year foundations build new business model improved productivity disciplined allocation capital key elements rd strategy currently around assets latestage pipeline level aim sustain augmentation pipeline past years accomplished without substantial increases total rd expenditure sir christopher gent andrew witty sales consumer healthcare billion chairman chief executive officer making good progress strategy investment innovation acquisitions marketing excellence area business find visit us constant exchange rates cer explained wwwgskcom gsk annual report strategy pharmaceutical industry experiencing time unprecedented corporate responsibility challenge patent expiries regulatory issues increased pressures running business responsible way fundamental healthcare providers combined create environment success inseparable strategic priorities sector associated lower growth higher risk operate way reflects values seeks understand addressing challenges three key strategic respond stakeholder views connects business decisions priorities believe transform gsk company ethical social environmental concerns way aim delivers growth less risk improved financial performance minimise negative impacts maximise positive benefits business key challenges patents many medicines driven sales growth responsibility vital parts business understand industry last decade coming end medicines need open operating also understand may replaced products equivalent financial size transparency key factor building trust stakeholders implemented number initiatives improve addition increasing pressures pharmaceutical transparency activities companies deliver products demonstrable benefits current treatments longer merely discover comprehensive information approach responsibility develop products help people feel better live issues found annual corporate responsibility report longer justify products represent wwwgskcomresponsibility greatest value healthcare providers time pharmaceutical sector exposed controversy regarding ethical patient safety issues industry danger eroding trust already actually need building stronger relationships governments regulators general public factors combined move industry one expected deliver high growth low risk opposite three strategic priorities established following three strategic priorities grow diversified global business deliver products value simplify operating model believe priorities enable us navigate coming years successfully retain leadingedge company able meet patients healthcare providers needs future updates progress published website wwwgskcom also feature regular financial resultsgsk annual report grow diversified global business reducing risk broadening balancing portfolio diversifying new product areas show potential also fully capturing opportunities products across geographic boundaries plans underpin strategic priority drive growth pharmaceutical business core markets deliver ambitious vaccines forecast fulfil potential emerging markets expand business japan grow consumer healthcare business find go deliver products value striving build one strongest pipelines industry transforming rd ensure deliver current pipeline also able sustain flow new products years come plans underpin strategic priority focus best science diversify externalisation repersonalise rd focus return investment find go simplify operating model manufacturing pharma rd vaccines consumer healthcare gsk complex organisation recognise need simplify operating model changing way work removing unnecessary processes structures slow us distract us mission plans underpin strategic priority evolve commercial model reshape manufacturing streamline processes reduce working capital find go gsk annual report reducing risk broadening balancing portfolio diversifying new product areas show potential also fully capturing opportunities products across geographic boundaries specifically expect generate future sales growth strengthening core pharmaceuticals business supplementing increased investment growth areas vaccines biopharmaceuticals consumer healthcare also seeking unlock geographic potential businesses particularly emerging markets japan made good progress priority believe remain many opportunities gsk diversify grow diversified global business plans targeting sustained growth vaccines portfolio launching new vaccines working expand franchise drive growth pharmaceutical business japan emerging markets core markets established strengths small molecule pharmaceutical cervarix new cervical cancer vaccine sectors larger markets usa uk france germany successful approximately tenders achieving several italy spain remain central business notable successes including europes largest vaccination programme received european approval tyverb advanced breast cancer cervical cancer taking place uk year also volibris treatment pulmonary arterial hypertension saw rotarix boostrix adult indication kinrix receive approval avamys new allergic rhinitis treatment us approval fda promacta treatment thrombocytopenia entereg postoperative ileus us pharmaceuticals business fulfil potential emerging markets initiated major change programme refocusing marketing emerging markets feature lessdefined distinction demonstrate value introducing new product offerings pharmaceutical overthecounter retail market structure focus volume opportunities ability operate across spectrum clear competitive advantage opportunity improve capability deliver ambitious vaccines forecast energise business fastgrowing emerging markets increasingly healthcare providers recognise important role vaccines play preventative healthcare proven capability strong pipeline plus high barriers entry faced competitors mean expected source future growth gskgsk annual report entered alliance aspen holdings grow consumer healthcare business south africa new relationship gives us priority access consumer healthcare business continues commercialised products portfolio drive growth portfolio powerful potential products brands three key segments overthecounter otc medicines oral healthcare nutritional healthcare year ended acquired bms portfolio egypt reached agreement acquire bms portfolio pakistan brand portfolio includes alli weight loss panadol early also agreed ucb acquire current range analgesics sensodyne toothpaste lucozade marketed product portfolio range territories supported strategy focused innovation marketing excellence geographic expansion acquisitions expand business japan japan key market gsk investment growth september launched sensodyne chinese extensive product pipeline expect launch market first major consumer launch country decade products market next five years preparing launch alli first otc weight loss product approved european commission across europe major approvals market recently lamictal epilepsy adoair copd find visit us wwwgskcom gsk annual report striving build one strongest pipelines diversify externalisation industry transforming rd ensure recognise monopoly best science deliver current pipeline new pharmaceuticals therefore proactively expanded collaborations vaccines consumer healthcare products also external partners well academia access innovation able sustain flow new products years come strengthen early pipeline move towards diversified business recent alliances organisations cellzome concentrate developing higher volume midsize harvard stem cell institute acquisitions sirtris products clearlydefined patient populations genelabs providing us competitive advantage important help develop lower risk portfolio areas research dependent performance one two large products last year completed expanded new drug discovery positive steps already taken latestage alliances adding significant breadth scale rd activities assets currently pharmaceuticals vaccines pipeline currently discovery units working either inside objective sustain throughput products company externally longterm biopharmaceuticals play increasingly important role future portfolio offering worldwide market approximately plans billion projected compound annual growth next five years biopharmaceuticals compounds capable focus best science manufactured living organisms usually cultured cells around assets pipeline entirely new compounds vaccines demonstrating strong drive currently pipeline comprises biopharmaceuticals towards innovation industry average significantly expanded biopharmaceutical pipeline inhouse discovery year rebalanced drug discovery organisation acquisition domantis inlicensing latestage products improve efficiency focus areas new science currently clinical research programmes underway believe likely lead new medicines together including five assets latestage development vaccines gsks rd focused eight therapy areas biopharmaceuticals immunoinflammation infectious diseases metabolic pathways neuroscience oncology ophthalmology respiratory deliver products valuegsk annual report repersonalise rd focus return investment want create environment impediment adopted disciplined approach best scientists making kind discoveries allocate resources within rd discovery projects transform companys future delivering value patients terminated following therapy area rebalancing exercise healthcare providers shareholders reviews new drug discovery investment board saw creation discovery performance units dpus within part process discovery performance units centres excellence drug discovery cedds dpu three year funding place develop projects compact fullyempowered focused integrated team responsibility small part pipeline realise reimbursement key longterm financial performance working hard bring health outcome also created new integrated rd units focus rd turn deliver greater value healthcare biopharmaceuticals oncology rd centre established providers example europe direct dialogue exists china people strong recruited payer organisations rd teams improve experienced scientists dedicated solely gsks understanding perceived benefit value new products neurodegenerative research find visit us wwwgskcom v ti c u r p p e p l e c udorp gsk annual report gsk complex organisation recognise need simplify operating model changing way work removing unnecessary processes structures manufacturing slow us distract us mission global restructuring programme vital catalyst strategy believe radically change business model giving us capability support diverse rd pharma growing business also expected profitable longterm vaccines consumer healthcare simplify operating model plans continue improve efficiency sites applying benchmarked studies seizing opportunities less evolve commercial model addition simplifying operating model clarify roles reorganised one single commercial responsibilities improve prioritisation decision making support structure europe emerging markets asia introduce simpler efficient ways working pacificjapan usa radically restructured pharmaceuticals business includes transformation us streamline processes sales force well decision designate single headquarters simplifying organisation speed decisionmaking us pharmaceuticals located research triangle park north improve alignment business priorities carolina reduce complexity streamline us operations many different programmes initiatives across gsk including comprehensive programme simplify reduce costs reshape manufacturing innovative partnership microsoft online manufacturing key capability gsk taking produce financial savings improve productivity enhance ambitious approach reshaping operations moving collaboration internally external partners match network capacity closely volume leveraging network sites contractors ensure flexibility sustain growth adapt changing business modelsgsk annual report manufacturing rd pharma vaccines consumer healthcare simplify operating model striving ensure crossbusiness processes structures simpler efficient example number reviews currently underway simplify support functions infrastructure create leaner corporate centre reduce working capital current working capital requirement around billion september started programme successfully delivered cash flow benefits million using invest strategic priorities find visit us wwwgskcom gsk annual report report directors financial trends ratios growth growth total results cer cer turnover cost sales selling general administration research development operating income operating profit profit taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p results major restructuring turnover cost sales selling general administration research development operating income operating profit profit taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p research development total pharmaceuticals consumer healthcare total net finance cost cover total net finance costs cover times times net finance cost cover profit tax plus net finance costs divided net finance costs tax rate total tax rate major restructuring borrowings net debt gearing gearing ratio calculated net debt percentage total equity c er represents growth constant exchange rates sterling represents growth actual exchange rates see calculation results major restructuring described note financial statements presentation financial statementsgsk annual report report directors report directors report directors provides users financial directors remuneration statements complete picture gsk supplements sets remuneration policies operated information financial statements discussion directors corporate executive team cet members aspects activities future environment disclosures directors remuneration including operate required directors remuneration report regulations regulations sections cover report divided number sections letter chairman remuneration committee business review remuneration policy discusses financial nonfinancial activities executive director terms conditions remuneration resources development performance nonexecutive director terms conditions fees outlines factors including trends principal risks directors senior management remuneration uncertainties likely affect future development annual remuneration sub divided nonexecutive directors remuneration financial trends ratios directors interests performance overview share options products intellectual property competition incentive plans global manufacturing supply pensions research development directors senior management employees directors interests contracts responsibility accounting presentation regulation report prepared accordance international financial economy world market outlook reporting standards ifrs adopted european union financial review also ifrs issued international accounting financial position resources standards board risk factors financial review data market share market growth rates gsk estimates based corporate governance recent data independent external sources appropriate valued sterling relevant exchange rates figures discusses management structures governance quoted product market share reflect sales gsk licensees procedures includes disclosures compliance combined code corporate governance financial reporting council exchange rates combined code us laws regulation group operates many countries earns revenues biographies board incurs costs many currencies results group biographies corporate executive team reported sterling affected movements exchange rates governance policy sterling currencies average exchange rates dialogue shareholders prevailing period used translate results share capital control cash flows overseas subsidiaries associates joint ventures donations eu political organisations eu sterling period end rates used translate net assets political expenditure entities annual general meeting currencies internal control framework currencies influence groups results remain committee reports us dollar euro yen pound combined code us law regulation pound weakened dollar yearend addition pound weakened euro yen new record low set december gsk annual report report directors performance overview key performance indicators strategies turnover bn cer growth set three new strategic priorities full details given pages grow diversified global business broadening balancing portfolio diversifying new product areas also fully capturing opportunities products earnings per share major restructuring across geographic boundaries pence cer growth total shareholder return deliver products value transforming rd ensure deliver current pipeline also able sustain flow products years come glaxosmithkline total return index glaxosmithkline pharma peers return index ftse total return index free cash flow simplify operating model simplifying operating model ensure fit purpose able support business efficient effective way calculation results major restructuring described note financial statements presentation financial statements free cash flow described gsk annual report report directors measures progress developing number measures track made good progress year progress strategic priorities number notable successes medium long term include following performance core pharmaceuticals business excluding genericised products avandia prepandemic including growth vaccines preparations core pharmaceuticals business turnover billion grew growth consumer healthcare market share consumer healthcare sales grew nearly billion continued market share growth oral healthcare nutritional healthcare sales fell otc due lower sales smoking cessation products contribution emerging markets overall sales emerging markets grew billion sales growth transactions aspen bms executed build broader geographically diverse portfolio expansion japanese business major recent approvals japan lamictal epilepsy adoair copd around new product opportunities development sales japan fell result price cuts mandated government contribution sales new products new product launches last two years contributed sales almost billion number reimbursable product approvals filings key product launches including tyverb volibris avamys europe treximet entereg promacta kinrix rotarix usa secured fda approvals new chemical entities vaccines sustaining latestage pipeline around assets late stage pipeline maintained around assets five new assets moved phase iii development including darapladib atherosclerosis syncria type diabetes enhanced productivity increased externalisation created discovery performance units small teams drug discovery threeyear funding place entered expanded new drug discovery alliances delivery major restructuring programme annual cost savings million already achieved programme expanded deliver annual savings billion evolution commercial model rescaled redeployed us pharmaceuticals sales force sales forces expanded emerging markets reshaping global manufacturing supply manufacturing network rationalisation continuing multiple site exits ongoing reduction working capital delivered million cash flow benefits working capital reduction programme started september gsk annual report report directors history development company business segments glaxosmithkline plc public limited company incorporated gsk operates two industry segments th december english law shares listed pharmaceuticals prescription pharmaceuticals vaccines london stock exchange new york stock exchange consumer healthcare otc medicines oral healthcare th december company acquired glaxo wellcome plc nutritional healthcare smithkline beecham plc english public limited companies way scheme arrange ment merger two results major restructuring companies gsk subsidiary associated undertakings october board approved implementation constitute major global healthcare group engaged creation detailed formal plan gsk announced significant new discovery development manufacture marketing pharma operational excellence restructuring programme second formal ceutical consumer healthrelated products plan representing significant expansion operational gsk corporate head office london us excellence programme approved board announced headquarters research triangle park operations february estimated total cost approximately countries products sold countries billion expanded programme expected deliver annual pretax savings approximately billion time substantially annual report summary complete gsk presents restructuring costs incurred report annual report glaxosmithkline plc solely direct result operational excellence programme year ended st december prepared accordance separate column income statement titled major restructuring united kingdom requirements approved board addition restructuring costs operational excellence directors rd march published th march programme major restructuring column income statement summary year intended shareholder needing includes restructuring costs incurred solely direct result full detail annual report produced separate restructuring programmes follow relate material document issued shareholders summary acquisitions operations acquired business overlap constitute set summary financial statements defined extensively gsks existing operations billion section companies act annual report million acquisition reliant pharmaceuticals december issued shareholders elected receive acquisition since october meets criteria documents available gsks website groups results costs operational excellence report glaxosmithkline group gsk means programme acquisitionrelated restructuring programmes glaxosmithkline plc subsidiary undertakings company meeting criteria described described results means glaxo smithkline plc glaxosmithkline share means major restructuring presentation gsk intends ordinary share glaxosmithkline plc p american depositary apply consistently future major restructuring programmes shares ads represents two glaxosmithkline shares material impact gsks operating results manner gsks business conducted brand names adopted show clearly groups results brand names appearing italics throughout report trademarks costs restructuring programmes management either owned andor licensed glaxosmithkline associated believes presentation assists shareholders gaining companies exception baycol levitra trademarks clearer understanding groups financial performance bayer bonivabonviva trademark roche citrucel trademark making projections future financial performance results merrell pharmaceuticals entereg trademark adolor include costs virtue size nature limited corporation usa volibris trademark gilead nicoderm comparative value presentation also consistent trademark sanofiaventis pfizer canada elan novartis merrell way management assesses groups financial performance glaxosmithkline vesicare trademark astellas pharmaceuticals cer growth many countries yamanouchi pharmaceuticals certain order illustrate underlying performance groups countries used certain countries licence practice discuss results terms constant exchange rate group cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates commentaries report presented terms cer unless otherwise statedgsk annual report report directors products intellectual property competition pharmaceutical products within pharmaceutical industry introduction new products processes competitors may affect pricing gsks principal pharmaceutical products currently directed eight result changing patterns product use assurance main therapeutic areas description products pages products become outmoded notwithstanding patent analysis sales therapeutic area trademark protection addition increased government competition pressures physicians patients use generic pharmaceuticals rather brandname medicines may increase principal pharmaceutical competitors range small competition products longer protected patent large pharmaceutical companies often substantial resources companies intellectual property abbott laboratories intellectual property key business asset company amgen effective legal protection intellectual property via astrazeneca patents trademarks registered designs copyrights domain name registrations critical ensuring reasonable return bristolmyers squibb investment rd eli lilly patents johnson johnson merck policy try obtain patents commercially important protectable inventions discovered developed rd novartis activities patent protection new active ingredients available pfizer major markets patents also obtained new drug roche holdings formulations manufacturing processes medical uses devices sanofiaventis administering products although may obtain patents products prevent challenged scheringplough expire grant patent provide wyeth assurance issued patent held valid enforceable pharmaceuticals may subject competition court significant litigation concerning challenges products period patent protection summarised note financial statements legal patent generic versions manufacturers proceedings court determines patent hold invalid generic products typically bear significant research non infringed unenforceable protect market development education marketing development costs third party entry prior patent expiry consequently able offer products considerably life patent countries years filing date lower prices branded competitors research patents protecting new active ingredients generally applied development based company normally seek achieve early development process long development time sufficiently high profit margin sales volume period pharmaceutical products may result substantial amount patent protection repay original investment patent life used launch markets including generally substantial generate profits fund research usa europe possible lost time future competition generic products generally occurs restored leads variations amount patent life patents major markets expire increasingly patent challenges actually available product market certain made prior patent expiry claiming innovator patent countries provide period data market exclusivity prevents valid andor infringed generic product third party company relying clinical trial data enter details challenges products see legal market copy period exclusivity proceedings pages following loss patent protection generic products rapidly capture large share patent expiry dates significant products market particularly usa following table dates provided expiry patents usa major european markets active ingredient unless believe remaining competitive dependent upon otherwise indicated include extensions patent term including discovery development new products together paediatric use usa available effective marketing existing products gsk annual report report directors products intellectual property competition continued product compounds indication major patent expiry dates competitor brands usa eu respiratory seretideadvair salmeterol xinafoate asthmacopd singulair symbicort fluticasone propionate spiriva asmanex pulmicort combination combination flixotideflovent fluticasone propionate asthmacopd qvar singulair expired expired serevent salmeterol xinafoate asthmacopd foradil spiriva expired expired veramyst fluticasone furoate rhinitis nasacort flixonaseflonase fluticasone propionate rhinitis nasonex rhinocort expired expired antivirals epzicomkivexa lamivudine abacavir hivaids truvada atripla combination combination combivir lamivudine zidovudine hivaids truvada atripla combination combination trizivir lamivudine zidovudine hivaids truvada atripla abacavir combination combination agenerase amprenavir hivaids prezista kaletra reyataz lexiva fosamprenavir hivaids prezista kaletra reyataz epivir lamivudine hivaids truvada atripla ziagen abacavir hivaids truvada atripla valtrex valaciclovir genital herpes coldsores famvir shingles zeffix lamivudine chronic hepatitis b hepsera relenza zanamivir influenza tamiflu central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired seroxatpaxil paroxetine depression various effexor cymbalta expired expired anxiety disorders lexapro wellbutrin sr bupropion depression effexor cymbalta expired lexapro requip ropinirole parkinsons disease mirapex expired restless legs syndrome use treating parkinsons disease treximet sumatriptan naproxen migraine zomig maxalt relpax na combination use cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride lovaza formulation omega acid high triglycerides tricor ethyl esters formulation coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular dysfunction post mi fraxiparine nadroparin deep vein thrombosis lovenox expired expired pulmonary embolism arixtra fondaparinux deep vein thrombosis lovenox fragmin expired expired pulmonary embolism innohep vesicare solifenacin overactive bladder detrol detrol la enablex na sanctura generic competition possible result patent settlement uk patent revoked uk courtsgsk annual report report directors products intellectual property competition continued product compounds indication major patent expiry dates competitor brands usa eu metabolic avandia rosiglitazone maleate type diabetes actos januvia avandamet rosiglitazone maleate type diabetes competact janumet metformin hci actoplus met bonvivaboniva ibandronate osteoporosis actonel fosamax antibacterials augmentin amoxicillinclavulanate common infections expired expired potassium altabax retapamulin skin infections oncology emesis hycamtin topotecan ovarian cancer small cell doxil gemzar lung cancer zofran ondansetron nausea vomiting kytril emend aloxi expired expired cancer tykerb lapatanib advanced metastatic herceptin breast cancer positive patients vaccines infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentavac pentaxim polio hepatitis b hepb polio hepatitis b hepb pediacel pentacel inactivated antigens fluarix split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone none none subtypes type b antigens influvac aggripal fluad flulaval split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone none none subtypes type b antigens influvac aggripal fluad cervarix hpv virus like particles human papilloma virus gardasil silgard vlps adjuvant mpl type aluminium hydroxide rotarix live attenuated rotavirus rotavirus gastroenteritis rotateq strain gip trademarks gsks commercial products protected registered trademarks major markets may local variations example usa trademark advair covers product sold eu seretide trademark protection may generally extended long trademark used renewing necessary gsks trademarks important maintaining brand identity products gsk enforces trademark rights prevent infringements consumer healthcare products portfolio comprises three main categories otc medicines oral healthcare nutritional healthcare sales key consumer healthcare products shown leading consumer healthcare products include following otc medicines alli first licenced weight loss medicine available without prescription launched usa approval launch across europe panadol global paracetamolacetaminophen analgesic smoking control products nicoderm niquitin cq nicabate usa nicorette brands include breathe right nasal strips tums citrucel contac fiberchoice gsk annual report report directors products intellectual property competition continued oral healthcare global manufacturing supply gms aquafresh range toothpastes toothbrushes people work gms across network mouthwashes sites countries gms supports commercial ambition sensodyne range toothpastes toothbrushes including gsk delivering quality medicines consumer products pronamel protect acid erosion patients customers around world biotene acquired late leading treatment scale manufacturing gsk staggering dry mouth manufacture billion packs per year different presentations including tablets creamsointments inhalers polident poligrip corega denture care cleansers injections liquids steriles supplied adhesives markets billion spent production year brands include odol macleans dr best gms operates procurement operation behalf group nutritional healthcare spend billion annually external suppliers purchasing active ingredients chemical intermediates packaging lucozade range energy sports drinks components partfinished finished products horlicks range milkbased malted food chocolate drinks commercial customers sought every ribena blackcurrant juicebased drink opportunity grow business focused cost competitive supply quality product meet ambition consumer healthcare competition began adapting emerging commercial model leveraging gsk holds leading global positions key consumer product network sites contractors give us builtin flexibility areas worldwide third largest oral healthcare sustain future growth adapt emerging commercial otc medicines nutritional healthcare holds leading business models increasingly rigorous external regulatory position uk india ireland environment continued leverage technology environment consumer healthcare business support process understanding control capability operates become ever challenging primary supply sites supply high quality competitively priced consumers demanding better quality better value bulk actives focus improvements primary technologies improved performance processes new product global supply sites work closely rds development teams ensure right technical retailers consolidated globalised competencies place support rapid successful new product strengthened negotiation power introduction sites serve focal point developing cycle times innovation reduced introducing new secondary manufacturing technologies sites regional pharma supply division focus reducing costs allowing gsk main competitors include major international companies compete effectively markets consumer healthcare colgatepalmolive johnson johnson procter gamble unilever sites deliver highquality competitively priced products support wyeth addition many smaller companies rapid new product introduction highly innovative competitive compete gsk certain markets business new technologies become fundamental platform major competitor products otc medicines driving innovation lowering costs providing flexibility operations usa metamucil laxative pepcid indigestion private embedding new ways working simplifying label smoking control products business achieving greater efficiencies focus customer service including support new product launches uk lemsip cold remedy nurofen anadin strong compliance culture commitment health safety analgesics nicorette nicotinell smoking control environment commitment developing people treatments delivered strong results gsk even external oral healthcare major competitors colgatepalmolives environment become demanding colgate procter gambles crest vaccine manufacturing particularly complex requires use nutritional healthcare major competitors horlicks innovative technologies living microorganisms sophisticated ovaltine milo malted food chocolate drinks quality assurance quality control procedures place competitors ribena primarily local fruit juice products ensure vaccines quality safety includes animal use lucozade competes energy drinks according health authorities requirements due biological nature individual health authorities may subject vaccines second control guarantee highest quality standardsgsk annual report report directors research development research development pharmaceuticals continue identify compounds companies would enhance portfolio create innovative gsk rd striving build one strongest pipelines collaborations ensure seen partner choice potential new medicines industry pharmaceutical large small companies internal rd expertise allows rd actively managing projects human clinical us strong position business development makes trials across globe delivering pipeline patients safely us able complement internal pipeline acquisitions efficiently number one goal inlicensing comarketingcopromotion deals future discovering potential medicines options collaborations late stage early research identifies biological targets interfering project team mdc development particular disease creates small molecules biopharmaceuticals interact disease targets drug discovery dd formed centres excellence drug discovery cedds groups focused around defined therapy areas therapy area review exercise conducted early helped rd refocus discovery effort around well identified promising areas science likely deliver products rd unit value rd invested growth areas ophthalmology ceased less promising areas science urology focus drug discovery gsk summarised table f ollowing therapy area review major transformation drug discovery conducted company create even nimble creative entrepreneurial environment building discovery cedd drug success existing cedd model cedd created performance discovery discovery performance units dpu gathering small integrated unit empowered groups scientists size ranging people delivering medicines patients focusing particular disease pathway taking cedd model one step number dpus cedd varies according progression latestage development consists optimising science standalone dpus created explore physical product properties medicine new therapy areas ophthalmology new ways working chemical steps formulation required manufacture deliver well much larger scale studies humans cedds standalone dpus submits year business confirming efficacy safety combination results plan overall budget clearly defined objectives cedds two steps regulatory file submission regulatory accountable production quality proofs concept agencies approval patient use responsibility tackling challenge internal discovery well regulatory team extensive collaborations academia biotech companies medicines development collection four therapeutically centres excellence drug discovery cedd aligned medicine development centres mdcs cardiovascular metabolic cvm infectious diseases id neurosciences include several discovery performance units dpu respiratory mdc ultimate accountability immunoinflammation developing experimental drugs regulatoryapproved infectious diseases medicines patients mdcs responsible creating metabolic pathways value execution full product development plans neurosciences ensuring strong partnerships rest rd gsk respiratory particular cedds preclinical development regulatory centre excellence external drug discovery ceedd commercial groups manufacturing additional standalone discovery performance units dpu emphasis put creation strongly macrolides empowered project teams creation medicine opthiris focusing ophthalmology development leader roles key late stage assets virtual poc centre clinical study excellence also created sirtris professional organisation providing study operations capabilities academic dpu partnership mdcs cedds delivers gsk clinical trials gsk annual report report directors research development continued major opportunity oncology creation rd employees oncology rd unit rd employs staff wide variety educational backgrounds created integrated oncology unit spanning biologists chemists clinical scientists physicians drug target identification late stage development prominent qualifications given number strong pipeline cancer medicines well unique aspects structural changes ensuring staff retention oncology medicines development behind creation top priority personal development programmes staff oncology rd unit oncology important investment area engagement strategies active talent management gsk seen late stage pipeline flourish diseases developing world future growth biopharmaceuticals creation continued investment research diseases developing biopharm rd unit world essential longterm improvement goal becoming leader biopharmaceuticals health people live regions part created biopharm rd unit biopharmaceuticals response challenge operate drug discovery unit based large molecules antibodies proteins peptides tres cantos spain focuses malaria tuberculosis manufactured using living cells different additional rd sites usa uk focused small molecules made chemical synthesis development new medicines treat hivaids drug rd process requires quite specific treatment discovery resistant bacteria vaccine research conducted development manufacturing perspective biopharm rd rixensart belgium unit brings functions together single cohesive rd efforts addressing prevention group discovery biopharmaceutical process development treatment three world health organizations late stage development forming part one organisation priority infectious diseases investment global rd growth rd china publicprivate partnerships ppps remain essential fund research line aim access best science ensure gsk commercially viable market potential truly global company announced creation product remain leader working ppps continue rd china group grew employees focusing collaborate closely many governments academic centres neurodegeneration created three dpus year united nations agencies global funding bodies rd china currently focusing discovery unit grows area maximise expertise knowledge pipeline matures expand capabilities fully integrated rd centre governance key projects reaching significant milestones reviewed month product management board pmb responsible determining medicine met criteria passing next phase development gsks chief medical officer working global safety board ultimately accountable oversight major decisions regarding patient safety global safety board responsible internally approving pivotal studies investigating issues related patient safety arising development programme information gsk clinical trials widely easily available clinical trial register gsks website oversight strategic issues organisation choices budget management across rd owned radex rd executive teamgsk annual report report directors research development continued vaccines rd animals research gsk active fields vaccine research development ethical regulatory scientific reasons research using production portfolio vaccines approved animals remains small vital part research development marketing scientists devoted new medicines vaccines use animals discovering innovative vaccines contribute health alternative numbers required test wellbeing people generations around world strive exceed regulatory standards care use discovery development new vaccine complex process animals used undertake internal external review assure requiring longterm investment vaccines standards clinical development one strongest vaccine vast majority experimental methods use animals pipelines industry although vaccines traditionally actively engaged research develop validate used ward illness gsks vaccine division developing tests either avoid use animals research reduce therapeutic immunotherapeutics aimed educating patients numbers needed animals used research unnecessary immune system identify attack cancer cells highly pain suffering scrupulously avoided specific manner decided initiate funding studies using great apes vaccine discovery involves many collaborations academia th october voluntary decision provides biotech industry identify new vaccine antigens tangible demonstration commitment rs expressed yeast bacteria mammalian cells animal research advocates replacement reduction purified high level followed formulation animals research refining experiments improve clinical lots vaccine may involve mixing antigens animal welfare selected gsk novel proprietary adjuvant systems combinations selected adjuvants designed elicit understand use animals research purposes appropriate immune response specific antigen right commands high level public interest public policy position combination antigen adjuvant system help body care ethical use animals research mobilise effective immunological pathway information reports available website designed provide maximum protection specific diseases research development targeted populations consumer healthcare formulated candidate vaccine evaluated safety continuous creation development innovative efficacy perspective different phases preclinical products keeps brands relevant vibrant valuable testing clinical trials involving healthy individuals portfolio spans three major categories overthecounter otc range safety analysis small group volunteers medicines oral healthcare nutritional healthcare phase dose adjustment proof concept phase ii major brands dedicated rd teams partner work largescale safety efficacy analysis phase iii results alongside commercial brand team colleagues officefree obtained clinical trials data regarding development hub environments foster collaboration fast decision quality largescale production process facilities making hubs quickly become preferred way working combined regulatory file submitted innovation centres weybridge uk parsippany usa authorities countries vaccine made available launch post marketing studies considerable size set assess vaccination programmes monitor vaccine safety gsk annual report report directors research development continued therapeutic area compound full diverse product development pipeline biopharmaceuticals belimumab systematic lupus erythematosus key late stage projects highlighted comprising otelixizumab type diabetes new chemical entities new combinations formulations syncria type diabetes existing assets advanced status shown includes ofatumumab follicular lymphoma approvals least one major market rheumatoid arthritis refractory chronic lymphocytic leukaemia key bosatria mepolizumab hypereosinophilic syndrome phase iii large comparative study compound versus placebo andor cardiovascular metabolic avandamet xr type diabetes extended release established treatment patients establish clinical benefit avandia simvastatin type diabetes safety darapladib atherosclerosis arixtra treatment acute coronary syndrome filed f following successful phase iii trials file product approval neurosciences almorexant insomnia regulatory authorities retigabine epilepsy partial seizures approval rosiglitazone xr alzheimers disease approval granted begin market lamictal xr epilepsy partial seizures oncedaily medicine vaccine lunivia insomnia solzira restless legs syndrome full pipeline pages website wwwgskcom oncology avodart reduction risk prostate cancer elesclomol metastatic melanoma pazopanib tyverbtykerb inflammatory breast cancer tyverbtykerb breast cancer adjuvant therapy breast cancer first line therapy gastric cancer head neck squamous cell carcinoma resectable disease pazopanib sarcoma renal cell cancer duodart avodart alpha blocker benign prostatic hyperplasia fixed dose combination zunrisarezonic chemotherapyinduced postoperative nausea vomiting revoladepromacta chronic liver disease induced thrombocytopaenia hepatitis c induced thrombocytopaenia idiopathic thrombocytopaenic purpura vaccines hibmencytt neisseria meningitis groups c disease haemophilus influenzae type b disease prophylaxis magea asci treatment nonsmall cell lung cancer treatment melanoma menacwytt neisseria meningitis groups c w disease prophylaxis new generation flu vaccine seasonal influenza prophylaxis elderly simplirix genital herpes prophylaxis synflorix streptococcus pneumoniae disease prophylaxis infants children cervarix human papilloma virus infection prophylaxis prepandrix flu prepandemic prepandemic influenza prophylaxis inlicence alliance relationship third party see note financial statements post balance sheet eventsgsk annual report report directors research development continued indication phase fila edpproved biopharmaceuticals belimumab systematic lupus erythematosus otelixizumab type diabetes syncria type diabetes ofatumumab follicular lymphoma rheumatoid arthritis refractory chronic lymphocytic leukaemia f bosatria mepolizumab hypereosinophilic syndrome f cardiovascular metabolic avandamet xr type diabetes extended release avandia simvastatin type diabetes darapladib atherosclerosis arixtra treatment acute coronary syndrome neurosciences almorexant insomnia retigabine epilepsy partial seizures rosiglitazone xr alzheimers disease lamictal xr epilepsy partial seizures oncedaily f lunivia insomnia f solzira restless legs syndrome f oncology avodart reduction risk prostate cancer elesclomol metastatic melanoma pazopanib tyverbtykerb inflammatory breast cancer tyverbtykerb breast cancer adjuvant therapy breast cancer first line therapy gastric cancer head neck squamous cell carcinoma resectable disease pazopanib sarcoma renal cell cancer f duodart avodart alpha blocker benign prostatic hyperplasia fixed dose combination f zunrisarezonic chemotherapyinduced postoperative nausea vomiting f revoladepromacta chronic liver disease induced thrombocytopaenia hepatitis c induced thrombocytopaenia idiopathic thrombocytopaenic purpura vaccines hibmencytt neisseria meningitis groups c disease haemophilus influenzae type b disease prophylaxis magea asci treatment nonsmall cell lung cancer treatment melanoma menacwytt neisseria meningitis groups c w disease prophylaxis new generation flu vaccine seasonal influenza prophylaxis elderly simplirix genital herpes prophylaxis synflorix streptococcus pneumoniae disease prophylaxis infants children f cervarix human papilloma virus infection prophylaxis prepandrix flu prepandemic prepandemic influenza prophylaxis gsk annual report report directors employees recruitment talent management face face communications activities town hall presentations leadership development led senior executives lunches cet senior executives every year recruiting retaining developing ensure communications activities effective employees critical enhancing sustaining enable us continue improve number performance reputation areas focus evaluation processes feedback monitoring mechanisms part every major communication event qa feedback recruiters proactively identify engage attract top external facilities core feature web communications channels talent assess potential fit organisation broader processes include global leadership survey takes places across functions businesses geographical every two three years survey asks managers areas assessment process aligned core set worldwide comment critical issues culture competencies ethics integrity central confidence gsks future streamlined annual performance development planning business evolves changes affect pdp process means employees businessaligned objectives employees remain committed consulting behavioural goals regular reviews progress changes via number internal consultation forums ongoing culminating endofyear review discussions european employee consultation forum annual talent management cycle identify similar bodies countries national practice highest performing people business followed tailored management leadership programmes key talent employee numbers region performance reward usa europe reward systems support high performance help attract emerging markets retain best people performancebased pay bonuses asia pacific share rewards share options align employee interests japan business targets canada communication employee involvement new fulltime employees join organisation diversity opportunity take part gsk experience interactive committed employment policies free discrimination induction programme offered many locations across uk existing potential employees grounds age usa programme modules also provided support race ethnic national origin gender sexual orientation faith local induction awareness seminars around world disability gsk committed offering people disabilities experience gives employees flavour communications access full range recruitment career opportunities engagement activities offer throughout gsk every effort made retain support employees become communication channels designed keep employees disabled working gsk details diversity informed engaged involved activities across areas measures see corporate responsibility report organisation encourage twoway open honest communication employees web technology healthy high performance used increasingly engage employees immediate able meet mission strategy employee health way new updated communication channels include performance initiatives focus health factors enable employees perform highest level sustaining myceo area gsk intranet allows employees energy engagement programmes developed engage directly ceo via discussion qa deliver health strategy range traditional ambassador community provides slides statements immunisations smoking control weight management films give employees company information keep cuttingedge programmes areas team personal uptodate issues affecting gsk resilience ergonomics energy performance pharmaceutical industry programmes available many languages designed address gsktv webbased library gsks video assets including root causes excessive work pressure low energy presentations strategy employee broadcasts engagement work home complimented commitment flexible working enables employees interactive multimedia events web broadcasts multisite best work environment helps integrate qa sessions give regular updates globally ceo business work personal lives details scope impact function leaders programmes see corporate responsibility reportgsk annual report report directors responsibility improving access medicines programmes countries also introduced orange cards providing discounts access healthcare developing world certain gsk prescription medicines eligible patients easy solutions challenge providing number countries nature discounts sustainable access healthcare developing countries poverty varies countries ways healthcare single biggest barrier many countries people systems operate enough food access clean water supply hospitals clinics receive treatment healthcare professionals care patient advocacy patient advocacy initiative demonstrated significant committed playing full part addressing progress since inception initially launched us healthcare challenges developing world taking programme critical initiative throughout gsk patient innovative responsible sustainable approach gsk advocacy teams usa europe share best practices making vital contribution developing country healthcare established processes optimise interaction patient groups action number areas including preferential typically relationships provide mutual opportunities pricing antiretrovirals antimalarials tiered pricing learn patient needs priorities patient groups vaccines investing rd targets diseases particularly develop understanding drug development challenges affecting developing world see community continued partner patient groups investment activities partnerships foster effective common issues advocating access medicines treatment healthcare see seeking innovative partnerships increasing funding health programs improving health solutions cover contribution improving access care delivery considered trustworthy partner medicines extensively corporate responsibility report patient groups worked patient groups clear leader first access medicines trade associations increase transparency index produced atm foundation continue build interactions product pricing partnership commitments help improve healthcare developing world february work communities announced new approach pricing un defined list work partner underserved communities least developed countries however significant increase developed developing world supporting programmes funding global community still needed support innovative sustainable bring real benefits rd provide access resultant medicines communities global community investment vaccines million compares million like like basis increase comprised product much achieved sustainable progress donations valued million cash giving million occur significant barriers stand way better inkind donations million plus costs million access healthcare tackled shared responsibility manage deliver community programmes sectors global society governments international agencies countries product donations include million gsks charities academic institutions pharmaceutical industry patient assistance programmes million worth albendazole others lymphatic filariasis lf programme million access medicines developed world humanitarian product donations product donations programmes usa first time valued cost average cost goods rather working provide access medicines people wholesale price wac new approach valuing donations limited financial resources without prescription accurate reflection cost gsk therefore drug insurance transparent believe first pharmaceutical company adopt practice comparative purposes uninsured americans qualify medicare total value donations using wac products would medicaid gsk pharmaceutical companies created million compared million together rx access programme qualified individuals offering reductions pharmacy cost medicines operate single charitable foundation together rx access cardholders saved community investment programmes number million country based foundations grants included investment total gsk annual report report directors responsibility continued cash giving targeted primarily health education phase initiatives follows phase programme personal hygiene sanitation education initiated us providing education thousands school children countries improve health hygiene health fight infectious diseases committed three years funding education extend programme india arts culture humanitarian product donations environment donated essential products antibiotics nonprofit partners including americares direct relief international map international project hope support humanitarian relief efforts community healthcare total value international humanitarian product donations global health programmes million average cost eliminating lymphatic filariasis community initiatives effort eliminate disabling disease lf world dedicated strengthening fabric communities continued close partnership governments countries providing health education initiatives support disease endemic partner local civic cultural institutions improve quality organisations committed donating much life uk contributed million antiparasitic drug albendazole required treat one continuing programme charitable activities supporting billion people risk countries million organisations health medical research science education albendazole treatments donated countries arts environment donated one billion albendazole treatments since global elimination programme started programmes north america national local level focused improving public education increasing access healthcare positive action hivaids children healthcare prevention access breast positive action pioneering global programme working gynaecologic cancers funding million communities affected aids started supports communitybased organisations deliver effective hiv aids gsk one companies manufacturing education prevention healthcare services company awarded new communitymark following positive action worked partners support programmes independent assessment mark created business countries positive actions larger programmes operate community bitc given work local national mexico kenya india china cambodia vietnam level uk well larger international programmes glaxosmithkline african malaria partnership malaria advocacy programme mobilising malaria launched country coalitions malaria uk belgium france ethiopia cameroon increase awareness malaria mobilise resources gsk cosponsored guardian international development journalism awards recognise work ngos addressing un millennium development goals included focus malariagsk annual report report directors responsibility continued health initiatives contribution improve healthcare included following grants non profit partner amount purpose grant childrens health fund extend referral management initiative rmi ensures usa continuity specialist medical care highrisk children often homeless pittsburgh mercy foundation provide access healthcare homeless men women usa pittsburgh usa gsk impact awards recognise excellence nonprofit community health uk philadelphia organisations charities receive unrestricted grants work dealing diverse difficult social issues medical research charities support medical research programmes uk education initiatives non profit partner amount purpose grant institute competitive workforce improve education create skilled workforce future usa working partnership broad business coalition staffed us chamber commerce science summer teach basic scientific concepts inspire school children philadelphia pittsburgh north carolina librarybased science education programme project enthuse support continuing professional development cpd science uk teachers ultimately encourage children engage science pursue careers science technology crest star investigators provide science activities awards school clubs uk uk primary schools working partnership british association advancement science information gsk grants programmes available gskcom employee involvement employees encouraged contribute local communities employee volunteering schemes support includes employee time cash donations charities employees volunteer matching gift programmes us gsk matching gift program matched employee retiree gifts value million plus million united way campaign gsks give programme provided grants organisations us employees volunteered ukbased nonprofit organisations via gsk making difference programme gsk annual report report directors responsibility continued responsibility environment health ehs sustainability strategy plan safety year strategic plan ehs extends aligned caring environment health safety ehs strategic priorities includes management objectives employees key part drive sustainable company performance measures targets gsks progress evaluated targets set traditional environmental control programmes address risks impacts wastes generated manufacturing focus embedding ehs business activities meet responsibility treatment waste fundamental making gsk sustainable business involves disposal systems comply laws regulations caring present thinking future making standards performance standard practice decisions supports three aspirations companies beginning even plan embedding ehs business environmental sustainability continue improve handling waste recognise open transparent stakeholder relations changes incremental rather transformative reviewed ehs sustainability priorities external internal stakeholders review identified following early concept sustainability emerging key issues sustainability means need concerned short term impacts pollution also long term manufacturing efficiency mass efficiency processes impact resource consumption types materials used development continues improve progress made persistence waste environment journey achieve target double mass efficiency thereby halve sustainability started looking holistically continuing waste per unit product manufacturing processes treat waste also finding ways prevent waste phase iii compounds late stage products produced requires called sustainable evaluated since efficiency making technologies efficient chemistries efficient progress toward goal processes recognise sustainability principles apply climate change comprehensive strategy climate change aspects operations apply minimising waste energy efficiency approved available gsks consumption natural resources possibly using website climate change energy reduction team renewable materials discovering manufacturing packaging formed manage special fund used support selling products even impacts consumers climate change projects team identified use products projects reduce energy consumption traditional environmental programmes seen increase use renewable energy cost without financial return sustainable approach using pharmaceuticals environment apply product less resource concerned social impact stewardship principles issue pharmaceuticals operations also financial benefit using less resource environment principally unmetabolised drugs excreted spend less money operations patients need continue address traditional environmental issues process safety process safety management system time integrate sustainability aspects enhanced new engineering standards training business discovering developing manufacturing programmes development standards used selling pharmaceutical consumer healthcare products design new process plant upgrade existing plants use energy resources produce emissions waste needed training programmes increase process safety awareness competencies engineers chemists managersgsk annual report report directors responsibility continued ehs management gsk remained track eliminate use cfcs meet target water consumption progress responsibility ehs highest level corporate made meet targets wastewater pollution disposal responsibility committee board directors provides waste emissions volatile organic compounds air oversight sustainability council formed due combination conservation programmes reduced representatives areas company corporate production several products rate injuries illnesses department reporting chief staff overall also improved line target due continued emphasis responsibility providing governance leadership ehs employee safety behaviours sustainability issues head department makes regular reports corporate executive team cet audit progress towards energy related corporate responsibility committees board within greenhouse gas emissions targets therefore carbon businesses executives managers responsible ehs footprint remained unchanged energy efficiency projects supported sitebased ehs occupational medical staff continue projects completed another identified gains projects fully realised part governance responsibility conduct ehs audits beyond gains experienced parts sites operating entities key suppliers assessing business offset continued expansion management key risks impacts performance vaccines business global ehs standards includes providing audited sites suppliers quantitative performance information well final ehs performance data explanations highlighting areas risk reduction improvement trends published corporate responsibility report ehs targets sustainability part ehs plan targets set every five years working towards sustainability addressing economic baseline year targets environmental social issues research manufacturing sales distribution medicines consumer healthcare selected measures performance improvement based products sustainability starts healthcare solutions found potential adverse impact people environment rd continues innovations improve efficiency business continuity business reputation manufacturing processes new products reduces resource measures selected similar reported use turn lowers waste cost lower costs companies recommended global products may available wider population around world reporting initiative longterm multistakeholder international future ehs plan excellence proposes investigating undertaking develop disseminate globally applicable use renewable resources manufacturing sustainability reporting guidelines seek dialogue external stakeholders consider targets set eliminate chlorofluorocarbons cfcs views developing approaches sustainable development uses year reduce nonhazardous waste information ehs programmes performance may disposed reduce water use volatile organic compound found gsks website voc releases air reduce pollution wastewater measured chemical oxygen demand reduce energy usage related greenhouse gas emissions targets normalised sales based constant exchange rates gsk annual report report directors regulation regulation pharmaceuticals generally national regulatory authorisation also required approve switch products prescription otc gsk operates within highly regulated environment regional however historymaking first otc industry countryspecific laws regulations define data required weight loss medicine alli received centralised european positive show safety efficacy pharmaceutical products well opinion committee medicinal products human govern testing approval manufacturing labelling marketing use chmp october resulted approval market alli drugs regulatory requirements major factor across eu member countries first licensed weight loss determining whether marketable product may successfully treatment available without prescription developed amount time expense associated development price controls drug safety remains primary focus fda us many countries prices pharmaceutical products congressional oversight committees europe evaluation controlled law governments may also influence prices benefit risk continues paramount consideration control national healthcare organisations may bear approval new drug fda amendments act us legislation large part cost supplying medicines consumers passed renewed user fee system drug reviews recent government healthcare reforms countries france mandates rigorous fda review safety approval spain germany may restrict pricing reimbursement postmarketing phase product legislation also provides fda authority convene advisory usa recent legislative proposals healthcare reform committees review new drugs prior approval decisions crossborder trade acceleration generics market fda require sponsors complete postmarketing studies comparative effectiveness increased focus direct companies make product labelling changes fda pricing currently government price controls routinely exercising new authorities private sector purchases federal law requires pharmaceutical manufacturers pay prescribed rebates certain drugs regulations requiring development prescription drugs eligible reimbursement medicaid state biologics paediatric populations place us federal healthcare programmes healthcare remains leading eu gsk fully supports objective ensuring development domestic issue us presidential elections better medicines children candidates focused health reforms address chronic disease europe proposals legislative change announced primary healthcare cost driver rather focusing drug european commission aim prices alone strengthen eu system safety monitoring medicines improve citizens access reliable information medicines medicare strengthen eu laws protect citizens better threats us medicare program federally funded posed fake medicines healthcare insurance programme benefiting senior citizens certain disabled americans included coverage prescription regulatory environment emerging markets asiapacific medicines coverage voluntary includes brandname continues evolve number countries continuing generic drugs open million americans develop regulatory review systems gsk actively participates medicare coverage number specific regional national regulatory initiatives provide opportunities meaningful scientific regulatory value money dialogue industry agencies stakeholders gsk payers around world concerned cost continues include broader sets patient populations healthcare pricing medicines requirement number countries medicine development programmes satisfy healthcare purchasers value money becoming order increase global patient access new innovative medicines additional hurdle product acceptance optimise regulatory approvals regulatory tests safety efficacy quality regulation consumer healthcare consumer healthcare industry subject national regulation comparable prescription medicines testing approval manufacturing labelling marketing products high standards technical appraisal frequently involve lengthy approval process new product launchedgsk annual report report directors economy world market outlook world economy world market pharmaceuticals world economy deteriorated sharply financial global pharmaceutical sales billion compared crisis deepened particularly following bankruptcy lehman billion brothers september despite aggressive cuts official interest rates fiscal stimulus measures national initiatives support world market value growth international banking system international monetary fund geographic region bn total forecasts global growth slow estimated usa mere lowest rate since world war ii europe advanced economies expected contract france first annual contraction postwar period germany italy slump global demand led collapse equity prices uk ftse index falling dow jones industrial rest world average also collapse commodity emerging markets prices weak economic activity lower commodity prices asia pacific dampened inflationary pressures advanced economies japan headline inflation rate forecast imf decline canada estimated record low total order engender economic recovery federal open market us market increased represents committee fomc decided december cut target global prescription pharmaceutical market compared federal funds rate decision signalled decade ago fomc would effectively target supply credit rather price credit nonetheless imf forecasts real th september gsk held second position world gdp usa contract housing market pharmaceutical market market share behind pfizer remains particular concern market share gsk three worlds top pharmaceutical products lamictal seretideadvair like fomc monetary policy committee bank england valtrex aggressively eased monetary stance cutting bank rate bank rate already cut world market value growth reinforce impact cuts bank rate top six therapeutic classes bn total government empowered bank england purchase central nervous system high quality assets like corporate bonds commercial paper cardiovascular commercial banks imf forecasts real gdp uk alimentary tract metabolic contract advanced economy antineoplasticimmunomodulatory antiinfectives bacterial european central bank maintained cautious approach viral fungal excluding monetary relaxation cutting refinancing rate vaccines refinancing rate cut another percentage respiratory point january additional monetary easing anticipated imf forecasts real gdp eurozone contract note data based months th september real gdp germany plunging outlook like major industrialised economies japan fell recession marked turning point factors impacted prime factor downturn external demand performance particular declines avandia sales bank japan cut overnight call money rate starting reduce also saw first steps towards real gdp forecast imf contract radical transformation business model enter confidence expect make good progress china india remained path economic expansion implementing strategic priorities enable us meet however pace expansion decelerated longterm objective reducing risk delivering sustainable deceleration expected economic activity brazil growth shareholders remained buoyant expected slow markedly uncertainties surrounding economic outlook unusually large downside risks continuing dominate gsk annual report report directors financial review pharmaceutical turnover cns growth rates included review turnover constant cns sales decreased billion exchange rates cer unless otherwise stated sterling growth majority gsks cns franchise impacted generic rates may found tables pharmaceutical turnover competition usa generic competition lamictal imigran therapeutic areas geographic region remaining presentation wellbutrin started course however positive news total pharmaceutical turnover declined year treximet approved migraine fda april billion driven largely us performance cardiovascular urogenital billion impacted expected generic competition cardiovascular urogenital sales increased billion several mature brands declines avandia sales sales asia pacific japan fell billion reflecting strong growth across portfolio products partly lower government orders relenza impact offset generic competition coreg ir lovaza high pharmaceutical price cuts japan declines partly triglycerides acquired reliant pharmaceuticals offset growth europe billion emerging grew proforma basis million markets billion sterling terms pharmaceutical grew us market share avodart benign prostatic turnover grew reflecting weakness sterling hyperplasia enlarged prostate grew million taking major currencies percentage point market share arixtra deep vein thrombosis pulmonary embolism grew million pharmaceutical turnover therapeutic area coreg cr grew million gsk turnover declined impact lower metabolic avandia sales us generic competition range gsks metabolic sales decreased billion products lower flu prepandemic sales partly offset strong growth key products advair valtrex epzicom strong growth bonvivaboniva postmenopausal osteoporosis avodart lovaza vaccines franchise million enough offset full year impact avandia whose sales started fall may see financial respiratory review avandia product sales declined respiratory sales increased billion year million us sales falling million european sales million sales seretideadvair asthma copd rose emerging markets avandia product sales returned growth billion usa advair sales rose billion second half year q sales return volume growth second half year fda granted advair indication copd prevention oncology emesis exacerbations helped grow copd segment oncology emesis sales decreased billion advair business europe sales increased billion advair performance particularly strong tykerb breast cancer continued grow following approval emerging markets million japan usa last year approvals countries achieved sales product doubled million following throughout european approval achieved launch june antivirals vaccines antivirals decreased billion vaccine sales increased billion gsks hiv business continues experience strong competition within vaccines portfolio strong performances epzicomkivexa grew million hepatitis vaccines million combination offset declines across rest portfolio sales paediatric vaccines infanrixpediarix million valtrex herpes rose billion us sales rotarix rotavirus gastroenteritis rose million fuelling growth sales flu antiviral relenza fell largely driven government tender orders latin america million reflecting fewer government orders launch product usa august new cervical prepandemic stockpiling cancer vaccine cervarix recorded sales million year following several tender wins including national government orders uk netherlandsgsk annual report report directors financial review continued pharmaceutical turnover therapeutic area total usa europe rest world therapeutic area growth growth growth growth major products total cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antivirals hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip requip xl treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin altabax oncology emesis hycamtin zofran tykerb vaccines hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix cer represents growth constant exchange rates represents growth actual exchange rates turnover quarter given financial record pages gsk annual report report directors financial review continued regional analysis following table gives adjustments made order restate turnover markets within europe turnover pharmaceutical turnover geographic region created basis invoiced basis turnover reported table represents sales invoiced region invoiced adjustment created invoiced adjustment created gsks local entity customers local market plus major markets copromotion income within market europe france region growth uk major markets total cer italy usa germany europe spain france europe uk italy adjustments gsks estimates based recent germany data independent external sources valued sterling spain relevant exchange rates management believes turnover europe created basis reporting turnover market provides better rest world reflection performance businesses market emerging markets within europe japan total turnover europe region unaffected asia pacific adjustments canada parallel trade occurs occasionally elsewhere world sufficiently material affect significantly turnover data market presented invoiced basis cer represents growth constant exchange rates represents growth pharmaceutical turnover geographic region actual exchange rates turnover created basis individual governments determine pricing medicines countries within europe result wide price variations turnover market within europe adjusted product parallel trade occurs third parties effects parallel trade show turnover basis exploit price differential purchasing products markets country product finally consumed low prices enforced selling governments product sold gsk purchasers markets higher prices agreed parallel trade permitted single region growth major markets total cer market rules european union gsk derive usa benefit profit resale higher price europe result management believes within european region france turnover market invoiced basis presented uk properly represent consumption products italy within market gsk employees based market germany instrumental promotion groups products within spain market thereby creating product sale final consumption europe market rest world emerging markets japan asia pacific canada cer represents growth constant exchange rates represents growth actual exchange rates turnover quarter given financial record pages gsk annual report report directors financial review continued usa otc medicines sales usa declined billion principally reflecting otc product sales declined billion sales full year impact avandia generic competition smoking cessation products million panadol sales significant products lamictal imigran grew million twice global average wellbutrin xl requip coreg ir declines partly offset advair oral healthcare valtrex lovaza proforma basis sales oral healthcare products rose billion whereas market grew strong performances sensodyne europe million aquafresh million sales europe increased billion continued growth sensodynes growth represented world toothpaste growth seretide particularly strong vaccines growth offsetting markets gsk competes impact generic competition number products continued price cuts governments across region nutritional healthcare within nutritionals horlicks sales rose million lucozade emerging markets sales rose million ribena sales flat million sales emerging markets increased billion strong although sales lucozade ribena second half year growth russia china latin america declined slightly largely result poor weather uk growth fuelled primarily vaccines billion respiratory franchise billion results major restructuring total results asia pacificjapan october board approved implementation increased sales seretideadvair million detailed formal plan gsk announced significant offset lower government orders relenza japan new operational excellence restructuring programme price cuts second formal plan representing significant expansion consumer healthcare turnover operational excellence programme approved board announced february restructuring growth programme comprising detailed formal plans covers total cer areas gsks business including manufacturing selling rd overthecounter medicines infrastructure estimated total cost approximately panadol franchise billion expanded programme expected deliver smoking cessation products annual pretax savings approximately billion time tums substantially complete approximately cold sore franchise costs incurred st december approximately breathe right expected incurred alli balance mostly total approximately oral healthcare costs expected cash expenditures expected aquafresh franchise accounting writedowns uncertainties exist exact sensodyne franchise amount timing cash outflows result potential dental care future exchange rate fluctuations many elements restructuring programme subject employee consultation nutritional healthcare lucozade procedures making difficult predict precision horlicks procedures completed however majority ribena remaining cash payments expected made given extent cost operational excellence programme management believes material cer represents growth constant exchange rates represents growth impact gsks operating results manner actual exchange rates turnover quarter given financial record gsks business conducted gsk presents restructuring costs pages incurred solely direct result operational excellence total consumer healthcare sales year rose billion programme amounted million compares growth benefited tax million separate column income launch stocking new antiobesity treatment alli sales alli statement titled major restructuring million excluding alli consumer healthcare sales rose gsk annual report report directors financial review continued addition restructuring costs operational excellence remaining costs million arose programme major restructuring column income miscellaneous expenditures incurred solely direct result statement includes restructuring costs incurred solely direct restructuring programmes including consultancy project result restructuring programmes follow relate management fees termination leases site closure costs material acquisitions operations acquired respect recognition foreign exchange losses business overlap extensively gsks existing operations following liquidation subsidiary puerto rico costs arising gsks ongoing operating activities reported restructuring activities follow relate major restructuring column acquisitions nature undertaken operational excellence programme also carried restructuring costs arise solely direct result following detailed formal plan management therefore considers operational excellence programme restructuring appropriate present costs restructuring activities programmes following relating acquisitions meeting manner billion million acquisition criteria described continue reported operating reliant pharmaceuticals inc december expenses within results major restructuring costs acquisition since october meets criteria set included restructuring costs related minor acquisitions thus acquisition costs incurred million costs million related direct result related restructuring programme restructuring activity initiated commencement included within major restructuring column total operational excellence programme none restructuring restructuring costs incurred direct result acquisition activity material impact gsks operating results million charged paid manner business conducted anticipated duration operational excellence groups results costs operational excellence programme gsk currently expect incur material programme acquisitionrelated restructuring programmes restructuring costs except related programme meeting criteria described also presented acquisitions meeting criteria described separate column income statement described unanticipated material restructuring costs arise results major restructuring presentation period gsk would expect also include major gsk intends apply consistently future major restructuring restructuring column programmes material impact gsks operating gsks operating profit profit taxation taxation profit results manner gsks business conducted year discussed terms total results adopted show clearly groups results include major restructuring costs results major costs restructuring programmes restructuring management believes presentation assists shareholders gaining clearer understanding groups financial operating profit total results performance making projections future financial total results include restructuring costs related new performance results include costs virtue operational excellence programme commenced size nature limited comparative value presentation october reliant restructuring programme also consistent way management assesses groups financial performance growth cer restructuring costs incurred solely direct result turnover operational excellence programme restructuring programme following reliant acquisition reported cost sales major restructuring column income statement selling general restructuring costs principally arisen impairments administration research property plant equipment termination development employment contracts staff made redundant part operating restructuring activities set note financial income statements major restructuring programmes asset impairments staff redundancies together accounted million operating profit million restructuring costs incurred reported major restructuring column milliongsk annual report report directors financial review continued cost sales profit taxation total results cost sales increased turnover constant exchange rates cost sales percentage turnover net finance costs increased percentage points reflecting charges related major restructuring programmes million finance income million unfavourable product regional interest finance income mix compared partly offset savings fair value adjustments hedges restructuring programmes selling general administration finance costs sga costs including legal charges turnover interest costs increase percentage points constant unwinding discount liabilities exchange rates increase percentage points legal fair value adjustments hedges costs million million included million charge announced january related us investigation gsks marketing promotional practices share tax profits associates joint ventures originated colorado sga costs included charges share tax profits associates million million million related major million arises principally groups holding restructuring programmes excluding legal costs sga decreased quest diagnostics inc profit taxation total results research development taking account net finance costs share profits rd expenditure increased included charges related associates total profit taxation million compared major restructuring programmes million million cer decline million excluding charges rd expenditure sterling decline increased cer terms investment late stage pipeline partly offset restructuring savings operating profit results major restructuring operating income operating income million million results major restructuring set included strong growth royalty income million million product intellectual property equity growth cer investment disposals realised million compared turnover million roche litigation settlement included cost sales selling general operating profit total results administration research total operating profit million decreased sterling development terms cer terms compared pharmaceuticals operating operating profit million consumer income healthcare operating profit fell million operating profit year gains asset disposals settlements million million costs legal matters cost sales million million fair value movements financial cost sales increased percentage points instruments resulted charge million income turnover constant exchange rates increase percentage million charges relating previous restructuring points turnover principally reflecting impact generic programmes million million charges competition higher margin products usa lower avandia related major restructuring programmes million sales higher proportion sales generated lower margin million impact items total vaccines brands sold emerging markets consumer operating profit million charge compared healthcare products partly offset savings million charge restructuring programmes gsk annual report report directors financial review continued selling general administration profit taxation results sga costs including legal charges turnover major restructuring constant exchange rates sga costs increased percentage points turnover legal costs net finance costs million million included million charge announced january related us investigation finance income gsks marketing promotional practices originated interest income colorado excluding legal costs sga percentage turnover fair value adjustments hedges fell percentage points growth sterling terms reduction constant exchange rates reflecting benefits restructuring finance costs programmes selling distribution fell advertising interest costs promotion general administration expenditure unwinding discount liabilities excluding legal charges fair value adjustments hedges research development rd expenditure increased turnover taking account net finance costs share profits investment late stage pipeline partly associates profit tax major restructuring offset restructuring savings million compared million cer decline flat sterling terms operating income operating income million million taxation included strong growth royalty income million million product intellectual property equity investment disposals realised million compared uk corporation tax million roche litigation settlement overseas taxation included current taxation operating profit results major restructuring deferred taxation operating profit major restructuring million taxation total profits year increased sterling terms decreased cer terms compared pharmaceuticals charge taxation profit major restructuring operating profit million consumer charges amounting million million healthcare operating profit flat cer terms million represents effective tax rate excluding legal costs operating profit decreased charge taxation total profits amounted greater turnover decline primarily due million million represented higher cost sales percentage turnover effective tax rate groups balance sheet st december included tax payable liability year gains asset disposals settlements million tax recoverable asset million million million costs legal matters million million fair value movements groups main open tax issues usa canada japan financial instruments resulted charge million july following discussions hmrc group settled income million charges relating previous substantially outstanding uk tax issues periods restructuring programmes million million including st december impact items operating profit major following audit period irs issued restructuring million charge statutory notices deficiency gsk asserting income million withholding tax deficiencies associated penalties arising reclassification intercompany financing arrangement years debt equity consequent recharacterisation amounts paid dividends subject withholding tax us uk treaty amounts due financing arrangement timely paid final payment made april gsk annual report report directors financial review continued irs commenced audit period june total results including restructuring costs produced basic eps examining issue years gsk disagrees p compared p decline irss position august initiated actions cer decline sterling terms excluding major united states tax court contest statutory notices restructuring costs eps p compared p deficiency gsk estimates irs claim tax penalties decline cer increase sterling terms interest st december net federal tax relief percentage point currency benefit arose weakness million gsk believes claim sterling major currencies merit adjustment warranted contrary gsks view irs prevailed argument court respect dividend years gsk would expect additional board declared fourth interim dividend pence per liability five year period amount share resulting dividend year pence four pence million tax penalties interest st december increase dividend pence per share net federal tax relief years event equivalent fourth interim dividend receivable adr holders company able resolve issue irs court cents per ads based exchange rate decision would expected exdividend date th february record date th february payment date th april lower courts japan upheld claims tax authorities yen billion million relating japanese cfc critical accounting policies legislation company paid fully provided full tax pursuing claim refund japanese supreme consolidated financial statements prepared accordance court canada court decision respect transfer pricing ifrs adopted use european union also early completed may gsk filed ifrs issued iasb following accounting policies appeal june court date awaited approved board described note financial statements accounting principles policies management gsk continues believe made adequate provision required make estimates assumptions affect liabilities likely arise open assessments amounts assets liabilities revenue expenses reported ultimate liability matters may vary amounts financial statements actual amounts results could differ provided dependent upon outcome litigation estimates critical accounting policies adopted relate proceedings negotiations relevant tax authorities following areas profit year turnover taxation growth legal disputes cer property plant equipment total profit taxation year goodwill total profit attributable intangible assets shareholders pensions postemployment benefits basic earnings per share pence p p basic earnings per ads us information judgements estimates made areas given note financial statements key accounting results major restructuring profit taxation year judgements estimates results major restructuring respect turnover accounting policy groups largest profit attributable shareholders business us pharmaceuticals us market adjusted earnings per share pence p p complex arrangements rebates discounts allowances adjusted earnings per ads us following briefly describes nature arrangements weighted average number existence groups us pharmaceuticals business shares millions gsk arrangements certain indirect customers whereby diluted total earnings per share pence p p customer able buy products wholesalers diluted total earnings per ads us reduced prices chargeback represents difference diluted weighted average number shares millions invoice price wholesaler indirect customers contractual discounted price accruals estimating chargebacks calculated based terms agreement historical experience product growth rates gsk annual report report directors financial review continued customer rebates offered key managed care group chargebacks decreased result sales purchasing organisations gpo direct indirect products us government stockpiles customers arrangements require customer achieve arise managed care medicare part gpo rebates certain performance targets relating value product purchased flat dollar terms despite additional tricare prescription formulary status predetermined market shares relative rebates january national defense authorisation act competitors rebates given medicare part included approved authorises department defense category medicare part programme introduced access discounted federal pricing drugs dispensed tricare replaced government medicaid subsidies individuals network retail pharmacies members us armed forces subsidised coverage provided private prescription plans dependants military retirees rebates given accrual rebates estimated based specific terms us government state programmes risen mainly agreement historical experience product growth rates due pricing adjustments imitrex lamictal following introduction generic competition together inclusion us medicaid programme stateadministered programme new products reliant pharmaceuticals acquisition providing assistance certain poor vulnerable patients medicaid drug rebate program established total accruals rebates discounts allowances returns reduce state federal expenditure prescription drugs us pharmaceuticals business follows gsk participates providing rebates states accruals st st medicaid rebates calculated based specific terms december december individual state agreements using combination historical experience product population growth anticipated price chargebacks increases impact contracting strategies managed care medicare part cash discounts offered customers encourage prompt gpo rebates payment accrued time invoicing us government state programmes adjusted subsequently reflect actual experience cash discounts customer returns historical experience customer returns gsk records accrual estimated sales returns applying total historical experience customer returns amounts invoiced together market related information stock levels sterling values increased largely result exchange wholesalers anticipated price increases competitor activity rate movements dollar terms provision largely unchanged monthly process operated monitor reconciliation gross turnover net turnover us inventory levels wholesalers abnormal movements pharmaceuticals business follows process uses gross sales volumes prescription volumes based third party data sources information received key wholesalers aim maintain inventories gross turnover consistent level year year based pattern consumption basis us pharmaceutical inventory levels chargebacks wholesalers distribution channels st december managed care medicare estimated amount approximately one month part gpo turnover calculation uses third party information accuracy rebates totally verified believed sufficiently us government state programmes reliable purpose cash discounts customer returns prior year adjustments items total deductions net turnover sterling values increased approximately compared result exchange rate movementsgsk annual report report directors financial position resources financial position property plant equipment gsks business sciencebased technologyintensive highly regulated governmental authorities group allocates significant assets financial resources renewal maintenance property noncurrent assets plant equipment minimise risks interruption production property plant equipment achieve compliance regulatory standards number goodwill processes use chemicals hazardous materials intangible assets investments associates joint ventures total cost groups property plant equipment investments st december million net book deferred tax assets value million land buildings represented derivative financial instruments million plant equipment million assets noncurrent assets construction million gsk invested million new renewal property plant equipment mainly total noncurrent assets related large number projects renewal improvement current assets expansion facilities various worldwide sites property inventories mainly held freehold new investment financed group liquid current tax recoverable resources st december gsk capital contractual trade receivables commitments future expenditure million operating derivative financial instruments lease commitments million gsk believes facilities liquid investments cash cash equivalents adequate current needs assets held sale group observes stringent procedures uses specialist skills total current assets manage environmental risks activities environmental total assets issues sometimes dating operations modified discontinued reported responsibility environment liabilities health safety note financial current liabilities statements legal proceedings shortterm borrowings trade payables goodwill derivative financial instruments goodwill increased year million current tax payable st december million increase primarily reflects shortterm provisions goodwill arising acquisition sirtris pharmaceuticals total current liabilities inc million arising acquisition bms noncurrent liabilities egypt business million well significant strengthening longterm borrowings overseas currencies translation existing foreign currency deferred tax provision goodwill balances pensions postemployment benefits provisions intangible assets derivative financial instruments intangible assets include cost intangibles acquired noncurrent liabilities third parties computer software net book value intangible assets st december million total noncurrent liabilities million increase reflects additions total liabilities million currency movements partly offset amortisation net assets impairment existing intangibles largest element equity additions million relating acquisition sirtris share capital pharmaceuticals inc reflecting existence technology share premium account large patent application portfolio covering areas sirtuin biology retained earnings reserves shareholders equity minority interests total equity gsk annual report report directors financial position resources continued investments pensions postemployment benefits gsk held investments including associates joint ventures group accounts pension postemployment carrying value st december million arrangements accordance ias net deficits million market value st december allowing deferred taxation million million million largest million pension arrangements million investments associate quest diagnostics inc million unfunded postemployment liabilities book value st december million pension liabilities increased following declines asset values million investments include equity stakes negative impact exchange movements partially offset companies group research collaborations special funding contributions uk pension funds provide access biotechnology developments potential interest million million uk pension schemes interests companies arise business divestments strengthening longterm interest rates including increase rate used discount uk pension liabilities derivative financial instruments assets decrease estimated long term inflation rate uk gsk noncurrent current derivative financial instruments held fair value million million increase net debt primarily reflects fluctuations far forward valuations foreign exchange contracts hedging intercompany loans deposits exchange movements largely due changes euro cash cash equivalents us dollar yen market rates liquid investments borrowings repayable within one year inventories borrowings repayable one year inventory million increased million net debt year majority increase arises strengthening overseas currencies remainder caused partly net debt increased million primarily due share strategic stock building support growth specific products repurchases acquisition businesses significant strengthening foreign currencies group debt trade receivables denominated partly offset increased cash inflows trade receivables million increased operating activities reflecting impact strengthening overseas currencies translation foreign currency receivables partly offset total equity completion nonrecourse factoring arrangements japan summary movements equity set reductions overdue receivables certain european markets derivative financial instruments liabilities gsk held noncurrent current derivative financial total equity beginning year instruments held fair value million total recognised income expense million relating primarily hedging exchange translation year currency assets consolidation increase reflects dividends shareholders impact euro us dollar yen currency fluctuations ordinary shares issued ordinary shares purchased held trade payables treasury shares trade payables amounting million ordinary shares purchased cancelled consideration received shares transferred increased primarily reflecting strengthening esop trusts overseas currencies ordinary shares acquired esop trusts provisions sharebased incentive plans tax sharebased incentive plans group carried deferred tax provisions shortterm distributions minority interests noncurrent provisions million st december million respect estimated future liabilities total equity end year million related legal disputes provision st december total equity decreased made legal disputes indemnified disposal million st december million decrease liabilities costs restructuring programmes extent arises principally actuarial losses defined benefit pension balance sheet date actual constructive obligation plans year share repurchases partially offset existed could reasonably estimated recognised income expenses yeargsk annual report report directors financial position resources continued share purchases contractual obligations commitments employee share ownership plan esop trusts acquired following table sets groups contractual obligations million shares gsk plc million shares held commitments st december fall due payment trusts satisfy future exercises options awards group share option award schemes proportion total yr yrs yrs yrs shares held trusts respect awards rules loans scheme require gsk satisfy exercises market purchases interest loans rather issue new shares shares held trusts finance lease obligations matched options awards granted finance lease charges st december esop trusts held million gsk shares operating lease future exercise share options share awards commitments carrying value million million intangible assets deducted reserves market value shares property plant equipment investments million million purchase commitments gsk repurchased million shares cancellation business combinations million nil shares held treasury shares pensions million order ensure gsk sufficient commitments flexibility deliver strategic priorities company expect total make significant repurchases existing share buyback programme exact amount timing future commitments respect loans future interest payable loans purchases extent repurchased shares held disclosed taking account effect derivatives treasury shares rather cancelled determined group entered number research collaborations develop company dependent market conditions factors new compounds pharmaceutical companies terms st december gsk held million shares treasury arrangements include upfront fees equity investments loans shares million shares cost million commitments fund specified levels research addition million deducted group often agree make payments future milestones retained earnings achieved agreements relate compounds early stages development milestone payments continue purchases since december number years compounds move successfully existing programme development process generally closer product marketing approval greater possibility success payments shown commitments contingent liabilities within intangible assets represent maximum would paid financial commitments summarised note financial milestones achieved statements commitments contingent liabilities obligations respect short longterm debt set note number new commitments made financial statements contingent liabilities note financial licensing agreements including arrangements statements net debt actelion pharmaceuticals limited archemix corporation dynavax technologies corporation mpex pharmaceuticals inc amounts provided pensions postretirement benefits set commitments relating business combinations reflect agreements note financial statements pensions post acquire issued share capital genelabs technologies inc bristol employment benefits amounts provided restructuring programmes myers squibb pakistan private limited az tika snc latter legal environmental disputes set note subject clearance swedish competition authority financial statements provisions gsk formalised agreement trustees uk pension schemes make additional contributions addition normal contributions four year period ending st december order eliminate funded pension deficits ias basis point table shows commitment net million additional contributions made excludes normal ongoing annual funding requirement approximately million gsk also committed eliminate future deficits may arise rolling fiveyear period agreement reviewed information pension obligations see note financial statements pensions postemployment benefits gsk annual report report directors financial position resources continued contingent liabilities net cash outflow investing activities million following table sets contingent liabilities comprising discounted decrease million reflected marginally lower capital bills performance guarantees letters credit items arising expenditure repayments liquid investments reduced cost normal course business expected expire business purchases including sirtris pharmaceuticals million net cash acquired million egyptian total yr yrs yrs yrs business bms million net deferred consideration million comparable acquisitions comprised reliant guarantees pharmaceuticals million domantis million net contingent liabilities cash acquired total free cash flow normal course business gsk provided various free cash flow indemnification guarantees respect business disposals legal disputes subsequently arisen provision made reasonable estimate made likely outcome dispute included note financial statements provisions groups policy provide settlement costs asserted claims environmental disputes reasonable estimate may made prior point liability recorded legal environmental costs discussed risk factors pages note financial statements legal proceedings gsk continues believe made adequate provision free cash flow amount cash generated business liabilities likely arise open taxation assessments ultimate meeting obligations interest tax dividends paid minority liability matters may vary significantly amounts provided interests capital expenditure noncurrent tangible dependent upon outcome litigation proceedings intangible assets million increase negotiations relevant tax authorities discussed principally reflecting higher operating profit noncash charges note financial statements taxation primarily major restructuring programmes working capital improvements partly offset higher levels interest paid result cash flow significant debt issuances year us billion summary consolidated cash flow set us shelf registration billion emtn programme free cash flow used gsks management planning reporting purposes discussions presentations investment analysts net cash inflow operating activities rating agencies gsks free cash flow measure defined ifrs net cash outflow investing activities measure may directly comparable similarly described net cash outflow financing activities measures used companies reconciliation net cash inflow increasedecrease cash bank overdrafts operating activities closest equivalent ifrs measure free cash flow shown exchange adjustments cash bank overdrafts beginning year reconciliation free cash flow cash bank overdrafts end year cash bank overdrafts end year comprise net cash inflow operating activities purchase noncurrent tangible assets cash cash equivalents purchase noncurrent intangible assets overdrafts disposal noncurrent tangible fixed assets interest paid net cash inflow operating activities taxation paid interest received million increase million reflecting dividends received joint ventures associated undertaking unchanged profit tax excluding impact significant dividends paid minority interests increase noncash charges made year primarily major restructuring programmes together improved working capital free cash flow managementgsk annual report report directors financial position resources continued movements net debt payment policies group companies responsible monitoring managing working capital terms sales collections supplier net debt beginning year payments reflect local commercial practice increase cash bank overdrafts cash inflowoutflow liquid investments uk company uk subsidiaries net increase longterm loans policies ensure suppliers paid time particular net repayment ofincrease shortterm loans uk companies seek exchange movements settle terms payment suppliers agreeing movements terms transaction net debt end year ensure suppliers made aware agreed terms investment appraisal payment gsk formal process assessing potential investment abide terms payment proposals order ensure decisions aligned groups overall strategy process includes analysis policy permits arrangements accelerated payment impact project earnings return invested small suppliers capital assessment return based discounted payment performance cash flows discount rate used perform financial analysis st december average number days payable decided internally allow determination extent outstanding represented trade payables parent company investments cover groups cost capital specific nil nil respect company uk investments discount rate may adjusted take subsidiaries aggregate days days account country risk weightings treasury policies capital expenditure financial investment cash payments tangible intangible fixed assets gsk reports sterling pays dividends sterling profits amounted million million role corporate treasury manage monitor million disposals realised million external internal funding requirements financial risks million million cash payments support corporate objectives treasury activities acquire equity investments million million governed policies procedures approved board million made year sales equity directors recently th september investments realised million million treasury management group tmg chaired chief million financial officer meets monthly basis review treasury future cash flow activities members receive management information relating group expects future operating cash flow sufficient treasury activities fund operating debt service costs satisfy normal levels capital management capital expenditure meet obligations existing licensing operations global primarily subsidiary companies agreements meet expenditure arising major established markets trade significant restructuring programmes precise timing uncertain levels patent protection products compete largely outlined note financial statements major restructuring product efficacy rather price selling margins sufficient programmes meet routine outflows including tax cover normal operating costs operating subsidiaries dividends subject risk factors discussed pages generally cash generative gsk may time time additional demands finance acquisitions access sources liquidity operating cash flow used fund investment research short longterm capital markets banks development new products also used make routine financial institutions addition cash flow operations outflows capital expenditure tax dividends repayment needs maturing debt extent determined board share repurchases policy borrow centrally using variety capital market issues borrowing facilities meet anticipated funding requirements gsk annual report report directors financial position resources continued borrowings together cash generated operations st december centrally available cash reserves onlent contributed equity certain subsidiaries used billion committed undrawn bank facilities pay dividends make acquisitions fund share buybacks billion date shortterm debt bank overdrafts loans repayable within one year billion details gsks share buyback programme please see note share capital share premium account manage net borrowing requirements portfolio longterm borrowings including bonds together short liquidity term finance billion commercial paper programme st december cash liquid investments year committed undrawn bank facilities reduced held follows billion billion consequence royal bank scotlands acquisition abn amro collapse lehman brothers facilities renewed october consider level committed facilities adequate given bank balances deposits treasuries treasuryrepo money current cash holdings information facilities market funds please refer note financial statements net debt corporate debt instruments also benefit strong positive cash flow operating units government securities european medium term note programme billion st december billion notes issue programme also us shelf billion amount managed centrally available registration statement st december within three months net debt st december billion billion notes issue programme billion table summarises cash gross debt tmg monitors cash flow forecast monthly basis longterm borrowings mature dates longterm debt ratings remained stable since cash liquid investments february currently rated stable outlook gross debt fixed floating standard poors negative outlook moodys shortterm debt ratings p standard poors net debt moodys respectively maturity profile gross debt shown table maturity profile gross debt equivalent usd eur gbp othergsk annual report report directors financial position resources continued treasury operations use interest rate swap redenominate one external borrowings interest rate coupon required gsk objective treasury activity manage posttax net duration swap matches duration principal cost income financial operations benefit earnings instrument interest rate derivative instruments accounted corporate treasury operate profit centre use fair value cash flow hedges relevant assets liabilities variety financial instruments including derivatives finance operations manage market risks operations counterparty risk management policy counterparty risk management work derivatives principally comprising forward foreign currency select group relationship banks global counterparty limits contracts interest rate currency swaps used swap assigned gsks banking investment counterparties borrowings liquid assets required currencies based longterm credit ratings moodys standard manage exposure funding risks changes foreign poors corporate treasurys usage limits monitored exchange interest rates daily corporate compliance officer cco independent hold issue derivative financial instruments corporate treasury breach limits reported speculative purposes treasury policies specifically prohibit cfo immediately cco also monitors credit rating activity transactions financial instruments counterparties changes ratings occur notifies undertaken manage risks arising underlying business corporate treasury appropriate amendment made activities speculation limits full counterparty analysis presented tmg annually approval foreign exchange management foreign currency transaction exposure arising internal since july tightened criteria holding cash external trade flows hedged exposure overseas equivalents liquid investments response credit crisis operating subsidiaries transaction risk minimised matching th september lehman brothers filed chapter local currency income local currency costs proceedings usa appointed administrators purpose internal trading transactions matched uk although lehman one gsks relationship banks centrally manage intercompany payment terms reduce exposure lehman time collapse limited risk exceptional foreign currency cash flows hedged selectively immaterial costs foreign exchange contracts management corporate treasury termination quest collar referred detail note financial statements investments associates manage shortterm cash surpluses borrowing joint ventures requirements subsidiary companies centrally using forward financial assets liabilities contracts hedge future repayments back originating currency analysis net debt given note financial seek denominate borrowings currencies statements net debt analysis financial assets liabilities principal assets cash flows primarily denominated carrying value fair value given note financial us dollars euros sterling certain borrowings swapped statements financial instruments related disclosures currencies required continue benefit strong positive cash flow borrowings denominated swapped foreign currencies operating activities net debt would decreased match investments overseas assets treated hedge year st december purchase relevant assets forward contracts also used major shares market billion acquisitions currencies reduce exposure investment overseas approximately billion group assets see net investment hedges section note financial assets liabilities st december details tmg review ratio borrowings assets representative treasury policies strategies applied since major currencies july gsk raised billion capital markets december may billion raised interest rate risk management expect make significant share repurchases policy interest rate risk management requires minimum amount net borrowings fixed rates increase ratio forecast interest payable trading profit fixed floating ratio reviewed monthly tmg gsk annual report report directors risk factors risk factors generic drug manufacturers seeking market generic versions many groups important products prior risks uncertainties relevant groups business expiration groups patents exhibited readiness financial condition results operations may affect future products future us launch generic performance include rd anticipated sales growth products competing lamictal imitrex paxil cr requip expected earnings factors among wellbutrin xl significant impact groups overall group thinks could cause actual results differ materially turnover earnings expected historical results risks potential changes intellectual property laws regulations uncertainties currently known group proposals change existing patent data exclusivity laws deemed immaterial management mitigation risk regulations major markets group sells discussed corporate governance products continuing feature political process major risks might affect gsks business countries include proposals could effect making prosecution patents new products difficult risk rd deliver commercially successful timeconsuming adversely affecting exclusivity period new products groups products including biological products continued development commercially viable new products well proposals enacted could adverse impact development additional uses existing products critical groups future sales results operations groups ability replace sales older products decline upon expiration exclusive rights increase overall sales weakness intellectual property protection developing new products costly lengthy uncertain process certain countries countries group operates patent new product candidate fail stage process protection may significantly weaker usa one latestage product candidates could fail receive european union effort control public health crises regulatory approval developing countries south africa thailand brazil new product candidates may appear promising development considered plans substantial reductions scope significant investment fail reach market limited patent protection pharmaceutical products particular commercial success example could result efficacy countries could facilitate competition within markets safety concerns inability obtain necessary regulatory approvals generic manufacturers would otherwise unable difficulty excessive costs manufacture erosion patent term introduce competing products number years result lengthy development period infringement patents loss patent protection including abrogation patent intellectual property rights others inability differentiate rights compulsory licensing likely affect adversely product adequately competes groups operating results national markets health authorities us fda european medicines expected material group overall absence adequate agency japan pharmaceuticals medicines device patent protection could limit opportunity look agency increased focus safety assessing markets future sales growth benefitrisk balance drugs payers also becoming increasingly risk substantial adverse outcome litigation demanding regard incremental benefit required government investigations gain reimbursement secure appropriate pricing see note financial statements legal proceedings risk unplanned loss patents discussion proceedings governmental investigations patent infringement litigation involving matters proven could give rise civil groups patents common patents challenged criminal liabilities group currently involved time efforts generic manufacturers may involve challenges unfavourable resolution similar future proceedings validity enforceability patent assertions investigations may material adverse effect groups generic product infringe groups patents financial condition results operations group gsk successful defending attack patents made material provisions related legal maintaining exclusive rights market one major proceedings investigations reduced earnings products particularly usa group highest group may also make additional significant provisions related turnover margins groups turnover margins would legal proceedings investigations future would adversely affected see note financial statements reduce earnings many cases practice plaintiff bar legal proceedings discussion patentrelated proceedings claim damages amounts bear relationship underlying group involved description harm accordingly potentially misleading quantify potential resolution prior proceedings affect dates exposure claims proceedings investigations type generic versions groups products may introduced described note financial statements legal proceedingsgsk annual report report directors risk factors continued recent insurance loss experience including pharmaceutical usa example group responding federal product liability exposures increased cost state governmental investigations pricing marketing narrowed coverage afforded insurance pharmaceutical reimbursement prescription drug products companies generally including group investigations could result related restitution civil false claims act litigation behalf federal state governments well order contain insurance costs recent years group related proceedings initiated group behalf continued adjust coverage profile accepting greater degree consumers private payers proceedings may result uninsured exposure addition claims made trebling damages awarded fines respect violation insurance policies insurers may reserve right deny coverage law criminal proceedings may also initiated group various grounds denial coverage ultimately upheld claims could result material additional charges risks competition price controls limitations product liability litigation sales preclinical clinical trials conducted third party competition development potential products determine safety group operates highly competitive markets efficacy products use humans following approval pharmaceuticals business faces competition proprietary regulatory bodies notwithstanding efforts drugs products large international manufacturers producers vaccines introduced marketplace unanticipated side generic pharmaceuticals significant product innovations technical effects may become evident advances intensification price competition competitors could adversely affect groups operating results group instances third parties may perform analyses published predict timing impact competitive products clinical trial results although necessarily accurate potential impact sales groups products continued meaningful may raise questions regarding safety pharmaceutical consolidation pharmaceutical industry could adversely affect products may publicised media may result groups competitive position continued consolidation product liability claims group currently defendant among groups customers may increase pricing pressures number product liability lawsuits including class actions involve substantial claims damages related groups group eight products million annual pharmaceutical products litigation particularly usa global sales among products augmentin ir imitrex inherently unpredictable excessive verdicts justified lamictal generic competition avandia evidence occur class actions sweep together persons valtrex respect groups intellectual property prescribed groups products inflate potential rights usa currently subject litigation settlement liability force numbers claims pain suffering agreements related litigation punitive damages frequently asserted product liability actions groups major products become subject allowed represent potentially openended exposure problem unplanned loss patent protection unexpected antitrust litigation side effects regulatory proceedings publicity affecting doctor usa become increasingly common following patient confidence pressure competitive products publicity around government investigations adverse outcome new effective treatment introduced adverse prosecution patent infringement actions defendants impact groups revenues operating results could direct indirect purchasers payers initiate antitrust significant particular group faces intense competition actions well claims direct indirect purchasers manufacturers generic pharmaceutical products payers typically filed class actions relief sought may major markets generic products often enter market include treble damages restitution claims damages adverse upon expiration patents data exclusivity periods antitrust verdicts subject automatic trebling usa groups products introduction generic products typically leads similarly antitrust claims may brought following settlement dramatic loss sales reduces groups revenues patent litigation alleging settlements anti margins proprietary products expiration dates competitive violation antitrust laws patents groups major products description litigation settlements may affect dates generic sales marketing regulation versions groups products may introduced set group operates globally complex legal regulatory legal proceedings involving patent challenges set environments often vary among jurisdictions failure note financial statements legal proceedings comply applicable laws rules regulations jurisdictions may result civil criminal legal proceedings governmental payer controls rules regulations change governmental pharmaceutical products subject price controls pressures interpretation rules regulations evolve prior conduct restrictions many markets including japan germany may called question spain france italy governments intervene directly setting prices gsk annual report report directors risk factors continued addition markets major purchasers pharmaceutical risk interruption product supply products whether governmental agencies private health care manufacture pharmaceutical products constituent providers economic power exert substantial pressure materials requires compliance good manufacturing practice prices terms access formularies regulations groups manufacturing sites subject review approval fda regulatory agencies compliance group predict whether existing controls pressures failure suppliers key services materials groups restrictions increase new controls pressures restrictions manufacturing facilities could lead product recalls seizures introduced reduce groups margins affect interruption production delays approvals new products adversely ability introduce new products profitably pending resolution manufacturing issues noncompliance also example usa group highest margins result fines disgorgement profits sales country pricing pressures could interruption supply fines disgorgement remedy could significantly increase experience develops outpatient materially adversely affect groups financial results pharmaceutical programme covering medicare beneficiaries example resolution fda observations deficiencies began private insurers coverage manufacturing practices groups cidra puerto rico facility offered enormous purchasing power referred note financial statements legal proceedings programme could demand discounts may implicitly create supplies certain products manufactured site curtailed price controls prescription drugs constricted adverse impact sales changes enabling legislation could afford us government although group undertakes business continuity planning direct role negotiating prices medicare programme single sourcing certain components bulk active materials additionally number states proposed implemented finished products creates risk failure supply various schemes control prices senior citizens event regulatory noncompliance physical disruption programmes including importation countries bulk manufacturing sites purchases drugs growth number patients covered large managed care institutions usa risk concentration sales wholesalers increased implementation medicare benefit also increases usa line pharmaceutical companies group pricing pressures groups products trends may adversely sells products small number wholesalers addition affect groups revenues margins sales usa hospitals pharmacies physicians groups sales regulatory controls three largest wholesalers amounted approximately group must comply broad range regulatory controls groups us pharmaceutical sales st december testing approval manufacturing marketing many group trade receivables due three wholesalers pharmaceutical consumer healthcare products particularly totalling million st december million usa countries european union affect group exposed concentration credit risk respect cost product development also time required reach wholesalers one affected financial market uncertainty successfully health authorities difficulty could materially adversely affect groups increased focus safety assessing benefit risk financial results balance drugs context initial product approval also context approval additional indications review reliance information technology information regarding marketed products stricter regulatory controls group increasingly dependent information technology also heighten risk changes product profile withdrawal systems including internetbased systems internal regulators basis postapproval concerns product communication well communication customers safety could reduce revenues result product recalls suppliers significant disruption systems whether due product liability lawsuits also greater regulatory scrutiny computer viruses outside incursions could materially especially usa advertising promotion particular adversely affect groups operations directtoconsumer advertising global political economic conditions addition cases group may voluntarily cease described many worlds largest economies marketing product face declining sales based concerns including major markets group operates efficacy safety example declines sales avandia financial institutions currently face extreme financial difficulty following publicity around questions regarding risks associated including decline asset prices liquidity problems limited product whether scientifically justified even availability credit uncertain long crisis last absence regulatory action development postapproval many countries concerned economies may enter adverse event profile product product class may deep prolonged recession major impact marketing sale productgsk annual report report directors risk factors continued decline economic activity may material adverse failure manage properly environmental risks could result effect groups sales results operations financial additional remedial costs could materially adversely affect condition ability raise capital groups groups operations see note financial statements legal businesses including consumer healthcare may particularly proceedings discussion environmentalrelated proceedings sensitive declines consumer spending addition group involved financial crisis may result lower return groups financial accounting standards investments may cause value groups investments new revised accounting standards rules interpretations pension plans decrease requiring group increase circulated time time international standard setting board funding pension plans could result changes recognition income expense group conducts substantial portion operations outside may adversely impact groups reported financial results uk groups management foreign exchange rates international standard changes market valuation certain discussed business review foreign exchange management financial instruments reflected groups reported results see fluctuations exchange rates sterling gains losses actually realised could currencies especially us dollar euro significant impact income statement given period japanese yen could materially affect groups financial results accounting deferred taxation intercompany inventory group control changes inflation interest may give rise volatility depending upon ownership rates foreign currency exchange rates controls inventory regulators regularly review financial statements economic factors affecting businesses possibility listed companies compliance accounting regulatory political unrest legal regulatory changes nationalisation requirements jurisdictions group operates group believes complies appropriate regulatory requirements concerning financial statements disclosures taxation however companies experienced investigations effective tax rate groups earnings benefits fact potential noncompliance accounting disclosure portion earnings taxed favourable rates requirements resulted restatements previously jurisdictions outside uk changes tax laws application reported results sometimes significant penalties respect matters transfer pricing foreign dividends controlled companies restriction tax relief allowed human resources interest intragroup debt could increase groups effective tax group approximately employees globally rate adversely affect financial results group open issues subject laws regulations concerning employees ranging revenue authorities usa japan canada discrimination harassment personal privacy labour matters discussed note financial statements taxation relations vary significantly jurisdiction jurisdiction group faces intense competition qualified individuals disruption pandemic influenza pharmaceutical biotechnology companies universities event pandemic influenza group could subject governmental entities research institutions failure disruption range factors national governments may continue recruit retain right people maintain willing abrogate intellectual property rights medicines culture compliance may significant adverse effect might otherwise short supply failure third party providers country afflicted pandemic flu would risk employees families affected consequence unaffiliated thirdparty suppliers provide number goods sales distribution manufacturing activities could services groups operations many services shut supply continuity active ingredients example services provided clinical research organizations support finished goods affected development key products important operations groups businesses materials provided thirdparty suppliers environmental liabilities necessary commercial production products including environmental laws various jurisdictions impose actual speciality chemicals commodities components necessary potential obligations group remediate contaminated sites manufacture fillfinish packaging many groups group also identified potentially responsible party pharmaceutical consumer health products group us comprehensive environmental response compensation believe thirdparty relationships individually liability act number sites remediation costs relating significant context overall group failure third groups use ownership sites party supplier fulfil contractual obligations timely manner may result delays service interruptions could constrain sales groups products gsk annual report report directors financial review accordance us sec disclosure requirements following sterling terms total pharmaceutical turnover decreased four discussion compares results year st december percentage points less cer principally due strength results year st december sterling us dollar group realigned regional reporting structure pharmaceutical turnover therapeutic area within pharmaceuticals business reallocated entities expenses pharmaceuticals consumer healthcare turnover line highvalue growth businesses comparative information products offset lower avandia sales us generic restated consistent basis see note financial competition coreg ir flonase wellbutrin xl zofran statements accounting principles policies highvalue growth products included seretideadvair vaccines lamictal valtrex requip avodart boniva exchange respiratory currencies influence groups results us continued global leader respiratory pharmaceuticals dollar euro japanese yen sales three key products seretideadvair flixotide us dollar fell pound flovent serevent amounting billion yearend yearend rates euro strengthened total sales seretideadvair asthma copd rose billion usa sales grew billion europe japanese yen sterling sales grew billion rest world markets sales world market pharmaceuticals grew million enhanced launch japan june global pharmaceutical sales billion compared billion cns cns sales decreased billion sales decreased world market value growth usa europe reflecting generic competition seroxatpaxil geographic region bn total regions rest world sales grew included usa growth paxil japan total seroxatpaxil sales declined europe million total wellbutrin sales declined rest world million owing us generic competition wellbutrin srir total wellbutrin xl mg tablet us market decreased still represents sales lamictal treatment epilepsy bipolar disorder global prescription pharmaceutical market compared grew billion driven sales usa decade ago million benefiting new indication th september gsk held second position world sales requip parkinsons disease restless legs pharmaceutical market market share behind pfizer syndrome rls grew million market share gsk four worlds top antivirals pharmaceutical products avandia lamictal seretide total sales hiv products billion advair valtrex competition older products combivir world market value growth million epivir million largely offset top six therapeutic classes bn total strong sales growth new products epzicomkivexa central nervous system grew million lexivaagenerase cardiovascular million alimentary tract metabolic sales valtrex herpes rose million us antineoplasticimmunomodulatory sales million driven increased use antiinfectives bacterial product prevention disease transmission sales europe viral fungal excluding grew million rest world grew vaccines million sales relenza antiviral treatment flu respiratory million million driven primarily oneoff government orders stockpiling possible flu pandemic note data based months th september pharmaceutical turnover metabolic total pharmaceutical turnover million sales avandia product group type diabetes compared million line declined billion usa sales fell turnover cer million fourth quarter sales milliongsk annual report report directors financial review continued pharmaceutical turnover therapeutic area restated total usa europe rest world therapeutic area growth growth growth growth major products total cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antivirals hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip cardiovascular urogenital avodart lovaza coreg fraxiparine arixtra vesicare levitra metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin altabax oncology emesis hycamtin zofran tykerb vaccines hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report report directors financial review continued followed publication article new england consumer healthcare turnover restated journal medicine article suggested may cardiovascular risk associated avandia despite gsks efforts growth doctors became reluctant start new patients avandia without total cer guidance fda following clarification overthecounter medicines fda october new approved label avandia panadol franchise outside usa sales europe grew million smoking cessation products tums rest world markets sales declined million cold sore franchise recorded turnover million share copromotion breathe right income bonivabonviva oncemonthly oral bisphosphonate alli treatment postmenopausal osteoporosis oral healthcare aquafresh franchise vaccines sensodyne franchise vaccine sales increased billion good dental care performances regions us sales rose million european sales grew million sales rest nutritional healthcare world million sales hepatitis vaccines lucozade grew million driven us growth horlicks ribena infanrixpediarix grew million driven us growth sales new twodose vaccine rotarix prevent rotavirus gastroenteritis doubled million cer represents growth constant exchange rates represents growth strong growth europe rest world sales cervarix actual exchange rates gsks vaccine prevent cervical cancer million oral healthcare oral healthcare sales grew billion sales cardiovascular urogenital aquafresh million helped success sales coreg heart disease fell million new aquafresh white trays sensodyne also grew strongly following introduction us generic competition coreg ir year million driven successful launch september sales coreg cr launched march sensodyne pronamel million avodart benign prostatic hyperplasia enlarged prostate continued perform strongly sales nutritional healthcare million nutritional healthcare product sales grew million lucozade grew million horlicks grew antibacterials million ribena sales million antibacterial sales declined million reflecting generic competition regions operating profit total results oncology emesis total results include restructuring costs related new tykerb achieved sales million first year million operational excellence programme commenced arose usa following launch march sales october zofran declined million reflecting generic competition usa europe rest world sales growth cer declined respectively turnover consumer healthcare sales cost sales selling general otc medicines administration overthecounter medicine sales grew billion research panadol million alli sales million development operating since launch usa june smoking control products income declined million due strong competition us market breathe right fiberchoice added portfolio operating profit acquisition cns december achieved combined sales milliongsk annual report report directors financial review continued cost sales total operating profit impact items million cost sales percentage turnover increased charge million charge percentage points constant exchange rates cost sales percentage turnover increased percentage points profit taxation total results reflecting charges related new operational excellence programme million nil unfavourable net finance costs product regional mixes compared finance income selling general administration interest income selling general administration sga costs percentage fair value adjustments hedges turnover reduced percentage points constant exchange rates decrease percentage points reflecting flat expenditure compared prior year turnover growth finance costs sga costs included charges related new operational interest costs excellence programme million nil advertising unwinding discount liabilities promotion increased selling distribution increased fair value adjustments hedges general administration expenditure declined research development finance costs increased owing increased levels debt rd expenditure declined included charges related finance share buyback programme new operational excellence programme million nil benefit arose lower impairment charges share tax profits associates windingdown previous restructuring activities excluding joint ventures items rd expenditure declined last year pharmaceutical share profits associates arises principally groups rd expenditure represented holding quest diagnostics inc pharmaceutical turnover profit taxation total results operating income taking account net finance costs contribution operating income includes royalty income equity associates total profit taxation million investment disposals impairments product disposals compared million increase fair value adjustments financial instruments operating constant exchange rates sterling decline income million million increase primarily due higher royalty income million major restructuring programmes compared million favourable fair october gsk announced significant new billion value movements financial instruments million operational excellence programme improve effectiveness compared million roche litigation productivity operations settlement relating carvedilol partially offset lower asset disposal profits expansion programme announced february programme expected deliver annual pretax operating profit total results savings billion oneoff charges million overall operating profit margin decreased percentage tax relating programme recorded q points operating profit decreased sterling terms significant acquisitionrelated restructuring costs million operating profit increased constant incurred exchange rates cer margin increased percentage extent cost operational excellence points reflecting flat sga expenditure higher programme columnar presentation adopted operating income partially offset increase cost sales income statement analysis operating profit gains asset disposals million subsequent discussion excludes restructuring costs related million costs legal matters million new operational excellence programme management million fair value movements financial believes presentation assists shareholders gaining instruments resulted income million income clearer understanding groups financial performance million charges related old restructuring activity consistent way management assesses groups million million charges related financial performance new operational excellence programme million nil gsk annual report report directors financial review continued operating profit results operating profit results major restructuring major restructuring overall operating profit margin increased percentage points operating profit increased sterling terms growth million operating profit increased constant cer exchange rates margin increased percentage points turnover reflecting declines sga rd expenditure turnover cost sales growth higher operating income selling general gains asset disposals million administration million costs legal matters million research million fair value movements financial instruments development resulted income million million operating charges related old restructuring activity million income million operating profit impact items operating profit million charge million cost sales profit taxation results cost sales percentage turnover increased major restructuring percentage points constant exchange rates cost sales percentage turnover increased percentage points net finance costs reflecting unfavourable product regional mix finance income selling general administration interest income selling general administration sga costs percentage fair value adjustments hedges turnover reduced percentage points constant exchange rates decrease percentage points reflecting decline expenditure compared prior year finance costs turnover growth sga costs due lower selling general administration expenditure partly offset interest costs higher advertising promotion advertising promotion unwinding discount liabilities increased accounted less increase fair value adjustments hedges total sga selling distribution declined general administration expenditure declined collectively items accounted decline total sga one profit taxation results major restructuring percentage point due lower charges related legal matters taking account net finance costs contribution associates results major restructuring profit taxation research development million compared million rd expenditure decreased partly result lower increase cer flat sterling terms impairment charges windingdown previous restructuring activities excluding items rd expenditure taxation flat pharmaceutical rd expenditure represented pharmaceutical turnover uk corporation tax operating income overseas taxation operating income million million increase primarily due higher royalty current taxation income million compared million deferred taxation favourable fair value movements financial instruments taxation total profits million compared million roche litigation settlement relating carvedilol partially charge taxation total profit amounting offset lower asset disposal profits million represents effective tax rate charge taxation results major restructuring profit amounting million represents effective tax rate gsk annual report report directors financial review continued group balance sheet st december included tax results major restructuring profit year payable liability million tax recoverable asset million increase sterling terms million profit attributable minority interests million profit attributable shareholders million increase integrated nature groups worldwide operations sterling terms interest cost share buyback involving significant investment research strategic programme adversely impacts groups profits benefits manufacture limited number locations consequential eps results major restructuring eps increased crossborder supply routes numerous endmarkets gives rise reflecting higher profits also reduction weighted complexity delay negotiations revenue authorities average number shares resulting groups share profits individual group companies liable buyback programme actual rates exchange earnings per tax disagreements revenue authorities share increased unfavourable currency impact eps intragroup transactions particular price goods six percentage points reflected strengthening sterling transferred group companies different us dollar compared four percentage point tax jurisdictions produce conflicting claims revenue unfavourable currency impact turnover authorities profits taxed individual territories resolution issues continuing fact life gsk dividend main open tax issues uk usa canada board declared fourth interim dividend pence per japan share resulting dividend year pence five pence increase dividend pence per share latest position taxation see taxation financial review profit year growth cer total profit taxation year total profit attributable shareholders basic earnings per share pence p p basic earnings per ads us results major restructuring profit taxation year results major restructuring profit attributable shareholders adjusted earnings per share pence p p adjusted earnings per ads us weighted average number shares millions diluted total earnings per share pence p p diluted total earnings per ads us weighted average number shares millions total results including restructuring costs related new operational excellence programme produced basic eps p compared p increase cer terms compared decline sterling terms gsk annual report report directors board sir christopher gent aged dr stephanie burns aged appointed st june chairman sir christopher appointed th february nonexecutive director chief executive officer vodafone group plc retirement dr burns chairman president chief executive officer july nonexecutive director lehman brothers dow corning corporation also member american holdings inc nonexecutive director ferrari spa member chemical society sits executive committee kpmgs chairmans advisory group senior adviser bain society chemical industry america section serves board co member advisory board reform directors american chemistry council board directors society womens health research dr burns andrew witty aged holds phd organic chemistry iowa state university appointed st january chief executive officer mr witty named chief executive officer designate gsk lawrence culp aged october appointed chief executive officer ceo appointed st july nonexecutive director st may joined group held senior mr culp president chief executive officer danaher positions asia africa usa immediately prior corporation prior joining danaher held positions appointed ceo andrew president pharmaceuticals europe accenture previously andersen consulting position held january member business sir crispin davis aged council britain board member phrma vicepresident appointed st july nonexecutive director efpia member singapore economic development sir crispin chief executive officer reed elsevier plc prior boards international advisory council chief executive aegis group plc joined professor sir roy anderson aged guinness plc member main board appointed st october nonexecutive director group managing director united distillers spent early professor anderson professor infectious disease epidemiology career procter gamble faculty medicine imperial college london rector julian heslop aged imperial college fellow royal society foreign appointed st april chief financial officer associate member institute medicine us national mr heslop joined glaxo wellcome financial controller april academy sciences september professor anderson january appointed senior vice president chief scientific adviser ministry defence uk operations controller prior joining group held senior finance roles grand metropolitangsk annual report report directors sir deryck maughan aged dr moncef slaoui aged appointed st june nonexecutive director appointed th may chairman research sir deryck partner kohlberg kravis roberts co development dr slaoui joined gsk biologicals nonexecutive director thomson reuters blackrock engineered development robust vaccines pipeline inc formerly chairman chief executive officer subsequently led worldwide business development citigroup international salomon brothers inc pharmaceuticals appointment lead rd member board agency science technology dr daniel podolsky aged research astar phd molecular biology appointed st july nonexecutive director immunology universit libre de bruxelles dr podolsky president university texas southwestern medical center dallas holds phillip obryan montgomery jr md tom de swaan aged distinguished presidential chair academic administration appointed st january nonexecutive director doris bryan wildenthal distinguished chair medical science mr de swaan member board directors zurich financial member board southwest medical foundation services vice chairman supervisory board chairman also chairman board scientific cofounder audit committee royal ahold member supervisory gi company board royal dsm chairman supervisory board vanlanschot bankiers january member sir ian prosser aged managing board chief financial officer abn amro appointed rd may senior independent director sir ian formerly nonexecutive director smithkline beecham sir robert wilson aged plc nonexecutive deputy chairman bp plc chairman appointed st november nonexecutive director navy army air force institutes naafi nonexecutive sir robert nonexecutive chairman bg group plc director sara lee corporation member cbi economist group previously executive chairman rio tinto presidents committee james murdoch aged dr ronaldo schmitz aged join board th may nonexecutive director appointed rd may nonexecutive director mr murdoch chairman chief executive news corporation dr schmitz formerly nonexecutive director glaxo wellcome europe asia also nonexecutive chairman bskyb plc nonexecutive director legal general group plc member board news corporation served member board directors rohm haas company chief executive officer bskyb also cabot corporation supervisory board sick ag previously chairman chief executive officer star tv also serves leadership council climate group directors dr jeanpierre garnier formerly chief executive officer retired board st may mr christopher viehbacher formerly details membership board committees may found president north american pharmaceuticals appointed board st january resigned board effect th september gsk annual report report directors corporate executive team cet andrew witty eddie gray chief executive officer andrew succeeded jp garnier chief president pharmaceuticals europe eddie became responsible executive officer may joined glaxo uk groups operations europe january joined career company held roles managing beecham prior current appointment senior director south africa vice president general manager vice president general manager pharmaceuticals uk marketing us senior vice president asia pacific julian heslop appointed president pharmaceuticals europe chief financial officer julian became chief financial officer glaxosmithkline january april head finance function responsible simon bicknell activities financial reporting control tax treasury senior vice president company secretary compliance finance systems internal audit insurance joined glaxo officer simon ensures compliance risk management wellcome financial controller april effectively embedded within business oversees corporate abbas hussain governance group simon joined corporate secretariat president emerging markets abbas joined gsk june appointed deputy company secretary glaxo eli lilly company spent years overseeing wellcome company secretary glaxosmithkline plc markets throughout europe africamiddle east australasia duncan learmouth john clarke senior vice president corporate communications president consumer healthcare john responsible community partnerships duncan responsible groups consumer healthcare business produces oral healthcare investor relations internal external communications image overthecounter nutritional healthcare products joined partnerships communities joined glaxo beecham president futures group vice president global investor relations appointment current appointment january current position july deirdre connelly bill louv president north american pharmaceuticals deirdre joined gsk chief information officer bill appointed chief information february working eli lilly company years officer january responsible information held variety positions including sales professional general technology across gsk bill joined glaxo vice president manager puerto rico executive director human resources medical data sciences prior current role bill senior vice recently president us operations president rd information technology marc dunoyer president pharmaceuticals asia pacificjapan marc appointed president pharmaceuticals asia pacificjapan may joined group president pharmaceuticals japan january current appointmentgsk annual report report directors dan phelan jean stphenne chief staff dan responsible corporate strategy president general manager biologicals jean led development hr real estate facilities environmental gsks global vaccines business since previously vice health safety global security joined smith kline president human vaccines research development french previously held role senior vice production joined company head bacterial president human resources appointment chief viral vaccines production jean named baron king albert ii staff may belgians recognition leading contribution rd industry belgium david pulman president global manufacturing supply david claire thomas responsible global manufacturing supply organisation senior vice president human resources claire leads global global procurement joined glaxo broad human resources hr function previously oversaw hr experience manufacturing operations previously led pharmaceuticals international pharmaceuticals europe claire primary supply european manufacturing north american joined company appointed director human manufacturing global logistics manufacturing strategy resources uk pharmaceuticals claire honoured organisations outstanding european woman achievement david redfern dan troy chief strategy officer david responsible proactive senior vice president general counsel dan joined gsk exploration new business opportunities strategic planning senior vice president general counsel september began career gsk corporate development previously partner washington law firm sidley appointed finance director europe pharmaceuticals austin llp chief counsel fda served appointed area director central europe primary liaison white house us department northern europe health human services hhs moncef slaoui members chairman research development moncef leads groups bob ingram continues act special consultant group drug discovery development activities joined group attends cet meetings capacity key player building gsks vaccines pipeline changes cet appointed senior vice president worldwide business jp garnier chief executive officer retired gsk may development current appointment june rupert bondy senior vice president general counsel left gsk march russell greig president pharmaceuticals international left cet may new role president gsk venture fund chris viehbacher president us pharmaceuticals left gsk december gsk annual report report directors corporate governance continued governance policy chairman ceo sir christopher gent chaired company since st january section discusses gsks management structures governance chairman throughout mr witty chief procedures includes disclosures compliance combined executive officer ceo succeeded dr garnier retired code corporate governance financial reporting council board end agm st may combined code us laws regulation mr wittys biographical details found board corporate executive team chairman leads board represents board directors listed board ceo cet members necessary board meetings ceo manages group implements board responsible groups system corporate strategy policies adopted board chairman governance ultimately accountable groups activities chairmen board committees communicate regularly strategy financial performance ceo cet members division responsibilities independence role chairman ceo set board considers nonexecutive directors writing agreed board appears full independent character judgement companys website dr schmitz served board ten years ceo responsible executive management group appointed board glaxo wellcome plc assisted cet cet meets least times per year st january consideration annual review otherwise necessary members responsibilities board effectiveness meeting january board listed corporate executive team concluded dr schmitz remained independent notwithstanding senior independent director length service opinion board dr schmitz sir ian prosser appointed senior independent director sid continued demonstrate characteristics independence st january held role throughout sir objectively challenging management taking part rigorous robert wilson become sid following sir ians retirement debate time possessing outstanding knowledge board may companys business affairs together experience gained chairman audit committee long cycle board process investment business gsk considered particularly board authority accountable shareholders important experienced members board ensuring company appropriately managed achieves strategic objectives sets board discharges sir christopher gent appointed board deputy responsibilities annual programme meetings chairman determined board independent includes approval overall budgetary planning business upon taking chairmanship board st january strategy board reviews companys internal controls accordance combined code excluded risk management policies approves governance structure determination whether least half board code ethics independent nonexecutive directors sir christopher gent member remuneration committee permitted board appraises approves major financing investment combined code light independence upon appointment licensing decisions excess defined thresholds addition chairman board evaluates monitors performance group whole includes board considers professor sir roy anderson dr burns mr culp sir crispin davis sir deryck maughan dr podolsky sir ian prosser engaging board meetings ceo executive dr schmitz mr de swaan sir robert wilson independent directors members cet appropriate accordance recommendations combined code financial operating performance gsk external issues material groups prospects mr james murdoch join board effect th may evaluating progress towards achievement groups board determined independent non financial business objectives annual plans executive director accordance combined code monitoring reports received directly various sir ian prosser dr schmitz retire board following committees significant risks facing group agm may date publication throughout majority board members excluding chairman independent non executive directorsgsk annual report report directors corporate governance continued board overall responsibility succession planning indemnification directors ceo executive directors board given ceo qualifying third party indemnity provisions defined section broad authority operate business group ceo companies act force benefit accountable reports board performance directors former directors held office business cet members make regular presentations board directors conflicts interest areas responsibility board meets cet directors duty avoid situation members annual basis discuss collectively groups strategy direct indirect conflict interest possible conflict primary element induction process new nonexecutive interest company duty applies particular directors undertaken members cet non exploitation property information opportunity whether executive directors encouraged separate informal gsk could take advantage companys articles discussions discretion cet members association include general power board authorise conflicts breach duty relevant matter board met six times member attending authorised advance follows board established procedures handling situational number meetings held whilst board number conflicts interest line best practice name member meetings attended guidance issued general counsel group sir christopher gent accordance companys articles authorised mr witty nominations committee grant review periodically mr j heslop event annually potential actual conflict authorisations dr slaoui directors counted quorum authorisation professor sir roy anderson actual potential conflicts company secretary minutes consideration conflict authorisations granted dr burns recorded company secretary register conflict mr l culp authorisations noted board next meeting sir crispin davis ongoing basis directors responsible informing sir deryck maughan company secretary new actual potential conflicts dr podolsky may arise changes circumstances sir ian prosser may affect authorisation previously given even provided dr r schmitz authorisation director absolved duty mr de swaan promote success company actual conflict arises sir robert wilson post authorisation board choose exclude director dr jp garnier relevant information debate suspend director mr c viehbacher board last resort require director resign mr witty mr viehbacher appointed board st company secretary january dr garnier retired board st may company secretary responsible board mr viehbacher resigned board th september available individual directors respect board procedures company secretary mr simon bicknell appointed addition six scheduled meetings board also met may barrister joined group quorate basis six occasions secretary board committees except remuneration business environment development committee deputy company secretary mrs victoria whyte ensure board kept uptodate important matters appointed secretary remuneration committee including legal governance regulatory developments presentations effect th january solicitor fellow made regular basis external internal advisers institute chartered secretaries administrators independent advice board committees board recognises may occasions one board established number committees provides directors feel necessary take independent legal sufficient resources enable undertake duties andor financial advice companys expense executive directors members audit remuneration agreed procedure enable explained nominations corporate responsibility committees although governance section companys website may invited attend meetings director member corporate administration transactions finance committees gsk annual report report directors corporate governance continued corporate governance framework board chairman executive directors independent nonexecutive directors audit committee remuneration committee corporate responsibility chief executive independent independent nonexecutive independent nonexecutive officer nonexecutive directors directors chairman directors chairman nominations committee corporate administration finance committee independent nonexecutive transactions committee cet directors directors chairman directors cet members key board committees management committee current membership committees shown table corporate audit remuneration nominations responsibility sir christopher gent c c professor sir roy anderson dr burns mr l culp sir crispin davis sir deryck maughan dr podolsky sir ian prosser dr r schmitz mr de swaan c sir robert wilson c key c chairman membergsk annual report report directors corporate governance continued committee written terms reference approved board following summary role terms reference committee current full terms reference committee may obtained company secretary governance section companys website meetings committee report committee role terms reference membership comprises per year audit reviews financial internal reporting process independent non system internal controls management executive directors risks external internal audit process committee also proposes shareholders appointment external auditors directly responsible remuneration oversight work remuneration determines terms service remuneration independent non executive directors members cet executive directors assistance external independent advisers chairman evaluates makes recommendations board overall executive remuneration policy chairman ceo responsible evaluating making recommendations board remuneration nonexecutive directors nominations reviews structure size composition independent non board appointment members board executive directors cet makes recommendations chairman board appropriate committee also monitors planning succession board senior management corporate provides boardlevel forum regular review independent non responsibility external issues potential serious executive directors impact upon groups business reputation chairman committee also responsible oversight gsks worldwide donations community support finance reviews approves behalf board executive non necessary annual report form f convening executive directors agm together preliminary quarterly statements trading results also approves certain major licensing capital transactions changes groups investment instrument counterparty limits corporate reviews approves matters connection executive non necessary administration administration groups business executive directors transactions certain corporate transactions cet members company secretary gsk annual report report directors corporate governance continued evaluation board board committees agm takes place london formal notification sent directors shareholders least one month advance meeting previous years evaluation performance business presentation made shareholders directors able chairman board committees directors attend available formally agm informally undertaken sid collaboration committee afterwards questions committee chairmen ordinarily attend chairmen board engaged dr long boardroom agm respond shareholders questions entire board review act independent facilitator board attendance companys agm may resolutions evaluation process agm decided poll required companys articles association results poll announced london process included tailored questionnaire onetoone stock exchange posted companys website details interview director company secretary agm set section annual general meeting observation board committee meetings held see notice agm published december review associated papers questions companys website covered variety aspects associated board effectiveness including board committee roles responsibilities culture ensure nonexecutive directors aware dynamics processes support individual effectiveness understand views major shareholders company feedback review provided form written board place process focusing sectorspecific issues report presentation board discussed well general shareholder preferences findings ceo cfo maintain dialogue institutional review concluded chairman board shareholders performance plans objectives committees operating effectively high level programme regular meetings following appointment board agreed following actions generate inclusive ceo may andrew witty undertaken extensive engagement executive management team series meetings gsks institutional shareholders improve collective decision making process groups investor relations department offices london identify utilise time spent board committee philadelphia acts focal point contact investors meetings effectively facilitate contribution throughout year nonexecutive directors broader range issues chairman meets regularly institutional investors seek enhance nonexecutive directors continuing hear views discuss issues mutual importance education process beyond initial induction communicates views investors board whole sid also available shareholders provide greater visibility board gsks executive talent management succession planning process chairman remuneration committee meets annually major shareholders discuss executive remuneration policy board members also met separately without chairman present discuss chairmans performance nonexecutive directors including new appointees contribution agreed meeting chairman available meet major shareholders requested performing well unanimous unequivocal companys website provides access current financial support directors executive nonexecutive business information group dialogue shareholders share capital control financial results announced quarterly details companys authorised issued share capital company reports formally shareholders twice year number shares held treasury st december halfyear fullyear results announced fullyear found note financial statements share results included companys annual report capital share premium account gsks shares listed published shareholders company produces london stock exchange also quoted new york annual summary sent shareholders advise stock exchange nyse form american depositary shares availability annual report notice meeting ads ads represents two ordinary shares wwwgskcom ceo cfo give presentations fullyear results institutional investors analysts media normally webcast teleconferences release first second third quarter results institutional investors analysts media annual report summary quarterly results available companys websitegsk annual report report directors corporate governance continued holders ordinary shares entitled receive dividends bank new york mellon depositary companys declared companys reports accounts attend ads listed new york stock exchange ordinary speak general meetings company appoint proxies shares representing companys adr program exercise voting rights managed depositary registered name bny nominees limited details number ordinary shares held restrictions transfer limitations holding depositary found ordinary shares requirements obtain prior approval transfers ordinary shares carry special rights company acquired disposed interests regard control company restrictions shares connection companys share voting rights major shareholders voting rights per buyback programme details shares purchased cancelled share shareholders known arrangements held treasury disclosed note financial financial rights held person statements share capital share premium account holder shares known agreements restrictions directors officers share transfers voting rights interests directors officers connected shares acquired gsk share schemes plans rank persons issued share capital company given equally shares issue special rights remuneration report pages trustees companys employee share ownership plan rules appointment replacement directors esop trusts waived rights dividends shares held contained companys articles association companys esop trusts articles must approved shareholders accordance change control essential contracts legislation force time time company contracts arrangements articles provide directors may appointed individually essential businesses party ordinary resolution members resolution significant agreements would take effect alter directors provided latter instance director appointed terminate upon change control following takeover bid way retires first agm following appointment company agreements director articles also provide directors subject officer would provide compensation loss office reelection agm intervals three years employment resulting takeover except provisions held office continuous period nine years companys share plans may cause options awards granted companys members may remove director passing ordinary plans vest takeover resolution special notice given director may interests voting rights automatically cease director stated far company aware becomes bankrupt compounds creditors generally persons significant direct indirect holdings company information provided company pursuant ceases director virtue companies acts financial services authoritys fsa disclosure transparency articles rules dtrs published regulatory information service suffering mental ill health companys website missed directors meetings continuous period six th february company received notifications months without permission board resolves shall accordance fsas dtrs following notifiable cease director interests voting rights companys issued share capital prohibited director law percentage issued shares capital resigns barclays plc offers resign board accept offer p ercentage ordinary shares issue excluding treasury shares th february directors least three number require resign gsk annual report report directors corporate governance continued memorandum articles association definitions political donations political expenditure powers directors determined uk legislation political organisations used legislation wide companys memorandum articles association particular definition eu political organisations may extend available gsks website articles may amended bodies concerned policy review law reform special resolution members directors may exercise representation business community special interest companys powers provided articles applicable groups concerned environment legislation stipulate powers must exercised company subsidiaries might wish support result members directors authorised issue definitions may cover legitimate business activities allot ordinary shares article company ordinary sense considered political donations political authorised make purchases shares article expenditure activities designed support powers articles subject shareholder political party independent election candidate authority authorities sought annual basis agm board sought annually precautionary measure shares purchased company may cancelled held ensure company subsidiaries inadvertently treasury shares breach legislation share buyback programme effect st january ensure consistent billion programme share repurchases commenced approach political contributions across gsk group july shares costing billion repurchased gsk introduced global policy stop voluntarily programme company expect make political contributions significant repurchases programme covered purchases company shares cancellation held political donations treasury shares accordance authority renewed eu political organisations shareholders companys agm noneu political organisations may company authorised purchase comprising maximum million shares details shares purchased usa held treasury shares cancelled disclosed canada note financial statements share capital share premium account total company purchased billion shares since st january prior introduction groups new approach political contributions usa largest recipient political exact amount timing future purchases extent donations line us law corporate donations repurchased shares held treasury shares rather made federal level candidates political cancelled determined company parties state local levels gsk supported dependent market conditions factors candidates sought environment appropriately donations eu political organisations eu rewarded highrisk highinvestment industries political expenditure situation similar canada rest world agm may shareholders first authorised donations rare low value company make donations eu political organisations incur eu political expenditure provisions political notwithstanding new policy company continues parties elections referendums act support gsk political action committee pac employees year authority since renewed annually law usa gives political donations pac employee requires companies continue obtain shareholder approval organisation allows employees contribute fund make donations eu political organisations political donations employees decide upon recipients incur eu political expenditure however company pac donations total make intend make donations political parties donated political organisations gsk pac independent election candidates make donations eu political organisations incur eu political expendituregsk annual report report directors corporate governance continued annual general meeting shareholders entitled appoint one proxies attend agm held pm wednesday th may agm speak vote behalf queen elizabeth ii conference centre broad sanctuary details appoint appointed corporate westminster london swp ee business transacted representative proxy found notice meeting include agm published companys website receiving adopting glaxosmithklines internal control framework annual report board recognises responsibility present balanced approving remuneration report understandable assessment groups position prospects remuneration report pages sets board accountability reviewing approving remuneration policies operated glaxosmithkline adequacy effectiveness internal controls operated disclosures directors remuneration including required group including financial operational compliance controls companies act directors remuneration risk management board delegated responsibility report regulations resolution proposed review audit committee receives reports approve remuneration report individuals identified committees report pages retirement election reelection directors responsibility management mr larry culp sir crispin davis dr moncef slaoui mr tom cet implement board policies risk control cet de swaan retire offer reelection responsible identifying approving monitoring enforcing board article companys articles key policies go heart group conducts association business internal control framework includes central direction resource allocation risk management key activities sir ian prosser dr ronaldo schmitz also retiring research development manufacturing marketing sales rotation seeking reappointment legal human resources information systems financial practice retiring board conclusion agm part framework comprehensive planning mr james murdoch appointed director effect system annual budget approved board results th may offer election operating units reported monthly compared board budget forecasts prepared regularly year reappointment remuneration auditors extensive financial controls procedures risk activities resolutions proposed reappoint reviewed groups internal auditors commercial pricewaterhousecoopers llp auditors authorise financial responsibility however clearly delegated local audit committee determine remuneration business units supported regional management structure special business principles designed provide environment company seek authority central leadership coupled local operating autonomy framework exercise accountability control within make donations eu political organisations incur eu group political expenditure capped group also attaches importance clear principles allot ordinary shares company procedures designed achieve appropriate accountability give directors authority disapply preemption rights control group policy risk management legal compliance allotting new shares connection rights issues mandates business units establish processes managing otherwise maximum current issued share monitoring risks significant businesses group capital purchase ordinary shares maximum internal control framework also relies following current issued share capital overseeing reporting risk compliance issues exempt auditors state name senior statutory auditor company gsks annual report reduce notice required call general meeting less clear days adopt new performance share share option deferred annual bonus plans gsk annual report report directors corporate governance continued risk oversight compliance council rocc cec managed corporate compliance officer rocc council senior executives authorised board reports directly ceo corporate compliance officer assist audit committee oversee risk management chairs rocc provides summary reports roccs internal control activities group membership comprises activities groups significant risks cet audit several cet members heads departments committee regular basis corporate compliance officers internal control risk management assurance audit direct reporting line audit committee provides mechanism compliance responsibilities bypassing executive management need ever arise rocc meets regular basis review assess significant risks mitigation plans provide oversight internal areas potentially significant risk controls ensure compliance applicable laws regulations details risks affecting group see risk factors internal gsk policies rocc responding group pages note financial statements policy referred provided business units legal proceedings framework risk management upward reporting effectiveness controls significant risks mitigation planning identification internal control framework operation manager overall responsibility management given whole year review continues operate risk requirement date approval report system internal controls risk management compliance boards rmcbs designed manage rather eliminate risk achieving risk management compliance boards rmcbs business objectives provide reasonable established major business units membership often absolute assurance material misstatement loss comprises members senior executive team respective audit committee receives reports areas significant business unit augmented specialists appropriate risk group related internal controls following rmcbs oversee management risks considered consideration reports audit committee reports important respective business units including risks annually board effectiveness controls designated significant glaxosmithkline whole controls may mitigate eliminate risks addition thus increasing number risks actively managed areas groups business necessary across group take risks achieve satisfactory return shareholders rmcb regularly reports status regarding significant investment rd acquiring new products businesses risks rocc cases groups objective apply expertise compliance functions prudent management rather elimination risk number risk areas specific standards meet directors review relates company subsidiaries exceed requirements applicable law established extend material associated undertakings joint specialist audit compliance functions example corporate ventures investments environment health safety audit global manufacturing board audit committee reviewed supply audit risk management research assessment risks internal control framework development global quality compliance assist operates glaxosmithkline considered effectiveness dissemination implementation audit standards system internal control operation group audit functions coordinated corporate assurance group year covered report date approval reporting corporate compliance officer board process followed board reviewing corporate ethics compliance cec system internal controls accords guidance internal rocc also supported corporate ethics compliance control issued turnbull committee department responsible supporting development implementation practices facilitate employees compliance laws group policy thrust groups compliance effort due diligence preventing detecting misconduct noncompliance law regulation promoting ethical behaviour compliance laws regulations corporate responsibility levels effective compliance systemsgsk annual report report directors corporate governance continued committee reports financial accounting experience board committees report regularly board mr tom de swaan chief financial officer abn amro performance activities assigned st december audit committee report etermined board audit committee financial expert defined attendance meetings sarbanes oxley act sarbanesoxley full quorate sir deryck maughan partner kohlberg kravis roberts co members committee member since meetings meetings kkr chairman kkr japan mr tom de swaan st january f ormer chairman ceo citigroup chairman international vice chairman st september citigroup inc sir deryck maughan st january former chairman cochief executive dr daniel podolsky st january officer salomon smith barney sir ian prosser th december former chairman chief executive officer salomon brothers inc dr ronaldo schmitz th december sir robert wilson th december sir ian prosser former cfo subsequently ceo bass plc chartered accountant attendees committee meetings dr ronaldo schmitz former member glaxo wellcome plcs ceo audit committee cfo former member executive board chairman directors deutsche bank ag general counsel former head investment banking head global internal audit deutsche bank company secretary corporate compliance officer external auditors former member executive board directors basf cfo committees main responsibilities include basf reviewing corporate accounting financial reporting process former chairman committee monitoring integrity financial statements april september evaluating system internal control management risks mba insead overseeing activities groups compliance audit functions overseeing compliance laws regulations sir robert wilson economist ethical codes practice chairman bg group plc r etired rio tinto held committees oversight role requires address regularly senior management positions culminating relationships management internal external appointment executive chairman auditors understand monitor reporting relationships tiers accountability scientific expertise committee receives regular reports members cet dr daniel podolsky world renowned researcher advanced senior managers covering key compliance activities knowledge underlying mechanisms disease group including concerning rd manufacturing sales new therapies gastrointestinal disorders marketing environment health safety president university texas qualifications audit committee members southwestern medical centre committee members exception dr podolsky f ormer mallinkrodt professor medicine bring considerable financial accounting experience chief gastroenterology committees work members past employment experience massachusetts general hospital harvard either finance accounting roles comparable experience medical school corporate activities dr podolskys background world renowned researcher enables bring scientific expertise committees deliberations gsk annual report report directors corporate governance continued committee worked structured programme audit committee management internal auditors activities standing items committee required full board work together ensure quality companys consider meeting together matters focused corporate accounting financial reporting committee coincide key events annual financial reporting cycle serves primary link board external internal auditors facilitates necessary independence external auditors r eported critical accounting management encourages external internal auditors policies significant judgements communicate freely regularly committee practices used group alternative committee met collectively separately accounting treatments external auditors head global internal audit discussed management corporate compliance officer without members management resultant conclusion material written present communications management committee primary responsibility making restrictions access information recommendation shareholders appointment cfo reported financial performance reappointment removal external auditors annually company technical financial assessing qualifications expertise resources independence accounting matters external auditors effectiveness audit process general counsel reported material litigation making assessment committee considers papers detail relevant regulatory requirements relating external company secretary reported corporate governance auditors evaluates reports external auditors corporate activities undertaken rocc compliance requirements external auditors compliance officer provide nonaudit services committee ensures auditor heads majority heads groups objectivity independence safeguarded policy requiring groups compliance reported audit scope annual preapproval committee services services audit groups coverage audit resources may include audit services auditrelated services tax services results audits conducted throughout services preapproval detailed particular service year categories services subject specific budget company secretary reported matters affected external auditors management report regularly chairman quality timely disclosure financial committee regarding extent services provided accordance disclosure material information preapproval fees services performed committee board public markets committee may also preapprove additional services shareholders enabled committee casebycase basis expenditure audit nonaudit services review clarity completeness set note financial statements operating profit disclosures published guidelines set companys policy engaging annual financial statements interim external auditors provide nonaudit services include ascertaining reports quarterly preliminary results skills experience external auditors make announcements formal suitable supplier nonaudit services adequate safeguards announcements relating financial place objectivity independence audit performance prior release compromised fee levels relative annual board audit fee within limits set committee company also wellestablished policies including code ethics available website helpline facility reporting investigation unlawful conduct waivers code made gsk annual report report directors corporate governance continued nominations committee report appointing new executive directors cet members committee considers skills knowledge experience attendance required particular executive position committee meetings consider potential external internal candidates recommending board approve new appointment full members committee member since meetings new directors offer election companys next agm appointments announced publicly sir christopher gent th december chairman committee recommended appointment mr larry culp st january sir robert wilson nominations committee march mr larry culp th march committee also recommended board appointment sir ian prosser th december mr james murdoch nonexecutive director member committee chairman corporate responsibility committee effect th may februarydecember additionally committees recommendation board dr ronaldo schmitz th may approved following changes take effect sir ian prosser sir robert wilson th march dr schmitzs retirement board conclusion agm may sir robert wilson replace sir ian attendees committee meetings sid sir crispin davis replace sir robert chairman remuneration committee professor sir roy anderson become ceo member audit committee sir crispin sir deryck chief staff maughan become members nominations committee head hr company secretary remuneration report remuneration report found pages committees main responsibilities include proposing appointment board committee members corporate responsibility committee report committees main focus recruitment attendance new nonexecutive directors refresh board meetings recruiting nonexecutive directors committee considers full members committee member since meetings particular skills knowledge experience would benefit board significantly appointment sir christopher gent th december chairman broad selection criteria used focus achieving st january balance representation european uk us markets individuals ceo experience skills dr stephanie burns th december developed various sectors specialities dr daniel podolsky st july particular focus placed upon recruiting replacements sir ian prosser th may sir ian prosser dr ronaldo schmitz retire agm mr tom de swaan st july process continues committee placing emphasis candidates current ceos following appointment board effect government administration experience professional th may mr james murdoch also become member search agencies engaged specialising recruitment committee high calibre nonexecutive directors dossiers potential nonexecutive appointees provided committee attendees committee meetings may include candidates shortlisted interview considering ceo relevant qualifications general counsel customised induction process conducted new head corporate communications nonexecutive directors focusing particular experience communitypartnerships taking account different backgrounds process head corporate responsibility includes meeting members cet senior executives chief staff visiting particular operational facilities group head hr company secretary gsk annual report report directors corporate governance continued main responsibilities corporate responsibility nyse rules committee set committee rolling general nyse rules permit company follow uk corporate agenda receives reports members cet governance practices instead applied usa provided senior managers ensure progress meeting gsks company explains significant variations explanation corporate responsibility principles reviewed five principles contained companys form f filing accessed access medicines standards ethical conduct research securities exchange commissions sec edgar innovation employment practices global community database via companys website nyse rules came partnerships reviewed annually principles discussed effect require company file annual interim written least every two years committee also reviews affirmations concerning audit committee companys approves corporate responsibility report statement significant differences corporate governance year committee reviewed following areas sarbanesoxley act following number corporate accounting scandals usa access medicines developing countries congress passed sarbanesoxley act sarbanesoxley community partnerships investment wide ranging piece legislation concerned largely financial reporting corporate governance humanitarian donations recommended sec gsk established disclosure employee volunteering committee committee reports ceo cfo sales marketing practices audit committee chaired company secretary members consist senior managers finance legal disclosure funding medical education patient compliance corporate communications investor relations advocacy groups external legal counsel external auditors invited attend product safety communication clinical trial results meetings periodically responsibility considering rd diseases developing world materiality information timely basis determining disclosure information responsibility timely use animals research filing reports sec formal review annual globalisation externalisation rd report form f committee met times reduction employee numbers restructuring sarbanesoxley requires annual report contains statement whether member companys audit employee consultation requirements committee audit committee financial expert defined employment litigation usa sarbanesoxley summary regarding boards judgement gsks corporate responsibility report available matter refer additional disclosure requirements companys website arise section section sarbanesoxley respect disclosure controls procedures internal control combined code financial reporting throughout company complied provisions combined code except follows b designing schemes performancerelated remuneration remuneration committee follow provisions schedule code item schedule states general basic salary pensionable companys position explained remuneration report pages us law regulation number provisions us law regulation apply gsk companys shares quoted nyse form adsgsk annual report report directors corporate governance continued section corporate responsibility ceo cfo expect complete certifications report financial reports conclusions effectiveness disclosure controls sarbanesoxley also introduced requirement ceo procedures th march following certificates cfo complete formal certifications confirming filed sec part groups form f reviewed annual report form f section managements annual report internal control financial reporting based knowledge contains material misstatements accordance requirements section sarbanes omissions oxley following report provided management respect based knowledge financial statements companys internal control financial reporting financial information fairly present material respects financial defined rules af df us securities condition results operations cash flows dates exchange act periods presented annual report form f management responsible establishing maintaining responsible establishing maintaining disclosure adequate internal control financial reporting group controls procedures ensure material information internal control financial reporting designed provide made known evaluated effectiveness reasonable assurance regarding reliability financial controls procedures yearend results reporting preparation financial statements external evaluation contained annual report form f purposes accordance ifrs responsible establishing maintaining internal management conducted evaluation effectiveness control financial reporting provides reasonable internal control financial reporting based assurance regarding reliability financial reporting framework internal control integrated framework preparation financial statements external purposes issued committee sponsoring organisations accordance generally accepted accounting principles treadway commission disclosed annual report form f changes groups internal control changes internal controls financial reporting financial reporting materially affected period covered annual report form f reasonably likely affect materially groups internal materially affected reasonably likely affect materially control financial reporting companys internal control financial reporting management assessed effectiveness internal control disclosed based recent evaluation financial reporting st december internal control financial reporting external auditors conclusion filed part groups form f audit committee significant deficiencies material pricewaterhousecoopers llp audited consolidated weaknesses design operation internal control financial statements group year ended st financial reporting reasonably likely affect adversely december also assessed effectiveness companys ability record process summarise report groups internal control financial reporting auditing financial information fraud regardless materiality standard public company accounting oversight involving persons significant role companys board united states audit report filed internal control financial reporting groups form f group carried evaluation supervision participation groups management including ceo cfo effectiveness design operation groups disclosure controls procedures st december inherent limitations effectiveness system disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives gsk annual report report directors remuneration report dear shareholder managing balance quantum versus risk behalf board pleased present committees current economic crisis emphasised need ensure report remuneration seeking potential quantum stretch performance approval shareholders agm may targets implicitly encourage inappropriate behaviour background principles proposed changes satisfied proposed structure following appointment new chief executive officer also improves alignment uk investor expectations may remuneration committee decided review capping longterm incentive plans senior executive arrangements ensure remuneration reflecting perhaps problems banking sector several policy supports future direction business shareholders raised question whether current longterm incentive plans expire clawback mechanism problems arise years therefore reviewing year earlier necessary awards made effort address current economic climate well change propose continuity executive usbased ukbased chief executive officer provided responsibility initiation adverse event opportunity make fundamental changes gsks emergence problem adverse event taken remuneration policy proposed changes designed account assessing annual bonuses year problem strengthen alignment gsks remuneration arrangements identified means course intend views expressed investors particularly uk penalise executive misjudgements predecessor reflect better gsks uk home base far annual bonus concerned although consequences fundamental changes apply largely companys adverse event share price inevitably reduce ukbased executives including chief executive officer potential value longterm incentives chief financial officer rebalancing longterm incentives following sets key principles review new policy executives including chief highlights main changes proposed executive officer chief financial officer whose remuneration benchmarked primarily uk crossindustry comparator aligning pay relevant market group receive share option grants foreseeable remuneration ukbased members cet future instead longterm incentives focused including chief executive officer chief financial performance shares order remain competitive officer benchmarked primarily uk cross global pharmaceutical market certain executives including industry comparator group although obvious reasons chairman research development continue receive ignore intraindustry comparison remuneration share options although weighting overall package chairman research development well certain kept review roles continue benchmarked global pharmaceutical companies reflect market gsk annual bonus plan competes talent operate additional bonus flagged remuneration report integrate within existing far benchmarking chief executive officer role annual bonus structure maximum annual bonus opportunity concerned shift global pharmaceuticals uk cross remain salary reducing industry companies represents major change performance threshold annual plans reflecting significant impact structure quantum stretching annual bonus plan targets remuneration time least proposed remuneration package chief executive officer would well addition chief executive officer chief financial officer median pharmaceutical industry peers executives participate share option plan also opportunity invest half annual bonus gsk shares matched subject relative total shareholder return performance three yearsgsk annual report report directors remuneration report continued aligning performance measures strategy performance conditions performance share plan broadened cet incentivised range measures intended broadly half award continue based relative total shareholder return global pharmaceutical companies remaining half based additional measure measures support gsks strategy coming years awards made award remain relative total shareholder return global pharmaceutical companies remaining targeted generating cash investment andor return shareholders accordingly awards subject achievement adjusted free cash flow targets committee may make adjustments acquisitions divestments currency movements distortions may arise subject shareholder approval performance share awards made following agm may satisfy concerns transparency disclose adjusted free cash flow targets performance share awards announcement london stock exchange time award made reflecting longterm nature pharmaceutical industry reflect better longterm nature pharmaceutical industry performance period performance shares granted members cet extended half total shareholder return element award measured three years half four years performance period share options granted cet members similarly extended addition support emphasis longterm decision making timeframes vesting awards retirement redundancy extended maturity rather vesting year departure time committee would like see range long term performance measures fully reflect companys strategic direction eg turnover growth rd productivity however introducing metrics committee wants satisfied measures robust capable creating unintended behaviour committee believes new policy represents significant step forward supporting future direction business best interests shareholders sir robert wilson chairman remuneration committee rd march gsk annual report report directors remuneration report continued directors remuneration report prepared course committees principal focus accordance directors remuneration report review appropriateness gsks current remuneration regulations regulations meets relevant policy light appointment new ceo changes requirements fsa listing rules accordance management team gsks new strategy led regulations following sections remuneration development policy appropriately support report subject audit annual remuneration non business going forward including design new longterm executive directors remuneration share options incentive incentive lti plans replace existing plans expire plans performance criteria vested performance share plan awards share options pension benefits two quorate meetings held year approve opinion thereon expressed remaining formal grant share options performance share awards sections subject audit pages referred accordance gsks remuneration policy within audited sections exceptions mr bicknell company secretary remuneration committee mrs whyte deputy company secretary employees sir robert wilson chairman committee since company involved conduct committee meetings th may sir crispin davis mr culp sir christopher gent dr garnier former ceo mr witty ceo mr phelan chief dr schmitz members committee throughout staff ms thomas senior vice president human resources board deemed members committee invited attend part meetings committee independent nonexecutive directors accordance required combined code exception chairman deloitte llp appointed committee provide company sir christopher gent independent independent advice executive remuneration appointment company provided tax services gsk year committee met times member provide advice executive remuneration matters attending follows committee towers perrin provided additional market data committee attendance full meetings commitment shareholders members committee member since committee engages regular dialogue shareholders sir robert wilson st january holds annual meeting gsks largest investors committee chairman discuss take feedback remuneration policy since may key developments year particular mr l culp st january committee discuss significant changes policy sir crispin davis st july measures used assess performance line sir christopher gent st january commitment gsks largest investors consulted proposed changes set report dr r schmitz th may summary proposals sir robert step chairman committee gsks remuneration policy based following conclusion agm principle achieving competitiveness global succeeded sir crispin davis sir robert remain member pharmaceutical industry primary pay committee comparator essential policy change underlying new role committee set companys remuneration proposals committee decide individual policy executive directors cet members together executive basis whether primary pay comparator executives ensuring consistent companys global pharmaceutical sector ukbased large cross scale scope operations supports business strategy industry multinationals comparator group growth plans helps drive creation shareholder example three executive directors committee value setting remuneration policy levels proposes primary comparator group ceo senior executives committee gives consideration cfo time ukbased large crossindustry remuneration policy levels wider employee multinationals chairman research development population committees full terms reference chairman rd comparator group continue available companys website global pharmaceutical companiesgsk annual report report directors remuneration report continued following charts summarise proposed changes gsks remuneration policy particularly gsks individual remuneration elements summary proposed changes gsks remuneration policy current proposed policy executive directors ceo cfo chairman rd remuneration global pharmaceutical ukbased large crossindustry global pharmaceutical comparator benchmarking comparator group comparator group group annual bonus bonus based financial changes calculation bonus target ranges reflect personal performance changes target setting line new strategy operational bonus na operational targets included within overall annual bonus framework standalone operational bonus lti share mix ltis provided though mix eligible performance shares eligible performance shares c performance shares deferred annual bonus share options c share options value performance based match eligible deferred annual receive share options bonus performance based foreseeable future match plan limits levels lti awards set annually annual individual limits introduced benchmarking projected value expected value methodology key terms remuneration elements current proposed policy salary benchmarked global benchmarked uk crossindustry comparator pharmaceutical comparator group group global pharmaceutical comparator group another comparator group appropriate annual bonus bonus based achievement addition current targets achievement financial targets based group profit operational efficiency also taken account interest tax business unit operating determining annual bonuses respect profit rd specific key performance indicators rd employees individual performance also taken account determining individual bonus payments performance based relative total shareholder return tsr based relative tsr comparator group share comparator group pharmaceutical currently comprising pharmaceutical companies plan psp companies based adjusted free cash flow measured three years tsr component measured half three years twoyear holding period half four years vesting median vesting adjusted free cash flow measured three years performance line second company twoyear holding period removed threemonth averaging period tsr tsr elements vesting median dividend equivalents vesting upper quartile performance cash flow element vesting threshold rising stretching performance exceeding set threshold specified margin twelvemonth averaging period tsr dividend equivalents share option based eps growth relative rpi intended certain executives plan measured three years based eps growth relative rpi vesting threshold performance measured three andor four years vesting threshold performance deferred annual na individuals eligible share options bonus plan bonus may deferred oneforone match subject relative tsr performance three years vesting psp dividend equivalents gsk annual report report directors remuneration report continued total remuneration benchmarking ceo committee reviews gsks total remuneration comparable companies regular basis ensure salary remuneration arrangements competitive structured cash bonus appropriately deliver value money shareholders deferred bonus including match new remuneration policy relevant comparator groups performance shares determined individual executive benchmarking purposes total remuneration incorporates base salary annual bonus including deferred element ltis cfo setting pay committee also takes account pension arrangements salary cash bonus uk crossindustry comparator group global pharmaceutical comparator group deferred bonus including match angloamerican france sanofiaventis performance shares astrazeneca switzerland novartis barclays roche holdings bg group uk astrazeneca bhp billiton usa abbott laboratories chairman rd bp amgen british american tobacco bristolmyers squibb salary diageo eli lilly cash bonus hsbc johnson johnson share options reckitt benckiser merck performance shares royal dutch shell pfizer rio tinto scheringplough standard chartered wyeth tesco unilever base salary vodafone base salaries set reference relevant comparator group secure talent needed deliver gsks strategic priorities mgen included benchmarking tsr comparator group salary levels reviewed annually influenced since gsk used projected value methodology executives role experience table sets current benchmark remuneration principal reason base salaries proposed recognise difference lti arrangements particular less common use performance targets global mr witty mr heslops salary increases form part pharmaceutical companies wider changes proposed remuneration packages particular reflect move benchmark remuneration given increased emphasis benchmarking uk uk crossindustry comparator group mr wittys proposed companies increasing introduction performance targets salary increase also reflects committees assessment ltis pharmaceutical comparators committee performance role since appointment dr slaouis increase decided move expected value benchmarking reflects progression within role intended bring methodology approach provides benchmark takes line market salary increases typically take possible outcomes account based probability effect april however integral part wider achieving different performance levels remuneration policy mr wittys mr heslops salary increases implemented agm individual elements remuneration balance fixed base salary variable annual base effective date base effective date bonus lti elements remuneration varies depending salary salary salary salary performance charts opposite show anticipated mix mr witty nd may st april fixed variable pay expected value basis mr heslop st april st april new remuneration policy actual mix may higher dr slaoui st april st april lower depending performance gsk individual reflects mr wittys base salary took effect succession ceo typically significant portion approximately may executive directors package variablegsk annual report report directors remuneration report continued annual bonus strategic objectives set focused particular annual bonus designed drive achievement gsks continued development launch latestage pipeline assets annual financial targets personal objectives delivery commercial targets execution restructuring programmes simplify operating model maximum annual bonus ceo remains salary maximum bonuses executives bonus measures rd employees including dr slaoui ceo range salary linked pipeline robust governance structure increases maximum bonus opportunity established ensure bonus payable fairly reflects rd productivity performance well performance profit part wider remuneration review committee revised targets plan relatively new committee reviewed annual bonus plan strengthen alignment new operation year decided continue business strategy budgeting process annual bonus rd committee continue keep majority annual bonus opportunity operation review may future consider extending based formal review performance stretching executives including ceo financial targets based group profit interest tax committee took account gsks success achieving business unit operating profit targets remainder objectives well individuals performance based achievements individual objectives annual determining bonus awards actual bonus payments bonuses calibrated reflect stretching targets shown ranged base established drive significant changes gsks salaries st december business model bonus threshold target maximum payable achievement target ltis reduction bonus threshold reflects currently lti awards provided mix performance stretching bonus targets shares share options gsks existing lti plans performance remuneration report reference made share share option plans expire light possible introduction additional bonuses encourage delivery changes within company committee decided operational targets review appropriate review terms lti plans part committee determined increase overall bonus wider remuneration review new longterm opportunity measures incorporated incentive plans therefore submitted shareholder within existing overall bonus approval agm bonus targets ceo set board setting line new remuneration policy based individual objectives ceo board focuses strategies market focus provide better alignment market practice developed company set intended ceo cfo receive share annual report reasons commercial sensitivity option grants foreseeable future instead ltis specific objectives kept confidential following end form performance shares also financial year board reviews ceos performance opportunity defer part bonus earned shares generally set objectives committee receive matching shares subject achievement additional determines bonus payable performance conditions changes based established practices within uk crossindustry comparator group executives ceo makes recommendations committee regarding performance objectives chairman rd certain executives continue recommendations considered committee determining receive share option grants well performance shares level bonuses payable committee considered whether remain competitive global pharmaceutical market reduce individual executives bonus award however use share options kept review reflect revised provisions relating prior year activities relative importance may reduced future share determined current executives materially involved options continue used incentivise employees management relevant issues therefore cet reduction bonus payments would appropriate proposed new lti plans committee may future bonus years committee continue review reduce grant vesting levels determines participant ongoing financial impact prior year activities role engaged conduct contrary legitimate individual executives activities committee may expectations company employee make appropriate adjustments future individual bonus awards participants position reflect circumstances gsk annual report report directors remuneration report continued typically performance shares share options delivered us provide focus sustained longerterm performance resident executives form ads awards delivered performance period extended half tsr form ordinary shares executives resident uk element award measured three years half countries awards made plans incorporate four years element based adjusted free cash flow dilution limits consistent guidelines provided measured three years retesting association british insurers current estimated dilution performance existing awards gsk employee share schemes made since tsr element percentage vesting median merger approximately companys share capital reduced align better remuneration policy st december shareholder expectations full vesting take place upper new plans summarised relevant sections quartile performance adjusted free cash flow element together basis awards made vest threshold performance rising stretching executives performance exceeding set threshold specified margin graph shows tsr vesting schedule awards performance shares granted gsks performance falls two performance share plan ensures focus gsks longterm companies vesting calculated straightline basis shareholder returns relative pharmaceutical companies delivery gsks strategic priorities proportion vesting plan measurement performance broadened senior team incentivised operational measures aligned gsks business strategy well tsr tsr considered remain appropriate comparative measure since focuses return shareholders wellunderstood tested mechanism measure performance allows comparison companies operating different countries therefore typically award made executives continue subject relative tsr balance based strategic operational measures support business strategy awards performance share awards executives made following approval new performance share plan tsr rank position agm individual annual limit maximum value performance awards made award based shares may granted individual one year relative tsr group currently comprising global introduced exceptional circumstances pharmaceutical companies maximum face value performance shares may granted order recognise importance effective working capital individual one year six times salary management generating cash remaining vest intended value performance shares granted ceo subject achievement adjusted free cash flow targets five times salary cfo receive award adjusted free cash flow target may adjusted material factors four times salary chairman rd receive award could distort free cash flow performance measure ads typically include exchange rate movements may provide stable assessment performance reflect include legal major taxation settlements special pension better longterm nature pharmaceutical industry contributions could materially distort calculation tsr averaging period twelve months awards either direction impact acquisition divestment onwards quantified adjusted time event major adjustments calculation disclosed shareholders awards threshold free cash flow target billion maximum vesting billiongsk annual report report directors remuneration report continued provide closer link shareholder returns payments vesting schedule awards shown executives notional dividends reinvested paid proportion vesting proportion vesting award value reinvested dividends incorporated benchmarking award levels performance share plan awards granted executive directors excluding dr slaoui february performance period starting st january ending st december vest gsks tsr performance median awards made senior executives including dr slaoui cet time awards made dependent part tsr performance part eps performance tsr element vest eps element vested full vesting tables recent performance share awards shown rpi rpi rpi rpi b share options eps target gsks share option plan designed ensure gsk remains individual annual limit maximum value share competitive global pharmaceutical peers also options may granted individual one year incentivises sustained delivery earnings growth shareholder introduced individual receives award value creation performance shares share options expected value share options granted year typically exceed noted earlier chairman rd well certain expected value aggregate ltis individual executives continue granted share options granted performance shares annual award limit share participate new deferred annual bonus options calculated equivalent basis ceo cfo receive share options applies performance share plan foreseeable future committee set basis decision considers part wider review committee reviewed appropriate make significant adjustments calculation performance measure used share options concluded eps performance measurement purposes eps remains important measure success vesting share options granted executives therefore continue significant adjustments made respect share linked achievement compound annual eps growth options granted february vested performance period targets reviewed set annually c deferred annual bonus taking account company market expectations new deferred annual bonus plan introduced awards executives longer receive share option grants targets awards remain unchanged including ceo cfo plan designed encourage longterm shareholding help drive longterm shareholder reflect better longterm nature pharmaceutical returns relative global pharmaceutical companies industry performance period extended half share option grant measured three years annual bonus earned may invested shares half measured four years retesting deferred three years company match performance shares oneforone depending companys relative tsr period performance measure vesting schedule percentage vesting threshold performance threeyear tsr component reduced award reflect better performance share plan described shareholder expectations threshold vesting take place compound eps growth rpi plus pa full vesting dividend equivalents accrue delivered respect compound eps growth rpi plus pa eps measured cer invested shares matching shares vest line gsks practice measure performance cer basis gsk annual report report directors remuneration report continued gsks lti performance conditions continue challenging executives participating defined contribution plan demonstrated table tsr important benefit company contribution base salary part lti measures many years maintained depending grade also opportunity receive proposed policy reasons set matched contributions line policy remains primary measure psp despite tsr members pension plan element paying legacy final salary plans provide twothirds final following table shows vesting levels gsks performance salary age employees subject cap benefits share share option awards executives since total excess cap currently provided unfunded vesting percentage indicates gsks tsr performance arrangements legacy final salary plans actuarial median comparator group reduction factors apply participant leaves employment performance period hisher accord age employment terminated company cause reduction share factors apply way members performance share plan option plan legacy final salary plans vesting vesting vesting performance tsr eps total eps b us pension arrangements period measure measure vesting measure usa gsk operates us cash balance plan provides annual contribution interest sum accumulated cash balance plan contractual promise provide specific levels retirement income plan incorporates executive pension credit senior us executives contribution rates plan range base salary performance measure psp awards executives changed exclude eps depending grade current senior us executives eligible following remuneration review award made new executive pension credit due change award cycle capped employees usa benefits cap pensions provided unfunded nonqualified plan executives participate gsk senior executive pension plans pension arrangements structured accordance plans operated executives country likely retire details individual arrangements executive directors set new executives gsk eligible either defined contribution scheme cash balance plan existing obligations defined benefit schemes uk continue honoured year committee reviewed competitiveness pension policy new employees ensure remains competitive enables company attract talent required run business successfully review highlighted defined contribution pension policy uncompetitive uk executives committee therefore made changes align better evolving practice wider market uk pension arrangements company currently operates defined contribution plan legacy final salary plans closed new entrants newly hired executives uk participate defined contribution plangsk annual report report directors remuneration report continued share ownership requirements executive director terms conditions remuneration align interests executives shareholders executive director contracts executives required build maintain significant policy set provides framework contracts holdings shares gsk time ceo required build executive directors shareholding value four times base salary executive directors required build value three times base salary notice period calendar months members cet value two times base salary termination shareholdings purpose share ownership requirements employing company executive sor st december termination payment x annual salary holding sor purposes x annual ontarget bonus mitigation required mr witty ordinary shares mr heslop ordinary shares vesting ltis rules relevant incentive plan dr slaoui ordinary shares pension based existing arrangements executives required continue satisfy shareholding terms relevant pension plan requirements minimum twelve months following retirement noncompete clause months termination company support longterm nature business notice date st december dr garniers holding excess share ownership requirements r wittys target bonus salary dr slaouis mr heslops salary reviewing policy level severance payments remuneration elements committee considered shareholder department business enterprise executives participate various allemployee share plans regulatory reform guidance however determined line competitive practice appropriate provide payment salary either uk usa target bonus termination sharesave plan sharereward plan uk hm revenue imposition month noncompete period nonsolicitation customs approved plans open uk employees restriction executives considered vitally important company order protect groups intellectual property staff light non terms mr witty mr heslop members sharesave plan compete clause competitor practice committee believes would mr witty contributes month plan appropriate provide mitigation contracts maturity savings contract december mr heslop also approved shareholders glaxosmithkline glaxo wellcome contributed month plan provides smithkline beecham appropriate option buy shares end threeyear savings period following table sets details executive directors line opportunity available uk employees service contracts mr witty mr heslop also contribute per month buy shares sharereward plan company matches current directors date contract effective date expiry date number shares bought month mr witty executives also receive benefits including healthcare mr j heslop medical dental personal financial advice life assurance dr slaoui cash value benefits received executive directors r wittys contract renewed june following appointment shown ceo th february company made conditional award termination payments made respect part ads mr viehbacher vesting subject continued notice period extending beyond contract expiry date employment gsk committees assessment performance vesting period following mr viehbachers resignation th september award lapsed gsk annual report report directors remuneration report continued entitlements nonexecutive director terms conditions fees addition contractual provisions outlined event nonexecutive directors glaxosmithkline executive directors service agreements terminated service contracts instead letters appointment employing company following apply agreed serve company non executive director conclusion agm following case outstanding awards glaxosmithkline third anniversary appointment case annual investment plan provided agreement extended term three years mutual terminated cause deferred amount agreement directors serve term longer three years income gains automatically distributed soon without offering reelection shareholders administratively practicable termination resign retire termination cause deferred amount following table shows date initial letter distributed end minimum threeyear deferral period appointment nonexecutive director line policy applicable us senior executives nonexecutive director date letter appointment dr garnier entitled receive continuing medical dental insurance retirement dr slaoui member plan professor sir roy anderson may become eligible future date receive continuing dr burns medical dental cover retirement mr l culp sir crispin davis following merger participants legacy share option sir deryck maughan schemes elected exchange legacy options options mr james murdoch glaxosmithkline shares receive additional cash benefit dr podolsky equal grant price original option additional sir ian prosser benefit triggered new option exercised lapses dr r schmitz qualify additional cash benefit participants retain mr de swaan options least second anniversary effective date sir robert wilson merger fee structures nonexecutive directors chairman outside appointments executive directors reviewed year changes made outside appointments must approved chairman board ensure remained competitive company aims behalf board companys policy remuneration provide nonexecutive directors fees competitive earned appointments may kept individual companies equivalent size complexity fees executive director applying follows per annum standard annual cash retainer fee supplemental fees senior independent director audit committee chairman scientificmedical experts chairman remuneration corporate responsibility committee nonexecutive director undertaking intercontinental travel meetings per meetinggsk annual report report directors remuneration report continued exchange rate tsr performance graph fees paid us dollars converted rate following graph sets performance company us period st january st march relative ftse index company exchange rate applied th july constituent pharmaceutical performance comparator fee arrangements initially approved group st january st december graph board following approval new fee arrangements prepared accordance regulations exchange rate applicable set board indication likely vesting awards granted us rate applied st april companys incentive plans st december tsr performance nonexecutive directors share allocation plan enhance link directors shareholders glaxosmithkline requires nonexecutive directors receive significant part fees form shares least nonexecutive directors total fees excluding chairman paid form shares ads allocated share account nonexecutive directors may also take opportunity invest part balance fees share account shares ads notionally awarded non executive directors allocated interest accounts included within directors interests tables accumulated balance shares ads together notional dividends subsequently reinvested paid nonexecutive directors retirement board upon retirement nonexecutive directors receive either shares ads cash amount equal value glaxosmithkline total return index shares ads date retirement nonexecutive glaxosmithkline pharma peers return index directors entitled compensation appointment ftse total return index terminated chairman directors senior management remuneration sir christopher gents letter appointment board following tables set directors glaxosmithkline dated th may agreed plc remuneration earned interests shares would serve company deputy chairman glaxosmithkline plc interests share options incentive st december st january chairman plans pension benefits members cet also conclusion agm following third anniversary participate remuneration plans executive appointment extended term directors aggregate remuneration interests three years mutual agreement directors senior management also provided chairmans fees increased per annum plus allocation shares value per annum previously effect st april line gsks policy ensure non executive directors fees remained competitive gsk annual report report directors remuneration report continued annual remuneration total total fees annual annual fees annual annual salary benefits bonus remuneration salary benefits bonus remuneration footnote executive directors mr witty ab mr j heslop b dr slaoui c nonexecutive directors professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson dr burns mr l culp sir deryck maughan dr podolsky former directors mr j coombe dr barzach sir richard sykes dr jp garnier bc mr c viehbacher f dr yamada b dr l shapiro e total remuneration analysed executive directors nonexecutive directors former directors total remuneration remuneration directors us payroll reported dollars dollar amounts included totals based conversion sterling average exchange rates year r witty joined board st january remuneration disclosed date b f ollowing merger order encourage employees convert nonsavings related options held glaxo wellcome smithkline beecham shares ads options glaxosmithkline shares ads employees granted additional cash benefit equal grant price original option additional benefit known exchange offer incentive eoi payable new option exercised lapses qualify additional cash benefit participants retain options least second anniversary effective date merger year mr witty received eoi payments result options granted march lapsing mr heslop received result options granted july lapsing dr garnier received mr viehbacher received dr yamada received c r garnier retired director st may retired company st may nonexecutive director united technologies corporation respect received end may form deferred stock units included dr slaoui nonexecutive director agency science technology research astar respect received included r barzach received fees glaxosmithkline france healthcare consultancy provided included within fees salary e dr shapiro retired board th may stepped member glaxosmithklines scientific advisory board st july received fees form ads included within fees salary f r viehbacher appointed board st january remuneration disclosed date resigned board th september none directors received reimbursement expenses year requiring separate disclosure required regulationsgsk annual report report directors remuneration report continued nonexecutive directors remuneration total cash sharesads total cash sharesads fees current nonexecutive directors professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson dr burns mr l culp sir deryck maughan dr podolsky total remuneration table sets remuneration received nonexecutive directors glaxosmithkline nonexecutive directors required take least part total fees form shares allocated share account paid retirement board see details total value shares ads date award together cash payment forms total fees included within annual remuneration table fees salary table sets value fees received form cash shares ads table sets accumulated number shares ads held nonexecutive directors relation fees received board members st december together movements accounts year number shares ads dividends nonexecutive directors share arrangements elected reinvested current nonexecutive directors shares professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson ads dr burns mr l culp sir deryck maughan dr podolsky gsk annual report report directors remuneration report continued directors interests following interests directors company connected persons shown accordance listing rules shares ads th february st december st january th february st december st january footnote executive directors mr witty ac mr j heslop c dr slaoui b nonexecutive directors professor sir roy anderson dr burns mr l culp sir crispin davis sir christopher gent sir deryck maughan dr podolsky sir ian prosser dr r schmitz mr de swaan sir robert wilson one glaxosmithkline ads represents two glaxosmithkline shares interests abovementioned directors th february reflect change year end date r witty joined board st january holdings disclosed date b ncludes ads purchased glaxosmithkline stock fund within us retirement savings plan us executive supplemental savings plan c ncludes shares purchased glaxosmithkline sharereward plan mr heslop totalling st december st december shares th february mr witty totalling st december shares th february ncludes shares ads received part fees described nonexecutive directors share allocation plan dividends received shares ads converted shares ads st december share options options shares granted footnote date grant exercise period grant price number exercised lapsed mr witty ac mr j heslop c dr slaoui b mr c viehbacher options ads granted date grant exercise period grant price number exercised lapsed dr slaoui bc dr jp garnier e mr c viehbacher r witty joined board st january options disclosed date b details include interests dr slaouis connected person also employee gsk c part main option grant occurred th february dr slaoui connected person awarded ads options grant price options granted dr slaoui vest two parts awards vesting february remaining vesting february line new remuneration policy mr witty mr heslop receive share options forseeable future r viehbacher joined board st january options disclosed date th september resigned board unvested options lapsed st december left company e dr garnier retired board st may closing balance options disclosed dategsk annual report report directors remuneration report continued options outstanding st december earliest latest vesting lapse dates options market price glaxosmithkline share yearend given table weighted average vesting date lapse date mr witty grant price number earliest latest earliest latest options market price yearend vested unvested options market price yearend vested unvested total share options st december weighted average vesting date lapse date mr j heslop grant price number earliest latest earliest latest options market price yearend vested unvested options market price yearend vested unvested total share options st december weighted average vesting date lapse date dr slaoui grant price number earliest latest earliest latest options market price yearend vested unvested options market price yearend vested total share options st december options market price yearend unvested total ads options st december includes share options held dr slaouis connected person also employee gsk weighted average vesting date lapse date dr jp garnier grant price number earliest latest earliest latest options market price yearend vested unvested options market price yearend vested total ads options st may gsk annual report report directors remuneration report continued gsk grants share options executive directors senior managers annual basis directors hold options various share option plans referred note financial statements employee share schemes none nonexecutive directors interest option companys shares table sets share options granted respect performance period whether options vested st december performance targets performance target vesting status annualised growth percentage grant footnote performance period eps award vesting february unvested rpi february unvested rpi february unvested rpi rpi rpi performance targets share options partially met result part option grant vest third anniversary date grant table sets share options granted respect performance period targets performance target vesting status annualised growth percentage grant performance period eps award vesting february award unvested rpi february award unvested rpi rpi rpi rpi options exercised grant market date number price price gain gain dr jp garnier aggregate gain options exercised highest lowest closing prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline ads year ended st december respectively market price glaxosmithkline share st december st december glaxosmithkline ads st december prices th february per glaxosmithkline share per glaxosmithkline ads incentive plans performance share plan psp awards market additional mr witty shares number price vested shares unvested granted date market dividends unvested performance period grant number price gain lapsed reinvested gsk annual report report directors remuneration report continued market additional mr j heslop shares number price vested shares unvested granted date market dividends unvested performance period grant number price gain lapsed reinvested market additional dr slaoui shares number price vested shares unvested granted date market dividends unvested performance period grant number price gain lapsed reinvested market additional dr slaoui ads number price vested ads number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested includes performance shares held dr slaouis connected person also employee gsk market additional dr jp garnier ads vested number price vested ads unvested deferred granted date market dividends unvested performance period grant number price gain lapsed reinvested deferred deferred set dr garniers contract unvested psp awards vest subject achievement performance conditions end performance periods set market additional mr c viehbacher ads number price vested ads unvested granted date market dividends unvested performance period grant number price gain lapsed reinvested mr viehbacher joined board st january psps disclosed date th september resigned board unvested psps lapsed mr viehbacher left company st december terms psp number shares actually vesting determined following end relevant measurement period dependent gsks performance period described pages gsk annual report report directors remuneration report continued dividends reinvested performance shares awarded executives throughout performance period date final award dividend reinvestment calculated exdividend date terms psp us participants may defer receipt part vested awards total gain vesting psp awards made executive directors psp awards granted executive directors february excluding dr slaoui performance period starting st january ending st december lapsed gsks relative tsr performance median comparator group awards made senior executives including dr slaoui member cet time award dependent part tsr performance part eps performance tsr portion lapsed eps portion vested full following vesting schedule applies psp awards made vesting schedule award performance period tsr rank companies percentage award vesting median median following vesting schedules apply psp awards made vesting schedule award performance period tsr rank companies percentage award vesting median median tsr measured prorata basis glaxosmithklines performance falls two comparators level vesting determined actual relative level tsr rather simple ranking dividends treated reinvested performance period awards made following approval new psp agm share value plan awards market dr slaoui shares ads number price vested deferred unvested granted date market unvested number ads plan year grant number price gain lapsed granted shares ads ads ads ads executive director dr slaoui eligible receive awards share value plan awards shown reflect holdings dr slaouis connected person employee gsk awards subject threeyear vesting periods vesting contingent continued employment gskgsk annual report report directors remuneration report continued vested additional ads vested deferred dividends deferred participations reinvested participations midterm incentive plan ads exercised market price gain dr jp garnier midterm incentive plan mtip share award scheme operated smithkline beecham plan closed new entrants upon completion merger participations granted final award ads made receipt award may deferred director dr garnier deferred receipt full amounts vested year deferred awards together additional ads subsequently received dividend reinvestment included directors interests table since retained mtip paid th february company made conditional award ads mr viehbacher following mr viehbachers resignation board effect th september conditional award lapsed full pension benefits accrued annual pension benefits transfer values executive directors office st december retirement set companies act requires disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year listing rules require additional disclosure change accrued benefit net inflation transfer value change pensions executive directors disclosed currency pension payable change change personal accrued transfer value accrued accrued accrued contributions transfer transfer change benefit change benefit benefit benefit made value value transfer year net accrued executive directors e r e r va l u e infla ti ben e fi mr witty mr j heslop dr slaoui dr slaoui former executive directors dr jp garnier mr c viehbacher shown net contributions made individual mr witty mr heslop participate glaxo wellcome defined benefit plan accrual rate th final pensionable salary per annum benefits accrued glaxo wellcome uk pension arrangements augmented trustees plans reflect distribution surplus augmentation apply element mr witty mr heslops pension earnings st march mr wittys mr heslops transfer values calculated basis actuarial advice accordance pensions regulation transfer value represents present value future payments made pension plan mr wittys annual accrued benefit increased excluding effects inflation transfer value less personal contributions increased year increase mr wittys pensionable salary reflecting appointment ceo primary reason increase transfer value mr heslops annual accrued benefit increased excluding effects inflation transfer value less personal contributions increased year gsk annual report report directors remuneration report continued pension benefits directors senior management dr slaoui mr viehbacher members us executive information also provided compensation cash balance pension plan plan provides executive interests directors senior management group pension credit gsk makes annual contributions group purpose group defined executive calculated percentage executives base salary nonexecutive directors members cet gsk makes contributions base pay fund financial year total compensation paid members increases interest rate set annually advance based group periods served year us treasury bond rate provide cash sum capacity aggregate increase accrued retirement plan entitlement spouses pension pension benefits net inflation pension increases aggregate payment defined contribution schemes mr viehbacher resigned board th september left company st december members group granted share options ads options transfer value cash sum increased share option plan awarded shares dr slaoui mr viehbacher year ads performance share plan awarded result accumulation interest contributions paid shares ads share value plan company awarded notional shares deferred investment dr slaoui active participant belgium fortis plan award plan members group also awarded st may plan defined benefit plan reinvestment dividends shares ads lump sum payable normal retirement age performance share plan notional shares plan transfer value cash sum dr slaouis plan notional ads deferred investment award plan increase year result th february group comprising persons accumulation interest owned shares ads constituting less dr garnier retired company st may issued share capital company group also member us cash balance pension plan held date options purchase shares gsk made annual contributions calculated ads shares ads awarded percentage base salary bonus gsk made annual performance share plan including shares contributions dr garniers annual salary bonus ads vested deferred vested deferred detailed contract fund increased interest ads legacy smithkline beecham midterm incentive rate set annually based year us treasury bond rate plan shares ads awarded share provide cash sum retirement plan entitlement value plan notional shares awarded spouses pension pension increases dr garnier deferred investment award plan holdings issued selected receive pension payments annual basis various executive share option plans described paid years commencing january transfer note financial statements employee share schemes value cash sum increased year dr garniers plan result accumulation directors interests contracts interest contributions paid company except described note financial statements related party transactions end financial year dr slaoui dr garnier mr viehbacher also members director connected person material interest us retirement savings plan k savings scheme open contract significance relation groups business us employees executive supplemental savings plan group company savings scheme open executives accrue benefits us government limits imposed retirement savings plan directors remuneration report approved contributions plans invested range funds board directors signed behalf value accumulated funds paid retirement contributions sir christopher gent paid two schemes gsk respect dr slaoui chairman respect dr garnier rd march respect mr viehbachergsk annual report financial statements financial statements financial statements set belowoverleaf provide directors statement responsibilities summary groups financial performance throughout independent auditors report position st december financial financial statements statements prepared accordance ifrs consolidated income statement adopted european union also ifrs issued consolidated balance sheet international accounting standards board financial consolidated cash flow statement statements comprise following audited primary statements consolidated statement recognised income expense related notes notes financial statements presentation financial statements consolidated income statement accounting principles policies consolidated balance sheet key accounting judgements estimates new accounting requirements consolidated cash flow statement exchange rates consolidated statement recognised income expense segment information major restructuring programmes operating income operating profit employee costs finance income finance costs associates joint ventures taxation earnings per share dividends property plant equipment goodwill intangible assets investments associates joint ventures investments noncurrent assets inventories trade receivables cash cash equivalents assets held sale trade payables pensions postemployment benefits provisions noncurrent liabilities contingent liabilities net debt share capital share premium account movements equity related party transactions adjustments reconciling profit tax operating cash flows reconciliation net cash flow movement net debt acquisitions disposals commitments post balance sheet events financial instruments related disclosures employee share schemes principal group companies legal proceedings financial statements glaxosmithkline plc prepared uk gaap gsk annual report financial statements directors statement responsibilities directors statement responsibilities relation group financial statements prepared group financial statements accordance ifrs adopted eu ifrs issued iasb give true fair view assets liabilities directors responsible preparing annual report financial position profit group remuneration report group financial statements accordance applicable law regulations business review section contained annual report includes fair review development performance company law requires directors prepare financial statements business position group together financial year law directors prepared description principal risks uncertainties faces group financial statements accordance international financial reporting standards ifrs adopted european union disclosure information auditors preparing group financial statements directors also elected directors office date report comply ifrs issued international accounting standards confirmed board iasb group financial statements required law give far aware relevant audit true fair view state affairs group end information companys auditors unaware financial period profit loss group period taken steps ought preparing financial statements directors required taken director make aware select suitable accounting policies apply relevant audit information establish companys consistently auditors aware information make judgements estimates reasonable confirmation given interpreted accordance prudent provisions section za companies act state group financial statements comply ifrs going concern basis adopted european union ifrs issued iasb making enquiries directors reasonable expectation subject material departures disclosed explained group adequate resources continue operational existence financial statements foreseeable future reason continue adopt directors responsible keeping proper accounting records going concern basis preparing financial statements disclose reasonable accuracy time financial internal control position group enable ensure group financial statements directors remuneration report comply board audit committee reviewed companies acts article ias assessment risks internal control framework operates regulation also responsible taking reasonable steps gsk considered effectiveness system internal safeguard assets group ensuring operation control operation group year covered report systems internal control hence taking reasonable steps date approval board directors prevention detection fraud irregularities combined code group financial statements year ended st december board considers glaxosmithkline plc applies principles comprising principal statements supporting notes combined code corporate governance financial set financial statements pages reporting council described corporate governance report pages complied provisions except described responsibilities auditors relation group financial statements set independent auditors required listing rules financial services report authority auditors considered directors statement compliance relation points combined code group financial statements year ended st december specified review included annual report published hardcopy printed form made available companys annual report website directors responsible maintenance annual report year ended st december integrity annual report website accordance comprising report directors remuneration report uk legislation governing preparation dissemination financial statements additional information investors financial statements access website available approved board directors signed behalf outside uk comparable legislation may different current directors whose names functions sir christopher gent listed corporate governance section annual report chairman confirms best knowledge rd march gsk annual report financial statements independent auditors report members glaxosmithkline plc audited group financial statements glaxosmithkline consider implications report become aware plc year ended st december comprise apparent misstatements material inconsistencies group consolidated income statement consolidated balance sheet financial statements consolidated cash flow statement consolidated statement responsibilities extend information recognised income expense related notes group financial statements prepared accounting basis audit opinion policies set therein conducted audit accordance international standards auditing uk ireland issued auditing practices board reported separately parent company financial audit includes examination test basis evidence relevant statements glaxosmithkline plc year ended amounts disclosures group financial statements st december information remuneration also includes assessment significant estimates report described audited judgments made directors preparation group respective responsibilities directors auditors financial statements whether accounting policies directors responsibilities preparing annual report appropriate groups circumstances consistently applied group financial statements accordance applicable law adequately disclosed international financial reporting standards ifrs adopted planned performed audit obtain european union set directors statement information explanations considered necessary responsibilities opposite order provide us sufficient evidence give reasonable responsibility audit group financial statements assurance group financial statements free material accordance relevant legal regulatory requirements misstatement whether caused fraud irregularity error international standards auditing uk ireland report forming opinion also evaluated overall adequacy including opinion prepared presentation information group financial statements companys members body accordance section opinion companies act purpose giving opinion opinion accept assume responsibility purpose person report shown whose hands group financial statements give true fair view may come save expressly agreed prior consent writing accordance ifrss adopted european union state groups affairs st december report opinion whether group financial profit cash flows year ended statements give true fair view whether group financial statements properly prepared accordance group financial statements properly prepared companies act article ias regulation accordance companies act article also report whether opinion information ias regulation given report directors consistent group information given report directors consistent financial statements group financial statements addition report opinion separate opinion relation ifrs received information explanations require explained note group financial statements group audit information specified law regarding directors addition complying legal obligation comply ifrs remuneration transactions disclosed adopted european union also complied ifrs review whether corporate governance statement reflects issued international accounting standards board companys compliance nine provisions combined opinion group financial statements give true fair code specified review listing rules financial view accordance ifrs state groups affairs services authority report required st december profit cash flows consider whether boards statements internal control cover year ended risks controls form opinion effectiveness groups corporate governance procedures risk control procedures pricewaterhousecoopers llp chartered accountants registered auditors read information contained annual report consider london whether consistent audited group financial statements rd march information comprises chairman ceo summary strategy report directors excluding audited part remuneration report directors statement responsibilities shareholder information gsk annual report financial statements consolidated income statement year ended st december results results major major total major major total total notes restructuring restructuring restructuring restructuring turnover cost sales gross profit selling general administration research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p calculation results major restructuring described note presentation financial statementsgsk annual report financial statements consolidated balance sheet st december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity minority interests total equity approved board rd march sir christopher gent chairman gsk annual report financial statements consolidated cash flow statement year ended st december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments share transactions minority shareholders purchase businesses net cash acquired disposal businesses interest associates investments associates joint ventures decreaseincrease liquid investments interest received dividends associates joint ventures net cash outflow investing activities cash flow financing activities proceeds shares employee share options shares acquired esop trusts issue share capital purchase shares cancellation purchase treasury shares increase longterm loans repayment longterm loans net repayment ofincrease shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders dividends paid minority interests financing cash flows net cash outflow financing activities increasedecrease cash bank overdrafts exchange adjustments cash bank overdrafts beginning year cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report financial statements consolidated statement recognised income expense year ended st december exchange movements overseas net assets tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments actuarial lossesgains defined benefit plans deferred tax actuarial movements defined benefit plans fair value movements cash flow hedges deferred tax fair value movements cash flow hedges net profitslosses recognised directly equity profit year total recognised income expense year total recognised income expense year attributable shareholders minority interests gsk annual report financial statements notes financial statements presentation financial statements estimated total cost approximately billion expanded programme expected deliver annual pretax description business savings approximately billion time substantially glaxosmithkline major global healthcare group complete given extent cost operational engaged creation discovery development manufacture excellence programme management believes material marketing pharmaceutical products including vaccines impact gsks operating results manner overthecounter otc medicines healthrelated consumer gsks business conducted gsk presents restructuring costs products gsks principal pharmaceutical products include incurred solely direct result operational excellence medicines following therapeutic areas respiratory central programme separate column income statement titled nervous system antivirals antibacterials metabolic vaccines major restructuring cardiovascular urogenital oncology emesis addition restructuring costs operational excellence compliance applicable law ifrs programme major restructuring column income financial statements prepared accordance statement includes restructuring costs incurred solely direct companies act article ias regulation result restructuring programmes follow relate international accounting standards ias international material acquisitions operations acquired financial reporting standards ifrs related interpretations business overlap extensively gsks existing operations adopted european union restructuring activities follow relate financial statements also compliance ifrs issued acquisitions nature undertaken international accounting standards board operational excellence programme also carried composition financial statements following detailed formal plan management therefore considers appropriate present costs restructuring activities consolidated financial statements drawn sterling manner billion million acquisition functional currency glaxosmithkline plc accordance reliant pharmaceuticals december acquisition ifrs accounting presentation financial statements comprise since october meets criteria set thus consolidated income statement acquisition costs incurred direct result consolidated balance sheet related restructuring programme included within consolidated cash flow statement major restructuring column consolidated statement recognised income expense groups results costs operational excellence notes financial statements programme acquisitionrelated restructuring programmes meeting criteria described also presented accounting convention separate column income statement described financial statements prepared using historical results major restructuring presentation cost convention modified revaluation certain items gsk intends apply consistently future major restructuring stated accounting policies programmes material impact gsks operating financial period results manner gsks business conducted financial statements cover financial year st adopted show clearly groups results january st december comparative figures costs restructuring programmes financial years st january st december management believes presentation assists investors appropriate st january st december gaining clearer understanding groups financial performance making projections future financial composition group performance results include costs virtue list subsidiary associated undertakings opinion size nature limited comparative value presentation directors principally affected amount profit net also consistent way management assesses groups assets group given note principal group companies financial performance presentation restructuring costs restructuring costs arise solely direct result october board approved implementation operational excellence programme restructuring detailed formal plan gsk announced significant programmes following relating acquisitions meeting new operational excellence restructuring programme criteria described continue reported operating second formal plan representing significant expansion expenses within results major restructuring operational excellence programme approved board announced february restructuring programme comprising detailed formal plans covers areas gsks business including manufacturing selling rd infrastructuregsk annual report financial statements notes financial statements continued accounting principles policies entities group power govern preparation financial statements conformity financial operating policies accounted subsidiaries generally accepted accounting principles requires management group ability exercise joint control make estimates assumptions affect reported amounts entities accounted joint ventures group assets liabilities disclosure contingent assets ability exercise significant influence accounted liabilities date financial statements reported associates results assets liabilities associates amounts revenues expenses reporting period joint ventures incorporated consolidated financial actual results could differ estimates statements using equity method accounting financial statements prepared accordance interests acquired entities consolidated date groups accounting policies approved board group acquires control interests sold deconsolidated described note accounting principles policies date control ceases information application accounting policies transactions balances subsidiaries eliminated including areas estimation judgement given note profit tax taken sales subsidiaries key accounting judgements estimates appropriate sales joint ventures associates products sold comparative figures reclassified ensure consistent customers outside group deferred tax relief unrealised presentation current year information intragroup profit accounted extent restated comparative information considered recoverable result review strategic direction group goodwill arising acquisition interests subsidiaries joint regional reporting structure within pharmaceuticals ventures associates representing excess acquisition business realigned russia number developing cost groups share fair values identifiable eastern european markets previously reported within europe assets liabilities contingent liabilities acquired capitalised included within emerging markets sector rest separate item case subsidiaries part world change made reporting structure cost investment case joint ventures associates consumer healthcare business markets still goodwill denominated currency operation reported within europe acquired cost acquisition fair value group also taken opportunity review allocation net assets acquired difference recognised directly entities expenses pharmaceuticals income statement consumer healthcare businesses result one entity foreign currency translation china reclassified pharmaceuticals consumer foreign currency transactions booked functional healthcare comparative information restated onto currency group company exchange rate ruling consistent basis date transaction foreign currency monetary assets liabilities reallocations impact group turnover group retranslated functional currency rates exchange operating profit ruling balance sheet date exchange differences included income statement parent company financial statements financial statements parent company glaxosmithkline consolidation assets liabilities including related goodwill plc prepared accordance uk gaap uk overseas subsidiaries associates joint ventures accounting presentation company balance sheet presented translated sterling rates exchange ruling balance accounting policies given sheet date results cash flows overseas subsidiaries associates joint ventures translated sterling using accounting principles policies average rates exchange consolidation exchange adjustments arising opening net assets consolidated financial statements include profits year retained overseas subsidiaries associates joint ventures translated sterling less exchange assets liabilities results cash flows differences arising related foreign currency borrowings company subsidiaries including esop trusts hedge groups net investment operations taken groups share results net assets associates separate component equity joint ventures financial statements entities consolidated made st december year gsk annual report financial statements notes financial statements continued accounting principles policies continued research development research development expenditure charged income translating sterling assets liabilities results statement period incurred development cash flows overseas subsidiaries associates joint ventures expenditure capitalised criteria recognising asset reported currencies hyperinflationary economies met usually regulatory filing made major adjustments made reflect current price levels loss market approval considered highly probable property plant net monetary assets charged consolidated equipment used research development depreciated income statement accordance groups policy revenue environmental expenditure revenue recognised income statement goods environmental expenditure related existing conditions resulting services supplied made available external customers past current operations current orders received title risk loss passed future benefit discernible charged income statement customer reliable estimates made relevant group recognises liability sitebysite basis deductions turnover represents net invoice value reliably estimated liability includes groups portion deduction discounts allowances given accruals total costs also portion potentially responsible estimated future rebates returns methodology parties costs probable able assumptions used estimate rebates returns monitored satisfy respective shares cleanup obligation recoveries adjusted regularly light contractual legal reimbursements recorded assets virtually certain obligations historical trends past experience projected market conditions market conditions evaluated using wholesaler legal disputes thirdparty analyses market research data internally provision made anticipated settlement costs legal generated information turnover also includes copromotion disputes group outflow resources income group records share revenue considered probable reasonable estimate made related cost sales value added tax sales taxes likely outcome addition provision made legal excluded revenue expenses arising claims received disputes respect product liability claims related products royalty income recognised operating income sufficient history claims made settlements incurred accruals basis accordance terms relevant reported ibnr actuarial technique used determine licensing agreements reasonable estimate groups exposure unasserted claims expenditure products provision made basis expenditure recognised respect goods services provision made unasserted claims received supplied accordance contractual terms obligation exists dispute possible make provision made obligation exists future liability reasonable estimate costs associated claims made respect past event amount obligation group third parties charged income statement reliably estimated manufacturing startup costs incurred validation achievement normal production expensed incurred advertising promotion expenditure pensions postemployment benefits charged income statement incurred shipment costs costs providing pensions defined benefit schemes intercompany transfers charged cost sales distribution calculated using projected unit credit method spread costs sales customers included selling general period benefit expected derived administrative expenditure employees services consistent advice qualified actuaries pension obligations measured present value restructuring costs recognised provided estimated future cash flows discounted rates reflecting appropriate respect direct expenditure business yields high quality corporate bonds reorganisation plans sufficiently detailed well advanced appropriate communication affected undertakengsk annual report financial statements notes financial statements continued accounting principles policies continued leases leasing agreements transfer group substantially pension scheme assets measured fair value balance benefits risks ownership asset treated sheet date actuarial gains losses differences finance leases asset purchased outright expected actual returns assets effect changes assets included ppe computer software capital actuarial assumptions recognised statement elements leasing commitments shown obligations recognised income expense year finance leases assets held finance leases arise groups contributions defined contribution plans depreciated basis consistent similar owned assets charged income statement incurred costs lease term shorter interest element lease rental postemployment liabilities calculated similar included income statement leases operating way defined benefit pension schemes spread leases rental costs charged income statement period benefit expected derived straightline basis lease term employees services accordance advice qualified actuaries goodwill goodwill stated cost less impairments goodwill deemed employee share plans indefinite useful life tested impairment annually incentives form shares provided employees share option share award schemes fair value interest acquired entitys assets liabilities contingent liabilities exceeds consideration paid fair values options awards calculated excess recognised immediately gain income statement grant dates using blackscholes option pricing model charged income statement relevant vesting periods intangible assets intangible assets stated cost less provisions amortisation group provides finance esop trusts purchase company impairments shares open market meet obligation provide shares employees exercise options awards costs running licences patents knowhow marketing rights separately esop trusts charged income statement shares held acquired acquired part business combination esop trusts deducted reserves transfer amortised estimated useful lives exceeding years made reserves retained earnings vesting using straightline basis time available periods related share options awards reflect ultimate use estimated useful lives determining amortisation proceeds receivable employees exercise charge take account patent lives applicable well value obtained periods nonexclusivity asset property plant equipment lives reviewed appropriate adjusted annually property plant equipment ppe stated cost contingent milestone payments recognised point purchase construction less provisions depreciation contingent event becomes certain development impairment financing costs capitalised costs incurred group associated acquired depreciation calculated write cost less residual value licences patents knowhow marketing rights written ppe excluding freehold land using straightline basis income statement incurred unless criteria expected useful life residual values lives reviewed recognition internally generated intangible asset met appropriate adjusted annually normal expected usually regulatory filing made major market useful lives major categories ppe approval considered highly probable freehold buildings years acquired brands valued independently part fair value leasehold land lease term years businesses acquired third parties brand buildings value substantial longterm brands plant machinery years either contractual legal nature sold separately fixtures equipment years rest businesses acquired brands amortised estimated useful lives except considered disposal ppe cost related accumulated useful economic life indefinite depreciation impairments removed financial statements net amount less proceeds taken costs acquiring developing computer software income statement internal use internet sites external use capitalised intangible fixed assets software site supports significant business system expenditure leads creation durable asset erp systems software amortised seven years computer software three five years gsk annual report financial statements notes financial statements continued accounting principles policies continued trade receivables trade receivables carried original invoice amount less impairment noncurrent assets provisions doubtful debts provisions made carrying values noncurrent assets reviewed evidence risk nonpayment taking account ageing impairment indication assets might previous experience general economic conditions impaired additionally goodwill intangible assets indefinite trade receivable determined uncollectable written useful lives intangible assets yet available firstly provision available use tested impairment annually provision income statement impairment charged income statement year concerned subsequent recoveries amounts previously provided credited income statement longterm receivables impairments goodwill reversed impairment losses discounted effect material noncurrent assets reversed change estimates used determine recoverable amounts trade payables extent revised recoverable amounts trade payables held amortised cost equates exceed carrying values would existed nominal value longterm payables discounted net depreciation amortisation impairments effect material recognised cash cash equivalents investments associates joint ventures cash cash equivalents comprise cash hand current balances investments associates joint ventures carried banks similar institutions highly liquid investments consolidated balance sheet groups share net assets original maturities three months less readily date acquisition postacquisition retained profits convertible known amounts cash insignificant losses together goodwill arising acquisition risk changes value availableforsale investments taxation liquid investments investments classified current tax provided amounts expected paid availableforsale investments initially recorded fair applying tax rates enacted substantively enacted value plus transaction costs remeasured subsequent balance sheet date reporting dates fair value unrealised gains losses deferred tax provided full using liability method availableforsale investments recognised directly equity temporary differences arising tax bases assets impairments arising significant prolonged decline liabilities carrying amounts financial statements fair value investment reduce carrying amount deferred tax assets recognised extent probable asset directly charged income statement future taxable profits available disposal impairment investments gains temporary differences utilised deferred tax provided losses deferred equity recycled temporary differences arising investments subsidiaries income statement dividends equity investments recognised associates joint ventures except timing income statement groups right receive reversal temporary difference controlled payment established equity investments recorded non probable temporary difference reverse current assets unless expected sold within one year foreseeable future deferred tax provided using rates tax purchases sales equity investments accounted enacted substantively enacted balance sheet trade date purchases sales availableforsale date deferred tax liabilities assets discounted investments accounted settlement date derivative financial instruments hedging inventories derivative financial instruments used manage exposure inventories included financial statements lower market risks treasury operations principal derivative cost including raw materials direct labour direct costs instruments used glaxosmithkline foreign currency swaps related production overheads net realisable value cost interest rate swaps forward foreign exchange contracts generally determined first first basis prelaunch group hold issue derivative financial instruments inventory held asset high probability trading speculative purposes regulatory approval product point provision made carrying value recoverable amount provision reversed point high probability regulatory approval determinedgsk annual report financial statements notes financial statements continued accounting principles policies continued level accrual reviewed adjusted regularly light contractual legal obligations historical trends past derivative financial instruments classified heldfortrading experience projected market conditions market conditions carried balance sheet fair value derivatives evaluated using wholesaler thirdparty analyses market designated hedging instruments classified inception research data internally generated information future events cash flow hedges net investment hedges fair value hedges could cause assumptions accruals based changes fair value derivatives designated cash flow change could affect future results group hedges recognised equity extent hedges group copromotes product third party effective ineffective portions recognised profit loss records sale group records share revenue co immediately amounts deferred equity recycled promotion income within turnover nature copromotion income statement hedged item affects profit loss activities group records costs sales net investment hedges accounted similar way cash pharmaceutical turnover includes copromotion revenue flow hedges million million million changes fair value derivatives designated fair value taxation hedges recorded income statement together current tax provided amounts expected paid changes fair value hedged asset liability deferred tax provided temporary differences tax bases assets liabilities carrying amounts changes fair value derivative instruments rates enacted substantively enacted qualify hedge accounting recognised immediately balance sheet date income statement group open tax issues number revenue discounting authorities gsk continues believe made adequate time effect money material balances discounted provision liabilities likely arise open assessments current values using appropriate rates interest unwinding open issues exist ultimate liability matters discounts recorded finance incomecosts may vary amounts provided dependent upon outcome negotiations relevant tax authorities key accounting judgements estimates necessary litigation proceedings preparing financial statements management required legal disputes make estimates assumptions affect amounts gsk provides anticipated settlement costs outflow assets liabilities revenue expenses reported financial resources considered probable reasonable estimate may statements actual amounts results could differ made likely outcome dispute legal estimates following considered key accounting expenses arising claims group judgements estimates made companys directors taken legal advice turnover established provisions taking account relevant revenue recognised title risk loss passed facts circumstances matter accordance customer reliable estimates made relevant accounting requirements provisions product liability claims deductions gross turnover reduced rebates discounts certain products made incurred reported allowances product returns given expected given basis sufficient history claims made settlements vary product arrangements buying groups available provisions made unasserted arrangements purchasing organisations dependent upon claims claims reasonable estimate likely submission claims time initial recognition outcome yet made sale accruals made time sale estimated rebates discounts allowances payable returns made ultimate liability pending unasserted claims may vary based available market information historical experience amounts provided dependent upon outcome litigation proceedings investigations possible amounts estimated may fully reflect settlement negotiations final outcome amounts subject change dependent upon amongst things types buying group product sales mix gsk annual report financial statements notes financial statements continued key accounting judgements estimates pensions postemployment benefits continued costs providing pensions postemployment benefits charged income statement accordance property plant equipment ias period benefit derived carrying values property plant equipment reviewed employees services costs assessed basis impairment indication values assumptions selected management assumptions include assets might impaired impairment determined reference future earnings pension increases discount rates expected higher fair value less costs sell value use long term rates return assets mortality rates measured assessing riskadjusted future cash flows discounted disclosed note pensions postemployment using appropriate interest rates future cash flows based benefits business forecasts therefore inherently judgemental future events could cause assumptions used expected long term rates return bonds determined impairment reviews change consequent adverse effect based portfolio mix indexlinked government future results group corporate bonds equity risk premium added equities goodwill discount rates based appropriate longterm indices including goodwill arising business combinations capitalised iboxx year aa index uk moodys aa index allocated appropriate cash generating unit deemed usa sensitivity analysis provided note pensions indefinite life amortised annual postemployment benefits reduction impairment tests relevant cash generating units discount rate would lead increase net pension performed impairment tests based established market deficit approximately million increase annual multiples riskadjusted future cash flows discounted using pension cost approximately million selection different appropriate interest rates future cash flows based assumptions could affect future results group business forecasts therefore inherently judgemental future events could cause assumptions used new accounting requirements impairment reviews change consequent adverse following ifrs ifric interpretations issued effect future results group iasb likely affect future annual reports although intangible assets none expected material impact results intangible assets acquired gsk third parties financial position group costs acquisition capitalised licences compounds ifrs operating segments issued november development amortised point required implemented gsk st january available use estimated useful lives may standard replaces ias aligns segmental include periods nonexclusivity estimated useful lives reporting requirements equivalent us reviewed annually impairment tests undertaken events standard whereby segmental information disclosed occur call question carrying values assets basis used internal reporting purposes brands acquired businesses capitalised independently gsk assessing impact standard presentation separable expected life segmental information one year brands amortised straightline basis estimated useful lives exceeding years except ias revised borrowing costs issued march end useful economic life foreseen brands implemented prospectively st january amortised subject annual impairment tests requires borrowing costs attributable acquisition impairment tests based established market multiples risk construction certain assets capitalised option adjusted future cash flows discounted using appropriate interest currently taken gsk expensing costs incurred rates future cash flows based business forecasts longer available therefore inherently judgemental future events could cause assumptions used impairment reviews change consequent adverse effect future results groupgsk annual report financial statements notes financial statements continued ias revised presentation financial statements issued exchange rates september effective st january group uses average exchange rates prevailing amendments standard mandate various presentation period translate results cash flows overseas formats disclosures many already adopted subsidiaries joint ventures associated undertakings gsk movements equity presented statement sterling period end rates translate net assets changes equity rather note financial statements undertakings currencies influence ifrs revised sharebased payment issued january translations relevant exchange rates revised standard apply retrospectively st january specifies cancellations share average rates based payment arrangements including employee us counterparty receive accounting treatment euro requiring immediate recognition income statement yen charge would otherwise recognised remainder service period period end rates us iasbs annual improvements project published may euro effective st january project yen makes minor amendments number standards topics including investments associates intangible assets borrowing costs impairment assets ifrs revised business combinations issued january apply business combinations arising st january amongst changes new standard require recognition subsequent changes fair value contingent consideration income statement rather goodwill transaction costs recognised immediately income statement fair value gains losses existing investments acquired company recognised income statement date acquisition ias revised consolidated separate financial statements issued january implemented time ifrs revised respect transactions noncontrolling interests group entities result change control revised standard requires difference consideration paid received recorded noncontrolling interest recognised equity case divestment subsidiary retained interest remeasured fair value difference fair value previous carrying value recognised immediately income statement ifrs revised ias revised applied prospectively transactions occurring implementation date therefore possible assess advance impact financial statements group gsk annual report financial statements notes financial statements continued segment information groups primary segment reporting business sector geographical reporting secondary format business sectors consist pharmaceuticals consumer healthcare geographical sectors usa europe rest world reflect groups significant regional markets consistent groups regional market management reporting structure business sector data includes allocation corporate costs sector appropriate basis sales business sectors groups activities organised global basis geographical sector figures influenced location groups operating resources particular manufacturing research variations time intragroup trading funding arrangements turnover shown business sector location customer location subsidiary operating profit shown business sector location subsidiary geographic information given location subsidiary following review strategic direction group year several entities reclassified europe rest world addition one entity china reclassified pharmaceuticals consumer healthcare comparative information restated onto consistent basis restated restated turnover business sector pharmaceuticals consumer healthcare turnover profit business sector pharmaceuticals consumer healthcare operating profit finance income finance costs share tax profits associates joint ventures pharmaceuticals consumer healthcare profit taxation taxation profit taxation year property plant equipment intangible assets business sector additions pharmaceuticals consumer healthcare total additions depreciationamortisation pharmaceuticals consumer healthcare total depreciationamortisation impairment pharmaceuticals consumer healthcare total impairment impairment reversal pharmaceuticals consumer healthcare total impairment reversal gsk annual report financial statements notes financial statements continued segment information continued restated investments associates joint ventures business sector pharmaceuticals consumer healthcare investment associates joint ventures total assets business sector pharmaceuticals consumer healthcare total operating assets investments associates joint ventures liquid investments derivative financial instruments cash cash equivalents current deferred taxation assets held sale total assets total liabilities business sector pharmaceuticals consumer healthcare total operating liabilities shortterm borrowings longterm borrowings derivative financial instruments current deferred taxation total liabilities net assets business sector pharmaceuticals consumer healthcare net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale net assets gsk annual report financial statements notes financial statements continued segment information continued restated restated turnover location customer usa europe rest world turnover turnover location subsidiary undertaking usa europe rest world turnover including intersegment turnover usa europe rest world intersegment turnover usa europe rest world external turnover operating profit location subsidiary undertaking usa europe rest world operating profit property plant equipment intangible asset additions location usa europe rest world total additions total assets location usa europe rest world intersegment trading balances total operating assets gsk annual report financial statements notes financial statements continued segment information continued net operating assets location usa europe rest world net operating assets uk segment uk included groups europe market region turnover location customer turnover including intersegment turnover intersegment turnover turnover location subsidiary noncurrent assets major restructuring programmes october gsk announced significant new operational excellence programme improve effectiveness productivity operations significant expansion operational excellence programme approved board announced february total costs implementation expanded programme expected approximately billion incurred period approximately costs incurred st december approximately expected incurred balance mostly total approximately costs expected cash expenditures expected accounting writedowns uncertainties exist exact amount timing cash outflows result potential future exchange rate fluctuations many elements restructuring programme subject employee consultation procedures making difficult predict precision procedures completed however majority remaining cash payments expected made programme expected deliver total annual pretax savings billion savings realised across business costs million incurred operational excellence programme arisen following areas commencement closure number manufacturing sites including dartford crawley uk cidra puerto rico giving rise asset writedowns staff reductions foreign exchange loss liquidation subsidiary adoption customised sales approaches leading staff reductions number sales forces principally usa cost saving projects rd focused primarily simplification streamlining support infrastructure projects eliminate unnecessary processes simplify continuing processes leading staff reductions administrative support functions addition costs million incurred year restructuring programme related integration reliant pharmaceuticals inc business usa following acquisition december gsk annual report financial statements notes financial statements continued major restructuring programmes continued analysis costs incurred programmes follows asset staff impairment reductions costs total cost sales selling general administration research development effect operating profit net finance expense effect profit taxation effect taxation effect earnings asset staff impairment reductions total cost sales selling general administration research development effect profit taxation effect taxation effect earnings asset impairments million million costs totalling million nil noncash items charges settled cash restructuring costs reported major restructuring column income statement costs related major restructuring programmes costs related minor restructuring activity initiated prior october amounting million million reported within results major restructuring costs major restructuring programmes arisen follows increase provision major restructuring programmes see note amount provision reversed unused see note impairments property plant equipment see note foreign exchange loss recognised liquidation subsidiary noncash charges cash costs net finance expense effect profit taxation noncash charges principally accelerated depreciation arising asset lives shortened result major restructuring programmes cash costs include consultancy project management fees termination leases site closure costsgsk annual report financial statements notes financial statements continued operating income royalty milestone income impairment equity investments disposal equity investments disposal assets legal settlements fair value adjustments derivative financial instruments income royalty milestone income principally core recurring income outlicensing intellectual property fair value adjustments derivative financial instruments include movements expired quest collar theravance put call options operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment amortisation intangible assets net foreign exchange gainslosses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor audit parent company consolidated financial statements fees payable companys auditor associates services reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration fees payable companys auditor associates services audit accounts groups uk overseas subsidiaries related pension schemes company pursuant legislation assurance services pursuant legislation tax services services including regulatory compliance treasury related services st december amount due pricewaterhousecoopers llp associates fees yet invoiced million comprising statutory audit million taxation services million services million fees payable pricewaterhousecoopers llp associates increased cer terms fees respect glaxosmithkline pension schemes included audit services gsk annual report financial statements notes financial statements continued employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities wages salaries declined cer terms group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans finance income interest income arising cash cash equivalents availableforsale investments derivatives fair value profit loss loans receivables realised gains liquid investments fair value adjustments derivatives fair value profit loss net investment hedge ineffectiveness unwinding discounts assets derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest income arising derivatives fair value profit loss relates swap interest incomegsk annual report financial statements notes financial statements continued finance costs interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value adjustments derivatives designated hedging instruments fair value adjustments hedged items fair value adjustments derivatives fair value profit loss unwinding discounts provisions derivatives fair value profit loss except designated effective hedging instruments classified heldfortrading financial instruments ias associates joint ventures associates share tax profits quest diagnostics inc share tax losses associates share tax profitslosses joint ventures share turnover joint ventures sales joint ventures associates summarised income statement information respect groups associates set total turnover quest diagnostics inc others total profit quest diagnostics inc others gsk annual report financial statements notes financial statements continued taxation taxation charge based profits year uk corporation tax uk statutory rate less double taxation relief overseas taxation current taxation deferred taxation reconciliation taxation rate group profits uk statutory rate taxation overseas taxes benefit special tax status rd credits intercompany stock profit impact share based payments tax profit associates differences prior year items restructuring tax rate additional uk corporation tax double taxation relief arise dividends received overseas subsidiaries group operates countries tax rate differs uk tax rate impact overseas taxes overall rate tax shown profits arising certain operations singapore puerto rico ireland accorded special status taxed reduced rates compared normal rates tax territories effect reduction taxation charge increased earnings per share p p p group required ifrs create deferred tax asset respect unrealised intercompany profit arising inventory held group yearend applying tax rate country inventory held rather tax rate country profit originally made tax paid practice uk us gaap result difference accounting treatment group tax rate ifrs increased decrease decrease arising changes workinprogress finished goods integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax resolution issues continuing fact life gsk groups main open tax issues usa canada japan july following discussions hmrc group settled substantially outstanding uk tax issues periods including st december following audit period irs issued statutory notices deficiency gsk asserting income withholding tax deficiencies associated penalties arising reclassification intercompany financing arrangement years debt equity consequent recharacterisation amounts paid dividends subject withholding tax us uk treaty amounts due financing arrangement paid timely basis final payment made april irs commenced audit period june examining issue years gsk disagrees irs position august initiated actions united states tax court contest statutory notices deficiency gsk estimates irs claim tax penalties interest st december net federal tax relief million gsk believes claim merit adjustment warranted contrary gsks view irs prevailed argument court respect years gsk would expect additional liability five year period amount million tax penalties interest st december net federal tax relief years event company able resolve issue irs court decision would expected gsk annual report financial statements notes financial statements continued taxation continued lower courts japan upheld claims tax authorities yen billion million relating japanese cfc legislation company paid fully provided full tax pursuing claim refund japanese supreme court canada court decision respect transfer pricing early completed may gsk filed appeal june court date awaited gsk continues believe made adequate provision liabilities likely arise open assessments ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings negotiations relevant tax authorities provision made taxation would arise distribution profits retained overseas subsidiary associated undertakings grounds remittance profit retained st december required way incremental tax arise aggregate amount unremitted profits balance sheet date approximately billion billion payable recoverable net movement current tax account st january exchange adjustments charge year cash paid transfer tofrom deferred tax movements st december movement deferred tax assets liabilities pensions manu share accelerated intra post legal facturing stock option net offset deferred taxation capital group retirement tax restruct valuation award temporary within allowances intangibles profit benefits losses disputes uring adjustments schemes differences countries total assetliability deferred tax asset st january deferred tax liability st january st january exchange adjustments chargecredit income statement creditcharge equity transfer tofrom current tax acquisitions st december deferred tax assets st december deferred tax liability st december deferred tax charge income relating changes tax rates million deferred tax movements arise origination reversal temporary differences net temporary differences include accrued expenses provisions gsk annual report financial statements notes financial statements continued taxation continued st december group recognised deferred tax asset million million respect income tax losses approximately million million losses million million due expire million million due expire million million available indefinitely st december group recognised deferred tax asset respect income tax losses approximately million million million million due expire million million due expire million million available indefinitely group capital losses st december approximately billion respect deferred tax asset recognised deferred tax assets recognised probable future taxable profit available utilise losses earnings per share pence pence pence basic earnings per share adjustment major restructuring results major restructuring earnings per share basic diluted earnings per share adjustment major restructuring results major restructuring earnings per share diluted basic adjusted earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares adjusted earnings per share calculated using results major restructuring earnings calculation results major restructuring described note presentation financial statements diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options diluted shares held esop trusts excluded trustees waived rights dividends shares held esop trustsgsk annual report financial statements notes financial statements continued dividends first interim second interim third interim fourth interim total total dividend dividend per share pence paidpayable th july th october th january th april total dividend dividend per share pence paid th july th october th january th april total dividend dividend per share pence paid th july th october th january th april ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders property plant equipment plant land equipment assets buildings vehicles construction total cost st january exchange adjustments additions additions business combinations disposals writeoffs reclassifications transfer assets held sale cost st december exchange adjustments additions additions business combinations disposals writeoffs reclassifications transfer assets held sale cost st december gsk annual report financial statements notes financial statements continued property plant equipment continued plant land equipment assets buildings vehicles construction total depreciation st january exchange adjustments provision year disposals writeoffs transfer assets held sale depreciation st december exchange adjustments provision year disposals writeoffs transfer assets held sale depreciation st december impairment st january exchange adjustments disposals writeoffs impairment losses reversal impairments impairment st december exchange adjustments disposals writeoffs impairment losses reclassifications reversal impairments impairment st december total depreciation impairment st december total depreciation impairment st december net book value st january net book value st december net book value st december net book value st december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million included land buildings st december leased assets cost million million accumulated depreciation million million impairment million nil net book value million million included plant equipment vehicles st december leased assets cost million million accumulated depreciation million million net book value million st january million lease agreements include renewal purchase options escalation clausesgsk annual report financial statements notes financial statements continued property plant equipment continued impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs sell value use value use calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate country specific risks impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately impairment losses charged cost sales million rd million sga million include million million arising major restructuring programmes reversals impairment arise subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales goodwill cost st january exchange adjustments additions business combinations impairments cost st december net book value st january net book value st december additions year translated acquisition exchange rates comprise million acquisition sirtris pharmaceuticals inc million acquisition bms egypt business see note acquisitions disposals details carrying value goodwill translated yearend exchange rates made balances arising acquisition following companies cash generating unit reliant pharmaceuticals inc us pharmaceuticals id biomedical corporation vaccines sirtris pharmaceuticals inc worldwide pharmaceuticals glaxosmithkline kk japan pharmaceuticals domantis limited worldwide pharmaceuticals cns inc consumer healthcare polfa poznan sa poland pharmaceuticals bms egypt emerging markets pharmaceuticals corixa corporation vaccines others gsk annual report financial statements notes financial statements continued goodwill continued goodwill allocated cash generating units tested impairment least annually valuations worldwide pharmaceuticals cash generating unit sirtris pharmaceuticals domantis us pharmaceuticals cash generating unit reliant pharmaceuticals prepared fair value less costs sell basis using turnover earnings multiples derived observed market data case value goodwill inherent cash generating units considerably excess book values acquired goodwill recoverable amounts cash generating units assessed using either value use fair value less costs sell model value use calculated net present value projected riskadjusted posttax cash flows plus terminal value cash generating unit goodwill allocated initially posttax discount rate applied calculate net present value posttax cash flows posttax discount rate used based group wacc cash generating units integrated operations across large parts group discount rate increased specific country risks sufficiently significant material impact outcome impairment test group wacc equivalent pretax discount rate approximately impairment test indicates recoverable value unit close carrying value reperformed using pretax discount rate pretax cash flows order determine impairment exists establish magnitude fair value calculated using similar discounted cash flow approach based groups acquisition valuation model posttax discount rate applied projected riskadjusted posttax cash flows terminal value details relating discounted cash flow models used impairment tests significant goodwill balances follows vaccines cgu japan pharmaceuticals cgu consumer healthcare cgu poland pharmaceuticals cgu id biomedical glaxosmithkline kk cns polfa poznan valuation basis fair value less costs sell fair value less costs sell fair value less costs sell value use key assumptions sales growth rates sales growth rates sales growth rates sales growth rates profit margins profit margins advertising profit margins discount rate discount rate promotion investment discount rate terminal growth rate determination growth rates internal growth rates internal growth rates internal growth rates internal assumptions forecasts based forecasts based forecasts based forecasts based internal external internal external internal external internal external market information market information market information market information margins reflect past margins reflect past advertising promotion margins reflect past experience adjusted experience adjusted investment based experience adjusted expected changes expected changes historical levels adjusted expected changes discount rate based discount rate based managements view discount rate based group wacc group wacc support needed group wacc innovation expansion terminal growth rate based managements estimate future long term average growth rates period specific years years years years projected cashflows discount rate terminal growth rate pa pa pa pa decline terminal growth rates exceed longterm projected growth rates relevant markets terminal growth rate used value use calculation poland pharmaceuticals cgu reflects impact future generic competition takes account new product launches consumer healthcare cash generating unit comprises collection smaller cash generating units including brands indefinite lives carrying value million million detailed note intangible assets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwillgsk annual report financial statements notes financial statements continued intangible assets computer licences amortised indefinite life software patents etc brands brands total cost st january exchange adjustments capitalised internal development costs additions business combinations additions disposals asset writeoffs transfer assets held sale cost st december exchange adjustments capitalised internal development costs additions business combinations additions disposals asset writeoffs reclassifications cost st december amortisation st january exchange adjustments provision year disposals asset writeoffs transfer assets held sale amortisation st december exchange adjustments provision year disposals asset writeoffs amortisation st december impairment st january exchange adjustments impairment losses disposals asset writeoffs impairment st december exchange adjustments impairment losses impairment reversals impairment st december total amortisation impairment st december total amortisation impairment st december net book value st january net book value st december net book value st december gsk annual report financial statements notes financial statements continued intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development additions business combinations year million comprise million acquired acquisition sirtris pharmaceuticals million acquired acquisition bms egypt see note acquisitions disposals st december net book value included million arising acquisition reliant pharmaceuticals inc million arising acquisition id biomedical corporation also included million million internally generated costs million million related computer software million million related compounds development amortised brands include otc rights relating alli book value st december million million indefinite life brands comprise portfolio consumer healthcare products acquired acquisitions sterling winthrop inc block drug company inc cns inc book values major brands follows panadol sensodyne breathe right polident corega biotene poligrip solpadeine others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortised brand tested annually impairment applying fair value less costs sell methodology generally using four year posttax cash flow forecasts terminal value calculation discount rate equal group posttax weighted average cost capital adjusted appropriate countryspecific risks main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment brandsgsk annual report financial statements notes financial statements continued investments associates joint ventures joint associated joint associated ventures undertakings total ventures undertakings total st january exchange adjustments additions transfer investments fair value adjustment retained profitloss year st december principal associated undertaking quest diagnostics inc us clinical laboratory business listed new york stock exchange investment book value st december million million market value million million st december group owned quest although group holds less ownership interest voting control quest group ability exercise significant influence significant shareholding nominated directors active participation quest board directors board subcommittees transfers investments relates groups holding chemocentryx previously classified within investments increased year summarised balance sheet information respect groups associates set total assets quest diagnostics inc others total liabilities quest diagnostics inc others net assets groups share associates net assets gsk hedged part equity value holding quest diagnostics inc series variable sale forward contracts contracts equity collar renewed structured five series two million quest shares due mature second series hedging contracts additional million shares entered th february contracts also structured five series two million quest shares due mature year contracts held lehman brothers finance sa respect total million quest shares terminated material financial impact gsk investments joint ventures comprise million share gross assets million million share gross liabilities million principally arise interests two joint ventures shionogiglaxosmithkline holdings lp developing specified chemical compounds glaxosmithkline shire canada primarily comarkets combivir trizivir epivir certain territories together interest another joint venture pharmaceutical insurance limited mutual insurance company covering pharmaceutical property risk gsk annual report financial statements notes financial statements continued investments st january exchange adjustments additions net fair value movements impairments transfer associates disposals st december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated reference current market value similar instruments reference discounted cash flows underlying net assets equity investments recorded noncurrent assets unless expected sold within one year case recorded current assets group holds number equity investments entities group entered research collaborations investments include listed investments million million offer group opportunity return dividend income fair value gains disposal investments fair value movements reclassified reserves income statement based average cost shares acquired different times impairment losses recorded tables recognised income statement year within operating income together amounts recycled fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement st december impaired assets fair value million million included investments transfer associates relates groups holding chemocentryx increased year noncurrent assets amounts recoverable insurance contracts pension schemes surplus receivables inventories raw materials consumables work progress finished goods gsk annual report financial statements notes financial statements continued trade receivables trade receivables prepaid pension contributions prepayments accrued income interest receivable employee loans advances receivables trade receivables include million million due associates joint ventures bad doubtful debt provision st january exchange adjustments charge year subsequent recoveries amounts provided utilised st december cash cash equivalents cash bank hand shortterm deposits commercial paper assets held sale land buildings plant equipment vehicles gsk annual report financial statements notes financial statements continued trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals accruals customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers principally usa provisions made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome amounts subject change dependent upon amongst things types buying group product sales mix level provision reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions provisions based change could affect future results group pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes postemployment costs costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service hybrid defined benefit schemes also include defined contribution sectionsgsk annual report financial statements notes financial statements continued pensions postemployment benefits continued pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement recognised income expense uk us discount rates derived aa rated corporate bond yields intended reflect term expected benefit payments expected rate return bonds reflects portfolio mix indexlinked government corporate bonds equity risk premium added longer term government bond yields give expected rate return equities projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting pa standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line medium cohort ie improvements recently observed higher levels assumed continue minimum improvements thereafter per year males females usa mortality rates calculated using rp fully generational table projected using scale aa white collar adjustment mortality assumptions uk us schemes reviewed updated gsk expects review average life expectancy assumed individual age projected apply individual age follows uk usa male female male female years years years years current projected assets funded schemes generally held separately administered trusts insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment following asset liability study group decided adopt strategy reduce gradually allocation investment equities uk proposed strategy linked funding levels schemes considered trustees uk schemes target allocation equities property us scheme reduced total uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one usa group applied following financial assumptions assessing defined benefit liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report financial statements notes financial statements continued pensions postemployment benefits continued amounts recorded income statement statement recognised income expense three years ended st december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial lossesgains recorded statement recognised income expense amounts included settlements curtailments include million augmentation costs arising major restructuring programmes see note provisions postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial gains recorded statement recognised income expense postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial gains recorded statement recognised income expense total actuarial losses recorded statement recognised income expense since st january amount milliongsk annual report financial statements notes financial statements continued pensions postemployment benefits continued fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk usa rest world group average expected rate fair expected rate fair expected rate fair fair st december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost restriction surplus recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets uk usa rest world group average expected rate fair expected rate fair expected rate fair fair st december return value return value return value value equities property bonds assets fair value assets present value scheme obligations included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report financial statements notes financial statements continued pensions postemployment benefits continued uk usa rest world group average expected rate fair expected rate fair expected rate fair fair st december return value return value return value value equities property bonds assets fair value assets present value scheme obligations included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report financial statements notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits movements defined benefit obligations uk usa rest world group group obligations st january exchange adjustments service cost interest cost settlements curtailments actuarial lossesgains scheme participants contributions benefits paid obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial gains scheme participants contributions benefits paid transfers provisions recognised balance sheet st december unrecognised past service cost obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial gains scheme participants contributions benefits paid transfers obligations st december unrecognised past service cost recognised balance sheet st december uk defined benefit schemes include defined contribution sections obligations totalling million st december million million liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation reducing per year thereafter us postretirement healthcare scheme amended main change increase cap company costs st december us plan obligation million million million however accordance ias unvested part benefit improvement recognised immediately balance sheet recognised gradually income statement st december unrecognised amount million primarily relates effect change us postretirement scheme st december past service cost recognised scheme amounted million gsk annual report financial statements notes financial statements continued pensions postemployment benefits continued defined benefit pension obligation analysed follows funded unfunded postretirement benefits unfunded postretirement pensions benefits movements fair values assets uk usa rest world group group assets st january exchange adjustments expected return assets settlements curtailments actuarial gains employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets settlements curtailments actuarial gains employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets settlements curtailments actuarial losses employer contributions scheme participants contributions benefits paid assets st december uk defined benefit schemes include defined contribution sections account balances totalling million st december million million group made special funding contributions uk pension schemes totalling million million uk pension schemes million related prepayment contributions would due gsk formalised agreement trustees uk defined benefit pension schemes make additional contributions year addition normal contributions fouryear period ending st december order eliminate pension deficits funded schemes ias basis gsk also committed eliminate future deficits arise rolling fiveyear period agreement reviewed employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefitsgsk annual report financial statements notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits history experience gains losses uk usa rest world group group experience losses scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experience gainslosses scheme assets percentage scheme assets st december experience gainslosses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficitssurpluses schemes experience gains scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficitssurpluses schemes experience gains scheme assets percentage scheme assets st december experience losses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experience gains scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes gsk annual report financial statements notes financial statements continued pensions postemployment benefits continued sensitivity analysis effect changes assumptions used annual defined benefit pension postretirement costs benefit obligations decrease discount rate would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation decrease expected rates returns assets would following approximate effect increase annual pension cost increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation provisions integration legal major employee restructuring related manufacturing disputes programmes provisions reorganisation provisions total st january exchange adjustments charge year reversed unused unwinding discount utilised transfer pensions obligations reclassifications movements st december settled within one year settled one year st december gsk annual report financial statements notes financial statements continued provisions continued provisions staff severance payments made management made formal decision eliminate certain legal disputes positions communicated groups gsk involved number legal disputes including employees affected provision made staff severance notification possible claims set note legal payments made immediately proceedings provisions legal disputes include amounts relating us antitrust product liability contract approximately costs incurred st december terminations selfinsurance environmental cleanup property approximately expected incurred rental companys directors taken legal balance mostly total specialist advice established provisions taking approximately costs expected cash account insurance agreements regard expenditures expected accounting write relevant facts circumstances matter downs uncertainties exist exact amount timing accordance accounting requirements cash outflows result potential future exchange rate fluctuations many elements restructuring charge year included charge million programme subject employee consultation procedures announced january related us investigation making difficult predict precision gsks marketing promotional practices originated procedures completed however majority colorado discount provisions decreased million remaining cash payments expected made million decrease calculated using riskadjusted projected cash flows riskfree rates return movement includes decrease million arising addition costs million incurred year change discount rate year number products restructuring programme related integration history claims made settlements makes possible reliant pharmaceuticals inc business usa following use ibnr incurred reported actuarial technique acquisition december determine reasonable estimate groups exposure pension augmentations arising staff redundancies unasserted claims relation products apart million charged year ibnr provision provisions made unasserted transferred pension obligations provision shown claims ultimate liability matters may vary note pensions postemployment benefits asset amounts provided dependent upon outcome litigation writedowns recognised impairments property proceedings investigations possible settlement negotiations plant equipment note property plant equipment nature groups business number employee related provisions matters including provided using ibnr actuarial technique employee related provisions includes exchange offer incentive may subject negotiation litigation several years programme operated time merger encourage largest individual amounts provided expected settled staff convert glaxo wellcome smithkline beecham share within three years options glaxosmithkline share options incentive paid st december expected million either employees exercise relevant options million provision made legal options lapse impact discounting disputes reimbursed third party insurers amount provision increased million included within current noncurrent assets discussion calculated using riskfree rates return group also provides legal issues refer note legal proceedings certain medical benefits disabled employees spouses usa st december provision benefits major restructuring programmes amounted million employee benefits reflect variety october gsk announced significant new operational provisions severance costs jubilee awards long excellence programme improve effectiveness service benefits productivity operations see note major restructuring programmes significant expansion operational integration manufacturing reorganisation excellence programme approved board group recognised costs previous years respect announced february total costs implementation plans integration glaxo wellcome smithkline expanded programme expected beecham businesses implementation integration following approximately billion incurred period merger substantially complete costs recognised remaining merger integration provision respect identified severances expected settled smaller costsaving initiatives since merger included within category gsk annual report financial statements notes financial statements continued noncurrent liabilities accruals deferred income payables contingent liabilities st december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million st december million million financial assets pledged collateral contingent liabilities discussions tax legal issues refer note taxation note legal proceedings net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange commercial paper bank loans overdrafts loans obligations finance leases longterm borrowings european medium term note london stock exchange us floating rate note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange loan stock bank loans loans private financing obligations finance leases net debt gsk annual report financial statements notes financial statements continued net debt continued current assets liquid investments classified availableforsale investments st december included government bonds us treasury notes effective interest rate liquid investments st december approximately approximately liquid investment balances st december earning interest floating fixed rates amount million million respectively million million effective interest rate cash cash equivalents st december approximately approximately cash cash equivalents balances st december earning interest floating fixed rates amount million million respectively million million gsk tightened criteria holding cash equivalents liquid investments response credit crisis gsks policy regarding credit quality cash cash equivalents referred note financial instruments related disclosures shortterm borrowings commercial paper comprises us billion programme nil nil issue st december billion billion backed committed facilities days duration billion billion billion billion renewable annually liquid investments cash cash equivalents shown table weighted average interest rate current bank loans overdrafts st december longterm borrowings yearend gsk longterm borrowings billion billion billion billion falls due five years longterm borrowings repayable five years carry interest effective rates repayment dates range average effective interest rate notes st december approximately approximately secured liabilities gsk loans secured charges noncurrent current assets year nil group pledged investments us treasury notes par value million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations finance lease obligations st december bearing interest floating fixed rates amount million million respectively million million gsk annual report financial statements notes financial statements continued share capital share premium account share ordinary shares p premium number share capital authorised st december st december st december share capital issued fully paid st december issued share option schemes st december issued share option schemes share capital purchased cancelled st december issued share option schemes share capital purchased cancelled st december st december st december number shares issuable outstanding options note number unissued shares option st december issued share capital shares held esop trust shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trust disclosed note employee share schemes share capital purchased cancelled includes cancellation million previously acquired treasury shares total billion spent company st january st december buying shares cancellation held treasury shares billion spent repurchases total billion repurchased current billion share buy back programme purchases since st december programme gsk expect make significant share repurchases table sets monthly purchases share buyback programme average share price excluding number shares commission stamp duty month january february march april may june july august september october november december total shares purchased cancelled details substantial shareholdings refer substantial shareholdings gsk annual report financial statements notes financial statements continued movements equity shareholders equity share share retained minority total total capital premium earnings reserves interests equity st january recognised income expense year changes minority shareholdings distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased held treasury shares ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax share based incentive plans st december recognised income expense year distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased cancelled ordinary shares purchased held treasury shares ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december recognised income expense year distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december gsk annual report financial statements notes financial statements continued movements equity continued retained earnings reserves amounted million st december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity shown following table net translation exchange included total fair value retained minority translation reserve earnings interest exchange st january exchange movements overseas net assets st december exchange movements overseas net assets st december exchange movements overseas net assets recycling exchange liquidation overseas subsidiary st december analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total st january transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares transferred esop trusts writedown shares held esop trusts st december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts st december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts st december reserves consist various nondistributable merger premerger reserves amounting million st december million million reserves also include capital redemption reserve created result share buyback programme amounting million st december million milliongsk annual report financial statements notes financial statements continued related party transactions gsk held interest quest diagnostics inc st december group quest diagnostics parties longterm contractual relationship quest diagnostics primary provider clinical laboratory testing support groups clinical trials testing requirements worldwide quest diagnostics provided services million million group st december balance payable gsk quest diagnostics nil million group shionogi co ltd entered transactions us joint venture company support research development activities conducted joint venture company gsk provided services joint venture million million st december balance due gsk joint venture million million dr shapiro former nonexecutive director glaxosmithkline plc received fees form ads subsidiary company membership groups scientific advisory board fees included within annual remuneration remuneration report aggregate compensation directors cet company secretary given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance incomecosts depreciation amortisation intangible assets impairment assets written profit sale intangible assets profit sale equity investments changes working capital increase inventories decreaseincrease trade receivables decreaseincrease receivables decreaseincrease trade payables decreaseincrease payables increasedecrease pension provisions sharebased incentive plans cash generated operations result two reclassifications cash generated operations million million lower given gsks unaudited preliminary results announcement issued th february addition decrease liquid investments year reclassified financing activities investing activities comparative amounts also reclassified gsk annual report financial statements notes financial statements continued reconciliation net cash flow movement net debt net debt beginning year increasedecrease cash bank overdrafts cash inflowoutflow liquid investments net increase longterm loans net repayment ofincrease shortterm loans net repayment obligations finance leases exchange adjustments noncash movements movement net debt net debt end year analysis changes net debt exchange acquisitions cash flow liquid investments cash cash equivalents overdrafts debt due within one year commercial paper eurobonds mediumterm notes debt due one year eurobonds mediumterm notes private financing net debt information significant changes net debt see note net debt acquisitions disposals details acquisition disposal subsidiary associated undertakings joint ventures businesses given acquisitions sirtris pharmaceuticals inc th june group acquired issued share capital sirtris pharmaceuticals inc biopharmaceutical company based massachusetts usa cash consideration million company focused discovering developing proprietary orally available small molecule drugs potential treat diseases associated ageing including metabolic diseases type diabetes sirtris drug candidates designed mimic certain beneficial health effects calorie restriction activation sirtuins recently discovered class enzymes sirtris believes control ageing process transaction accounted purchase method accounting goodwill arising acquisition reflects potential enabling gsk enhance metabolic neurology immunoinflammation research efforts establishing worldleading presence sirtuin field aided existence company highly experienced development team encompasses aspects sirtuin biology sirtris pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax related period since acquisition included group accountsgsk annual report financial statements notes financial statements continued acquisitions disposals continued book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration bristol myers squibb egypt th october group acquired egyptian mature products business bristol myers squibb bms cash consideration million amount million deferred payment made alternative supply arrangements established group acquired branded products occupy leading market positions four therapeutic disease areas egypt including duricef antibiotic capozide capoten ace inhibitors theragranh iron supplement kenacomb topical steroid total sales combined mature products pharmaceuticals business million group also take ownership bmss high quality manufacturing facility giza greater cairo continue supply acquired products group ability export generic versions acquired products markets outside egypt thereby creating opportunity drive sales growth middle east north africa region fact reflected goodwill arising acquisition business turnover million profit tax million year million turnover million profit tax related period since acquisition included group accounts fair values set based provisional valuations may subject change future book fair value fair value adjustment value net assets acquired intangible assets property plant equipment inventory goodwill total consideration sirtris bms egypt acquired beginning year combined group turnover year would million combined group profit year would million shionogi euclid sr glaxosmithkline cash flows sirtris bms egypt partners lp holdings ltd total cash consideration cash cash equivalents acquired net cash payment acquisitions euclid sr partners lp additional million invested euclid sr partners lp associate group share shionogiglaxosmithkline holdings ltd additional million invested shionogiglaxosmithkline holdings ltd joint venture group share gsk annual report financial statements notes financial statements continued acquisitions disposals continued acquisitions reliant pharmaceuticals inc th december group acquired issued share capital reliant pharmaceuticals inc pharmaceutical company based usa cash consideration million company specialises development marketing speciality medicines combat heart disease includes us rights lovaza treatment adult patients high levels triglycerides transaction accounted purchase method accounting goodwill arising acquisition reflects potential product growth throughout usa puerto rico expected synergies group reliant pharmaceuticals inc turnover million profit tax million year million turnover million profit tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration domantis limited th january group acquired issued share capital domantis limited drug discovery company based uk cash consideration million company developing next generation antibody therapies transaction accounted purchase method accounting goodwill arising acquisition reflects potential combining worldleading technology domantis development programme already place within gsk put group forefront biotechnology domantis limited turnover nil loss tax million year nil turnover million loss tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration gsk annual report financial statements notes financial statements continued acquisitions disposals continued praecis pharmaceuticals inc th february group acquired issued share capital praecis pharmaceuticals inc biopharmaceutical company based usa cash consideration million company developed efficient method identifying drug leads targeting human disease using proprietary technology transaction accounted purchase method accounting praecis pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax asset liabilities goodwill total consideration reliant domantis praecis total cash flows cash consideration cash cash equivalents acquired net cash payment acquisitions reliant domantis praecis acquired beginning year combined group turnover year would million combined group profit year would million acquisitions cns inc th december group acquired issued share capital cns inc consumer healthcare company based usa cash consideration million company markets breathe right nasal dilator strips fiberchoice dietary fibre supplements key intangible assets acquired valued using discounted cash flow calculation transaction accounted purchase method accounting goodwill arising acquisition reflects potential expansion brands overseas markets expected synergies group cns inc turnover million million profit million profit million million turnover nil profit related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration gsk annual report financial statements notes financial statements continued acquisitions disposals continued euclid sr partners lp additional million invested euclid sr partners lp associate group share shionogiglaxosmithkline holdings ltd additional million invested shionogi glaxosmithkline holdings ltd joint venture group share pliva research institute ltd may group purchased entire share capital pliva research institute ltd cash consideration million amount million deferred payment made phase clinical trials initiated glaxosmithkline kk august japanese subsidiary group made cash payment million complete purchase remaining share capital held minority shareholder payment preceded year dividend minority shareholders million representing additional consideration shionogi pliva euclid sr glaxosmithkline research glaxosmith cns partners lp holdings ltd institute kline kk total cash flows cash consideration cash cash equivalents acquired net cash payment acquisitions net cash proceeds disposals commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments business combinations pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted majority intangible commitments denominated us dollars significant strengthening foreign currencies year led increase commitments reported number commitments made licensing agreements including arrangements actelion pharmaceuticals limited archemix corporation dynavax technologies corporation mpex pharmaceuticals inc commitments relating business combinations reflect agreements acquire issued share capital genelabs technologies inc bristol myers squibb pakistan private limited az tika snc latter subject clearance swedish competition authority gsk formalised agreement trustees uk pension schemes make additional contributions addition normal contributions fouryear period ending st december order eliminate funded pension deficits ias basis point table shows commitment net million additional contributions made excludes normal ongoing annual funding requirement approximately million gsk also committed eliminate future deficits may arise rolling fiveyear periodgsk annual report financial statements notes financial statements continued commitments continued group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases post balance sheet events rd january gsk acquired ucbs marketed product portfolio across certain territories africa middle east asia pacific latin america million th february synta pharmaceuticals corp announced following identification safety concerns stopped phase iii study elesclomol compound developing jointly gsk gsks intangible assets include million relating milestones paid synta pharmaceuticals relation compound likely impaired yet possible determine final amount impairment pending completion full analyses data subsequent yearend gsk also completed business product acquisitions genelabs bms pakistan collaboration agreements archemix idenix gsk annual report financial statements nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss continued financial instruments related disclosures selling margins sufficient cover normal operating costs operations cash generative glaxosmithkline plc reports sterling pays dividends sterling profits role corporate treasury manage operating cash flow used fund investment research monitor external internal funding requirements development new products also used make financial risks support corporate objectives routine outflows capital expenditure tax dividends treasury activities governed policies procedures repayment maturing debt extent determined approved board directors recently th board share repurchases september policy borrow centrally using variety capital treasury management group tmg chaired chief financial market issues borrowing facilities meet anticipated officer meets monthly basis review treasury activities funding requirements members receive management information relating treasury borrowings together cash generated activities internal auditors review treasury internal control operations onlent used fund ongoing environment regularly operations acquisition strategy gsk uses variety financial instruments including total capital group increased derivatives finance operations manage market million million resulted risks operations derivatives principally comprising primarily increase net debt partially set forward foreign currency contracts interest rate currency decrease total equity decrease total equity principally swaps used swap borrowings liquid assets arises actuarial losses defined benefit pension plans currencies required group purposes manage year share repurchases partially offset exposure funding risks changes foreign exchange retained earnings net debt primarily increased rates interest rates issuance billion debt us shelf registration gsk hold issue derivative financial instruments statement million emtn programme speculative purposes treasury policies specifically primarily long term debt part proceeds used prohibit activity transactions financial instruments repay maturing shortterm debt resulting overall increase undertaken manage risks arising underlying cash position st december business activities speculation liquidity risk capital management manage net borrowing requirements manage capital ensure entities group portfolio longterm borrowings including bonds together able operate going concerns optimise return shortterm finance us billion commercial shareholders appropriate balance debt paper programme equity board reviews groups dividend policy year committed undrawn bank facilities funding requirements annually reduced billion billion consequence capital structure group consists net debt see acquisition abn amro collapse lehman brothers note net debt shareholders equity see note facilities renewed october consider movements equity level committed facilities adequate given current cash holdings recent changes financial markets expect investment opportunities arise allow group european medium term note programme invest support strategic priorities ensure billion st december billion sufficient flexibility take advantage opportunities notes issue programme also us shelf currently expect make significant share repurchases registration statement st december investment opportunities continue assessed billion billion notes issue programme strict financial criteria tmg monitors cash flow forecast monthly basis operations global primarily subsidiary longterm borrowings mature dates companies established markets trade longterm debt ratings remained stable since significant levels patent protection pharmaceutical february currently rated stable outlook products compete largely product efficacy rather standard poors negative outlook moodys pricegsk annual report financial statements notes financial statements continued financial instruments related disclosures gsks greatest concentration credit risk billion continued billion invested us treasuries treasuryrepo money market funds bear credit exposure us shortterm debt ratings p standard government see details groups total poors moodys respectively well committed financial assets facilities also substantial cash liquid investments treasuryrelated credit risk amounted billion st december also benefit strong positive cash flow operating units credit risk increased global credit crisis report relationship banks credit ratings presented market risk annually tmg approval interest rate risk management policy interest rate risk management requires aggregate credit risk respect financial instruments minimum amount net borrowings fixed rates increase group may one counterparty limited reference ratio forecast interest payable trading profit longterm credit ratings assigned counterparty fixed floating ratio reviewed monthly tmg moodys standard poors table sets credit ratings counterparties liquid investments cash use interest rate swap redenominate one cash equivalents derivatives external borrowings interest rate coupon required gsk duration swap matches duration ccreredditi tr raatitningg fc coouunnteterprpaartryty principal instrument interest rate derivative instruments aaaaaa aaaa aaaa aaaa aa aa total accounted fair value cash flow hedges relevant bank balances assets liabilities deposits foreign exchange risk management us treasury foreign currency transaction exposure arising internal treasury repo external trade flows hedged exposure overseas money operating subsidiaries transaction risk minimised market funds matching local currency income local currency costs corporate debt purpose internal trading transactions matched instruments centrally manage intercompany payment terms government securities reduce risk exceptional foreign currency cash flows hedged rd party financial selectively management corporate treasury derivatives manage shortterm cash surpluses borrowing total requirements subsidiary companies centrally using forward contracts hedge future repayments back ccrreeddiitt rraattiinngg ooff ccoouunntteerrppaarrttyy originating currency aaaaaaaaaa aaaa aaaa aa aa total seek denominate borrowings currencies bank balances principal assets cash flows primarily deposits denominated us dollars euros sterling certain us treasury borrowings swapped currencies required treasury repo money borrowings denominated swapped foreign market funds currencies match investments overseas group assets corporate debt treated hedge relevant assets forward instruments contracts also used major currencies reduce government exposure investment overseas group assets see net securities investment hedges section note details rd party financial tmg review ratio borrowings assets major derivatives currencies monthly total credit risk credit ratings tables assigned group considers maximum credit risk moodys investor services standard poors respectively million million total global associates opinion two groups financial assets exception rating agencies differ gsk assigns lower rating two investments bear credit risk counterparty gsk annual report financial statements nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd financial instruments related disclosures cash cash equivalents approximates continued carrying amount liquid investments based quoted market prices centrally managed cash reserves amounted billion case marketable securities based principal amounts st december available within months case nonmarketable securities short group invests centrally managed liquid assets bank deposits repricing periods treasuryonly money market funds credit rating aaa aaa standard poorsmoodys investors services short investments investments traded active market term corporate debt instruments minimum shortterm determined reference relevant stock exchange quoted credit rating ap bank deposits bid price investments determined reference current market value similar instruments reference global counterparty limits assigned gsks discounted cash flows underlying net assets banking investment counterparties based longterm shortterm loans overdrafts approximates credit ratings moodys standard poors corporate carrying amount short maturity treasurys usage limits monitored daily instruments corporate compliance officer cco independent corporate treasury breach limits would reported longterm loans based quoted market prices cfo immediately cco also monitors credit rating case eurobonds fixed rate borrowings counterparties changes ratings occur approximates carrying amount case floating notifies corporate treasury appropriate amendment rate bank loans loans made limits forward exchange contracts based market data wholesale retail credit risk exchange rates balance sheet date usa line pharmaceutical companies currency swaps based market data balance group sells products small number wholesalers sheet date addition hospitals pharmacies physicians interest rate swaps based net present value groups sales three largest wholesalers amount discounted cash flows approximately groups us pharmaceutical sales receivables payables approximates st december group trade receivables due carrying amount three wholesalers totalling million lease obligations approximates carrying amount million group exposed concentration credit risk respect wholesalers one fair value investments gsk shares encounters financial difficulty could materially st december esop trusts held gsk shares adversely affect groups financial results carrying value million million groups credit risk monitoring activities relating fair value million million based wholesalers includes review quarterly financial quoted market price shares represent purchases information standard poors credit ratings development esop trusts satisfy future exercises options awards gsk internal risk ratings establishment periodic employee incentive schemes carrying value review credit limits however group believes lower cost expected proceeds shares credit risk provision required excess normal recognised deduction reserves provision bad doubtful debts see note trade st december gsk held treasury shares cost receivables outside usa customers account million million trade receivables balance deducted retained earnings fair value financial assets liabilities committed facilities table presents carrying amounts group committed facilities back commercial fair values groups financial assets liabilities paper programme billion billion billion st december st december billion days duration renewable annually st december undrawn committed facilities totalled fair values financial assets liabilities included billion billion billion billion amount instrument could exchanged current transaction willing parties forced liquidation sale following methods assumptions used estimate fair valuesgsk annual report financial statements notes financial statements continued financial instruments related disclosures continued carrying fair carrying fair value value value value cash cash equivalents availableforsale investments liquid investments redeemable shares government bonds total liquid investments investments loans receivables trade receivables noncurrent assets scope ias heldfortrading financial assets derivatives designated accounting hedges derivatives total financial assets financial liabilities measured amortised cost borrowings bonds designated hedging relationship bonds commercial paper bank loans overdrafts loans private financing obligations finance leases total borrowings trade payables noncurrent liabilities scope ias heldfortrading financial liabilities derivatives designated accounting hedges derivatives total financial liabilities net financial assets financial liabilities gsk annual report financial statements nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd financial instruments related disclosures continued trade receivables noncurrent assets scope ias following table reconciles trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts assets include tax receivables pension surplus balances prepayments outside scope ias financial assets predominantly noninterest earning trade receivables note noncurrent assets note analysed financial assets scope ias assets following table shows age financial assets past due provision bad doubtful debts raised past due days past due days past due days past due days past due days amounts past due greater days total million million balance million million relates receivables due state hospital authorities certain european countries given profile customers including large wholesalers government backed agencies credit risk identified trade receivables past due balances allowance made trade payables noncurrent liabilities scope ias following table reconciles trade payables noncurrent liabilities fall within scope ias relevant balance sheet amounts liabilities include payments account tax social security payables outside scope ias financial liabilities predominantly noninterest bearing trade payables note noncurrent liabilities note analysed financial liabilities scope ias liabilities gsk annual report financial statements notes financial statements continued financial instruments related disclosures continued debt interest rate repricing table following table sets exposure group interest rates debt effect interest rate swaps maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases effect effect interest interest debt rate swaps total debt rate swaps total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing sensitivity analysis sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations place st december financial instruments affected market risk include borrowings deposits derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes relevant foreign exchange interest rates foreign exchange sensitivity table shows groups sensitivity foreign exchange rates us dollar euro yen financial instruments excluding obligations finance leases certain nonderivative financial instruments net debt present material exposure three currencies major currencies gsks financial instruments denominated gsk considered movements currencies last three years concluded movement rates reasonable benchmark table financial instruments considered sensitive foreign exchange rates functional currency entity holds intercompany loans fully hedged maturity currency swap excluded analysis increasedecrease reduction increasedecrease reduction income equity income equity appreciation appreciation us dollar appreciation appreciation euro appreciation appreciation yen depreciation stated currencies would equal opposite effect movements income statement relate primarily hedging instruments us dollar legal provisions trade payables trade receivables whilst economic hedges provisions financial instruments therefore included table sensitivity hedging instruments would insignificant provisions included movements equity relate foreign exchange positions used hedge group assets denominated us dollar euro yen therefore depreciation currency swap would give rise corresponding appreciation group asset foreign exchange sensitivity group assets financial instruments included gsk annual report financial statements nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd financial instruments related disclosures continued interest rate sensitivity table shows groups sensitivity interest rates floating rate sterling us dollar euro financial instruments currencies gsk historically issued debt held investments gsk considered movements interest rates last three years concluded increase reasonable benchmark debt maturity less one year floating rate calculation movement interest rates deemed material effect equity increasedecrease increasedecrease income income increase increase sterling interest rates increase increase us dollar interest rates increase increase euro interest rates decrease interest rates would equal opposite effect exception us dollar interest rates could decreased currently less maximum decrease income would therefore limited million interest rate movements obligations finance leases foreign currency interest rate derivatives trade payables trade receivables financial instruments net debt present material exposure groups balance sheet based increase decrease interest rates contractual cash flows nonderivative financial liabilities derivative instruments following analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held st december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates st december finance charge trade obligations obligations interest finance finance payables st december debt debt leases leases net debt total due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance charge trade obligations obligations interest finance finance payables st december debt debt leases leases net debt total due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows gsk annual report financial statements notes financial statements continued financial instruments related disclosures continued following table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options using undiscounted cash flows cash flows foreign currencies translated using spot rates st december receivables payables receivables payables less one year one two years two three years three four years four five years greater five years gross contractual cash flows derivative financial instruments hedging programmes following table sets principal amounts fair values derivatives held gsk fair value fair value principal principal amount assets liabilities amount assets liabilities cash flow hedges cross currency swaps fair value hedges interest rate swaps net investment hedges foreign exchange contracts cross currency swaps derivatives designated accounting hedges foreign exchange contracts equity related instruments options warrants equity collar embedded derivatives derivatives total derivative instruments analysed current noncurrent total gsk annual report financial statements nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd financial instruments related disclosures employee share schemes continued group operates share option schemes whereby derivative financial instruments options granted employees acquire shares ads principal amount foreign exchange contracts calculated glaxosmithkline plc grant price savingsrelated based outstanding positions balance sheet date share option schemes share award schemes whereby calculated net currency buysell side position majority awards granted employees acquire shares ads contracts periods months less glaxosmithkline plc cost subject achievement group specified performance targets st december group held outstanding foreign exchange contracts consisting primarily currency swaps group also operates share award scheme share value total fair value million million plan whereby awards granted employees acquire shares represent hedges intercompany loans deposits ads glaxosmithkline plc cost three year vesting designated accounting hedges changes fair value period granting restricted share awards replaced taken profit loss period offset exchange gains granting options certain employees cost scheme losses related intercompany lending borrowing readily equates potential gain made cash flow hedges employee group entered cross currency swap designated grants share option schemes normally exercisable cash flow hedge converting fixed euro interest euro debt three ten years date grant grants within groups japanese subsidiary payable annually fixed restricted shares share awards normally exercisable yen payments bond matures risk hedged end three year vestingperformance period grants variability cash flows arising currency fluctuations savingsrelated share option schemes normally exercisable ineffectiveness assumed hedge cash flows three years saving options share option schemes relating hedge expected occur within next year granted market price ruling date grant amounts recognised equity recycled income accordance uk practice majority options statement offset exchange gains losses savingsrelated share option schemes granted price period underlying bond result revaluation market price ruling date grant share options balance sheet date awarded directors effect grant cet subject performance criteria amount recognised equity cross currency interest rate swaps million debit million credit amount recycled equity income statement cross currency interest rate swaps offset exchange gain underlying bond recognised income statement million million net fair value movements cash flow hedges disclosed consolidated statement recognised income expense fair value hedges group designated interest rate swap fair value hedge risk hedged variability fair value bond arising interest rate fluctuations gains losses fair value hedges disclosed note finance costs net investment hedges foreign exchange contracts designated net investment hedges respect foreign currency translation risk principally arising consolidation groups net investment us dollar euro yen foreign operations addition euro loan capital issued billion million previous years designated nonmonetary net investment hedge respect foreign currency translation risk principally arising consolidation groups net investment euro operations net investment hedge ineffectiveness disclosed note finance incomegsk annual report financial statements notes financial statements continued employee share schemes continued option pricing purposes valuing options arrive stockbased compensation charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years years savingsrelated share option share award schemes years years years weighted average share price grants year ordinary shares ads volatility determined based three five year share price history appropriate fair value performance share plan grants take account market conditions expected lives options determined based weighted average historic exercises options options outstanding share option share option savingsrelated schemes shares schemes ads share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value st january options granted options exercised options lapsed st december options granted options exercised options lapsed st december options granted options exercised options lapsed st december range exercise prices weighted average remaining contractual life years years years gsk annual report financial statements nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd employee share schemes continued order encourage employees convert options excluding savingsrelated share options held glaxo wellcome smithkline beecham shares ads glaxosmithkline shares ads programme established give additional cash benefit exercise price original option provided employee voluntarily leave group two years date merger exercise option earlier six months expiry date original option two years date merger cash benefit also paid options expire unexercised market price exercise price date expiry share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes st december weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options normally become exercisable three years date grant may certain circumstances vest earlier set within various scheme rules change effective exercise price outstanding options year share option share option savingsrelated options exercisable schemes shares schemes ads share option schemes st december weighted weighted weighted number exercise number exercise number exercise price price price st december st december st december gsk annual report financial statements notes financial statements continued employee share schemes continued glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group three year measurement period performance conditions consist two parts applies award first part condition compares gsks tsr period tsr pharmaceutical companies comparator group period second part performance condition compares gsks earnings per share growth increase uk retail prices index three year performance period awards granted directors members cet subject single performance condition compares gsks tsr period tsr companies comparator group period shares weighted ads weighted number shares ads issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december share value plan group operates share value plan whereby awards granted form shares certain employees cost awards vest three years performance criteria attached shares weighted ads weighted number shares ads issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december gsk annual report financial statements nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd employee share schemes continued deferred investment award plan group operates deferred investment award plan whereby awards granted form notional shares certain senior executives cost awards typically vest threeyear period commencing fourth anniversary date grant award initially vesting subsequent two years performance criteria attached shares weighted ads weighted number shares ads issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares open market finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves held value proceeds receivable employees exercise deemed permanent diminution value reflected transfer retained earnings trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report financial statements notes financial statements continued principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group st december details given principal country operation location headquarters business segment business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary segment activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline holdings one limited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc ph f brentford smithkline beecham plc phch e h p r brentford wellcome limited phch h greenford glaxo group limited ph h greenford glaxo operations uk limited ph p brentford glaxo wellcome international bv phch h brentford glaxo wellcome investments bv phch h brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uk limited ph p brentford smithkline beecham investments limited phch f brentford setfirst limited phch h brentford setfirst limited phch h greenford wellcome foundation limited ph p cambridge domantis limited ph r brentford smithkline beecham overseas limited ph h brentford smithkline beecham holdings uk limited ph h brentford glaxosmithkline netherlands bv ph h austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biologicals sa ph e p r czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch st amand les eaux glaxosmithkline biologicals sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h p r munich glaxosmithkline gmbh co kg ph h p r greece athens glaxosmithkline aebe phch hungary budapest glaxosmithkline medicine healthcare products limited phch e italy verona glaxosmithkline spa ph h r milan glaxosmithkline consumer healthcare spa ch h verona glaxosmithkline manufacturing spa ph p gsk annual report financial statements notes financial statements continued principal group companies continued europe location subsidiary segment activity luxembourg mamer glaxosmithkline international luxembourg sa phch f h netherlands zeist glaxosmithkline bv ph utrecht glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk services spz oo ph warsaw glaxosmithkline consumer healthcare spz oo ch e portugal alges glaxosmithklineprodutos farmaceuticos limitada ph republic carrigaline smithkline beecham cork limited ii ph p r ireland cork glaxosmithkline trading services limited ii ph e dublin glaxosmithkline consumer healthcare ireland limited ii ch dublin glaxosmithkline ireland limited ph russian moscow glaxosmithkline trading zao ph federation moscow glaxosmithkline healthcare zao ch spain madrid glaxosmithkline sa ph madrid glaxosmithkline consumer healthcare sa ch aranda de duero glaxo wellcome sa ph p sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa hamilton corixa corporation ph p philadelphia smithkline beecham corporation phch e h p r pittsburgh cns inc ch pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h liberty corner reliant pharmaceuticals inc ph r wilmington glaxosmithkline holdings americas inc phch h wilmington glaxosmithkline capital inc ph f wilmington sirtris pharmaceuticals inc ph r americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc ph p r oakville glaxosmithkline consumer healthcare inc ch laval id biomedical corporation ph h laval id biomedical corporation quebec ph p r asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china beijing glaxosmithkline china investment co ltd phch h hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd phch p r gsk annual report financial statements notes financial statements continued principal group companies continued asia pacific location subsidiary segment activity india mumbai glaxosmithkline pharmaceuticals limited ph p nabha glaxosmithkline consumer healthcare limited iii ch p malaysia petaling jaya glaxosmithkline pharmaceutical sdn bhd ph selangor glaxosmithkline consumer healthcare sdn bhd ch new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch p e philippines makati glaxosmithkline philippines inc phch singapore singapore glaxochem pte ltd ph h singapore glaxo wellcome manufacturing pte ltd ph h p r singapore glaxosmithkline pte ltd phch south korea seoul glaxosmithkline korea limited ph ch p thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch e p brazil rio de janeiro glaxosmithkline brasil limitada phch e p colombia bogota glaxosmithkline colombia sa phch mexico delegacion tlalpan glaxosmithkline mexico sa de cv phch e p puerto rico guaynabo glaxosmithkline puerto rico inc ph venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithkline sae ph p south africa bryanston glaxosmithkline south africa pty limited phch p turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p usa usa madison quest diagnostics incorporated iv clinical testing incorporated netherlands ii exempt provisions section companies amendment act ireland iii c onsolidated subsidiary undertaking accordance section companies act grounds dominant influence iv equity accounted grounds significant influence directly held wholly owned subsidiary glaxosmithkline plc key business segment ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r research service full details group subsidiary associated undertakings attached companys annual return filed registrar companies glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report financial statements notes financial statements continued legal proceedings october group filed complaint patent dispute chamber regional court dsseldorf germany group involved significant legal administrative neolab uk infringement german patent proceedings principally product liability intellectual property claiming compositions containing combination salmeterol tax antitrust governmental investigations well related fluticasone propionate used seretide known viani private litigation group makes provision proceedings germany complaint based neolabs stated intention regular basis summarised note accounting principles letter market salmeterolfluticasone combination product policies note provisions group may germany event occur trial took place make additional significant provisions legal proceedings patent dispute chamber regional court dsseldorf required event developments january neolab argued letter stating matters consistent generally accepted accounting principles proposed intent sell future constitute basis litigation particularly usa inherently unpredictable infringement decision decision expected march excessive awards may occur even may justified january neolab filed action invalidate evidence group could future incur judgements combination patent federal court germany revocation enter settlements claims could result payments actions combination patent germany also exceed current provisions amount would filed mylan dura gmbh march hexal ag material adverse effect groups financial condition results december trial date set actions operations andor cash flows intellectual property claims basic patent covering combination product seretide expires include challenges validity enforceability groups september subject supplementary protection patents various products processes well assertions certificate extends protection september noninfringement patents loss cases could result loss patent protection product issue march group initiated infringement action consequences loss could significant decrease federal court hague number internet sales product could materially affect future results pharmacy organisations together cipla limited operations group infringement groups dutch combination patent relating seretide action heard th october legal expenses incurred provisions related legal claims decision dated th november court find charged selling general administration costs provisions infringement indicated saw evidence brought made taking appropriate legal specialist advice patent validity question particular court noted reasonable estimate made likely outcome prior uk revocation decision corresponding dispute group established actuarially determined uk patent outdated reached using provision product liability claims incurred yet reported interpretation law relating inventive step described note provisions st december longer followed groups aggregate provision legal disputes including tax matters described note taxation revocation action basic patent covering seretide billion ultimate liability legal claims may vary combination ireland filed high court dublin amounts provided depends upon outcome litigation behalf ivax july trial scheduled begin proceedings investigations possible settlement negotiations march significant matters described argatroban december encysive pharmaceuticals inc mitsubishi kasei intellectual property corporation group filed action us district court advairseretide southern district new york barr laboratories september group applied us patent inc infringement mitsubishis pharmaceutical composition trademark office uspto reissue combination patent patent covering argatroban pursuant license mitsubishi advair inhaled combination salmeterol fluticasone encysive developed argatroban treatment heparin propionate expires september uspto reissued induced thrombocytopenia holds new drug application patent february reissued patent approved us fda encysive licensed us marketing september expiration date original combination rights argatroban group mitsubishi patent patent listed register pharmaceutical patents expires june barr filed abbreviated new drug maintained us fda orange book application anda fda certification invalidity unenforceability noninfringement mitsubishi patent fda approval anda stayed earlier may resolution patent infringement action case discovery phasegsk annual report financial statements notes financial statements continued legal proceedings continued august group filed suit lupin district court district delaware infringement avodart combination patent group file suit lupin january group received notice barr laboratories crystal form patent fda approval lupins anda filed anda fda allegation invalidity stayed earlier january resolution patent three patents listed orange book cover infringement action favourable lupin neither teva lupin active ingredient avodart use treat benign prostatic challenged compound patent claims lamivudine one hyperplasia bph february smithkline beecham filed active ingredients combivir patent expires action us district court district delaware barr infringement patents basic compound coreg cr patent expires two patents expire december group received notice united research fda approval barrs anda stayed earlier july laboratories incmutual pharmaceuticals company inc filed resolution patent infringement action case anda fda certification invalidity unenforceability discovery phase noninfringement patents covering crystalline salt form delayed release technology used manufacturing boniva product expire respectively february group participates marketing boniva pursuant group filed suit crystal form patent copromotion agreement roche september roche alternative requested court dismiss mutuals certification laboratories commenced actions us district court ineffective anda accepted filing district new jersey eight generic drug manufacturers fda sent certification april court case roche alleged infringement roche patents relating dismissed case summary judgement mutual appealed boniva tablets defendants filed anda court appeals federal circuit appeal fda certification invalidity unenforceability dismissed november noninfringement least one roche patents two manufacturers challenged basic compound patent march fda accepted mutuals anda mutual expires final fda approval andas stayed filed second certification coreg cr alleging groups earlier november resolution relevant patent patents coreg cr invalid unenforceable infringed infringement action august roche obtained new group filed suit april district court patent monthly dosing regimen boniva brought suit eastern district pennsylvania crystal form patent anda filers challenging patents new patent covering use coreg cr treating congestive heart patent expires cases ongoing failure october group filed motion dismiss action gave mutual covenant nottosue patents combivir mutual opposed dismissal case parties await patents listed orange book combivir include composition decision motion dismiss coreg cr granted matter tclamivudine combination lamivudine azt data exclusivity fda precludes approval generic lamivudine crystal form patents expire april respectively september group received notice teva filed anda fda alleging paxilseroxat combination patent invalid usa number manufacturers distributors generic paxil filed applications fda market generic november group filed action district court versions prior expiration groups patent district delaware teva pharmaceuticals paroxetine hyrdrochloride hemihydrate actions infringement combination patent fda approval tevas one remains pending namely action apotex anda stayed earlier march resolution district court eastern district pennsylvania patents patent infringement action favourable teva case composition matter process manufacture claims discovery phase october teva filed certification case discovery phase antitrust counterclaim groups patent covering crystal form lamivudine invalid asserted apotex discussed europe infringed group file suit patent generic products containing paroxetine hydrochloride july received notice lupin pharmaceuticals market european countries litigation synthon filed certification fda alleging combination bv recently settled litigation fal ongoing patent invalid infringed product lupin also filed counterclaims unfair competition asserted certification groups patent covering crystal form group following litigation canada apotex lamivudine invalid infringed several patents related paroxetine apotex launched generic product canada october gsk annual report financial statements notes financial statements continued legal proceedings continued wellbutrin xl december biovail commenced actions us district apotex alleged result litigation court central district california anchen enjoined launching product receipt pharmaceuticals us district court southern regulatory approval action apotex recover damages district florida abrika pharmaceuticals case related delay occasioned injunctions ongoing alleging infringement biovail formulation patents wellbutrin paxil cr xl april biovail filed action us district court us patent covering delayed controlled release formulation eastern district pennsylvania impax laboratories paroxetine hydrochloride paxil cr issued group infringement patents patents expire june listed fda orange book thereafter anchen abrika impax filed anda group filed action us district court district fda certification invalidity noninfringement new jersey mylan infringement newly issued biovail patents group licensee patents patent subsequently parties reached settlement mylan august judge granted anchens motion ruled entered market may terms anchens anda product infringe biovails patent biovail settlement agreement appealed decision cafc case remains appeal group party actions requip xl september biovail commenced actions us district january group received letters impax court southern district new york watson laboratories inc actavis south atlantic llc indicating laboratories alleging infringement biovail formulation andas requip xl accepted fda patents watsons third party counterclaim group letters included allegation patent licensed group based listing activities associated fda orange book skyepharma covering extended release formulation dismissed october mg generic product infringed products group bring suits launched usa december companies march biovail announced comprehensive settlement treximet anchen impax watson teva following voluntary october group received letter par review us federal trade commission certain aspects pharmaceuticals fda accepted anda treximet settlement remain confidential however parties disclose included certification patents owned pozen defined exceptions generic companies would inc relating treximet invalid unenforceable andor market mg strength wellbutrin xl infringed pozens patents licensed group november generic version mg tablet launched usa pozen filed suit par three patents may district court eastern district texas november group received letter alphapharm designated uspto action agent mylan pharmaceuticals fda accepted october group filed action us patent anda treximet included certification pozens trademark office us district court eastern patents relating treximet invalid unenforceable andor district virginia enjoin permanently final regulations infringed pozen filed suit alphapharm mylan january published us patent trademark office would infringement two patents district court limit number continuation patent applications patent eastern district texas delaware treximet data claims patent applicant could prosecute office exclusivity precludes approval generic product regulations due become effective april group party lawsuits st november brought pozen october court issued order preliminarily enjoining valtrex implementation rules full hearing decision may group commenced action us district parties crossmotions summary judgement following court district new jersey ranbaxy laboratories hearing february court issued permanent injunction alleging infringement groups compound patent implementation usptos proposed rules april valacyclovir active ingredient valtrex patent expires uspto appealed ruling us court appeals december ranbaxy filed anda fda federal circuit cafc appeal heard cafc certification groups compound patent invalid december parties await decision unenforceable infringed case settled terms permit ranbaxy enter market late taking account expected paediatric exclusivity respect groups compound patentgsk annual report financial statements notes financial statements continued legal proceedings continued others claim persons took baycol although injured may risk future injury may suffered economic product liability damages purchasing using baycol plaintiffs seek preclinical clinical trials conducted remedies including compensatory punitive statutory damages development potential products determine safety creation funds medical monitoring efficacy products use humans following approval group bayer corporation principal us subsidiary regulatory bodies notwithstanding efforts drugs bayer ag signed allocation agreement vaccines introduced marketplace unanticipated safety bayer corporation agreed pay settlements issues may become evident group currently defendant compensatory damages judgements party retaining number product liability lawsuits related groups responsibility attorneys fees punitive damages pharmaceutical products significant matters federal cases consolidated mdl proceeding described us district court district minnesota date two avandia statewide class actions certified medical monitoring may new england journal medicine nejm case pennsylvania consumer fraud deceptive published article avandia author based business practices act case illinois medical monitoring metaanalysis clinical trials raised concerns use action dismissed court summary judgement drug rosiglitazone avandia may associated increased certification consumer fraud case currently appeal risk heart attack cardiovascular death comparison illinois appellate courts use placebo antidiabetic therapies following nationwide class thirdparty payers certified publication nejm article group named pennsylvania state court case settled trial another product liability lawsuits behalf individuals purported class action gsk named defendant class action cases asserting consumer fraud andor personal injury certified oklahoma case decertified claims behalf purchasers users avandia federal deadline appealing decertification order passed cases part multidistrict litigation mdl proceeding claims death serious injury pending us district court eastern district settled thousands others alleging muscle aches pains pennsylvania cases also filed state courts cases filed voluntarily involuntarily dismissed philadelphia coordinated mass tort program matters discovery phase additionally purported paxil paxil cr nationwide class action suit filed february us group received lawsuits claims alleging use district court eastern district pennsylvania behalf paxil paroxetine pregnancy resulted birth third party payers seeking economic damages various child birth defects health issues separately group state unfair trade practices consumer protection laws received lawsuits claims patients took paxil group process evaluating complaint committed attempted commit suicide andor acts violence group also received lawsuits claims filed behalf finally one purported class action filed israel patients alleging suffered symptoms discontinuing briefing whether certify class action underway seven treatment paxil cases filed philadelphia class actions pending canada early stage coordinated mass tort program september baycol us label paxil updated reflect new information august bayer ag withdrew baycol cerivastatin sodium suggested increased risk congenital malformations worldwide light reports adverse events including deaths particularly cardiovascular malformations infants born involving rhabdomyolysis group participated mothers took paxil first trimester pregnancy marketing baycol usa pursuant copromotion december paxil us label updated agreement bayer licence holder include new data strengthen pregnancy warning manufacturer product following withdrawal bayer category c category category indicates evidence group named defendants thousands lawsuits risk foetus potential benefits use filed state federal courts usa behalf drug pregnant women may outweigh risk individuals putative classes former baycol users number suits allege plaintiffs suffered personal injuries including rhabdomyolsis use baycol gsk annual report financial statements notes financial statements continued legal proceedings continued two cases purported class actions although determination whether cases may paxil us label updated include permitted proceed class action number purported class warning concerning persistent pulmonary hypertension class actions jurisdictions withdrawn newborn arising mothers took selective serotonin reuptake dismissed plaintiffs seek remedies including compensatory inhibitor ssri antidepressants th week pregnancy punitive statutory damages well cost fund group also received purported class action litigation medical monitoring research canada date report limited number cases group received numerous claims lawsuits alleging approached trial dates vaccine manufacturers treatment paxil caused homicidal suicidal behaviour manufacturers thimerosal containing medicinal products exhibited users product class certification denied successful excluding testimony plaintiffs expert january purported personal injury class action lawsuit witnesses causation specifically grounds plaintiffs cases remain pending federal state courts cases filed failed establish hypothesized link thimerosal philadelphia coordinated mass tort program neurodevelopmental disorders generally accepted reliable january fda approved boxed warning within relevant scientific community additionally february antidepressants increased risk suicidal thoughts behaviour office special masters united states court paediatric patients strengthened warnings ssri federal claims rejected first three approximately products including paxil class may paxil us label autism claims filed national vaccine injury compensation updated warn young adults especially program nvcip grounds claimants failed produce major depressive disorder may increased risk suicidal reliable scientific evidence linking vaccinations medical behaviour treatment paroxetine conditions including autism august fda required updated us labels antidepressants group party proceedings findings class state boxed warning antidepressants used evidence pending lawsuits increased risk suicidal thinking behaviour children group three nvicp claimants option adolescents young adults increase shown beyond appealing decisions rejecting instead pursuing age reduction risk adults aged older personal injury lawsuits manufacturers vaccines depression psychiatric disorders administered remaining approximately nvcip associated increased risk claimants also ultimately option pursuing personal group received lawsuits filed state federal courts injury lawsuits vaccine manufacturers including usa canada behalf thousands plaintiffs group early determine whether announcement including purported class actions alleging paroxetine nvcip decisions likely lead increase number active ingredient paxil addictive causes dependency civil cases filed group date report withdrawal reactions us federal cases consolidated cases scheduled trial group mdl proceeding january conditional settlement defendant agreement became effective group admit liability respect allegations lawsuits virtually us sales marketing regulation actions resolved california court appeals marketing promotion reversed dismissal class claims purported class action february group received subpoena us consumer fraud lawsuit focused discontinuation symptom attorneys office colorado regarding groups sales case proceeding decision yet class certification promotional practices relating nine largest selling products purported class action litigation canada group period january particular also defending litigation commenced uk government inquired alleged promotion drugs behalf hundreds plaintiffs allege paroxetine offlabel uses well groupsponsored continuing medical caused suffer withdrawal reactions dependency education programmes speaker events special issue boards thimerosal advisory boards speaker training programmes clinical studies group along number pharmaceutical related grants fees travel entertainment although original companies named defendant numerous subpoena issued us attorneys office colorado individual personal injury lawsuits state federal district scope inquiry nationwide courts usa alleging thimerosal preservative used manufacture vaccines causes neurodevelopmental disorders injuries including autismgsk annual report financial statements notes financial statements continued legal proceedings continued number states respective attorneys general counties new york state filed civil lawsuits government also inquiring groups response state federal courts gsk many drug companies october letter fdas division drug marketing claiming damages restitution due awp andor wac price advertising communication requesting information reporting pharmaceutical products covered states medicaid groups alleged promotion wellbutrin sr offlabel use programmes states seek recovery behalf states payers group cooperating investigation providing cases behalf instate patients consumers requested information group separately resolved awp claims state medicaid february verona public prosecutor commenced programmes twothirds states criminal investigation groups sales marketing doj settlement separate negotiations litigation concerning practices italy specific areas investigation include medical awp issues continuing eleven states well new education programmes clinical studies congresses well york counties july alabama state court jury returned interaction groups representatives physicians million verdict group one case filed public prosecutor proposed number physicians state alabama group seeking decision representatives group face criminal charges reversed appeal alabama supreme court however hearing january public prosecutors nominal pricing agreement verona court dismissed charges group responded two letter requests us remaining defendants closes case us securities senate committee finance dated april february exchange commission sec staff initiated investigation documents information relating nominal allegations group cooperated investigation price exception best price reporting requirements received requests information sec medicaid drug rebate programme january committee released findings pharmaceutical following united nations report alleging bribes manufacturers inappropriately used nominal price exception paid iraqi government officials connection un oil contrary committees interpretation congressional intent food programme group received subpoena may group advised us department sec february respect groups participation justice investigating certain groups nominal programme us department justice also initiated pricing bundled sales arrangements determine whether investigation december uk serious fraud office arrangements qualify exception best price issued formal notice group requiring production reporting requirements violate civil statutes laws march documents related groups participation programme group received broad letter request us group cooperating investigations department justice seeking range documents relating provided documents responsive subpoena notice groups nominal pricing arrangements since responding follow questions requests possible bundled sales group continuing cooperate average wholesale price investigation produce documents group also united states department justice number states received subpoenas requests documents information putative classes private payers several years delaware michigan related groups nominal price investigating andor bringing civil litigation regarding allegations arrangements group cooperating investigations numerous pharmaceutical companies including gsk violated producing responsive documents addition federal state fraud abuse laws result way average governmental investigations allegations concerning nominal wholesale price awp wholesale acquisition cost wac pricing made certain government payers part determined reported various drugs reimbursed awp litigation group entered nominal medicare medicaid insurance programmes price arrangements since december group reached million civil settlement federal government resolve allegations relating pricing marketing zofran kytril group also amended existing corporate integrity agreement requirement settlement group received final approval million nationwide private payer class action settlement relating groups price reporting mdl proceeding us district court district massachusetts gsk annual report financial statements notes financial statements continued legal proceedings continued october group announced plans cease operations b programme cidra site gsk expects continue production paxil cr site production transferred another facility group defending action filed federal court group currently expects take place production us district court northern district california products site discontinued end county santa clara two counties seek represent putative class hospitals clinics entities california eligible receive discounted ceiling prices april fda completed general gmp inspection pharmaceuticals federal programme known b resulted one inspectional observation group programme plaintiffs allege group numerous responded observation completed corrective pharmaceutical manufacturers setting ceiling prices action commitment higher allowed law contract governs april group advised fda site completed programme therefore overcharged entities corrective action plan group submitted fda california eligible participate b programme september group continues provide fda lawsuit dismissed reinstated august quarterly reports activities associated closure following appeal actively litigated facility july group successfully completed final trial court level three annual inspections site independent third party paxilseroxat expert required consent decree following groups settlement lawsuit filed new october us federal government executed search york state attorney generals office alleging failure disclose warrant cidra facility seized records relating data use paxil children adolescents similar cases manufacturing operations site purported class actions filed private plaintiffs seeking recover amounts paid paxil purchased april group received subpoena us attorneys use patients age minnesota court office boston requesting production records regarding approved million class settlement ensuing lawsuits manufacturing cidra site covering information similar seeking recovery behalf insurance companies seized us government puerto rico subsequently thirdparty payers payments prescriptions paxil group received additional subpoenas government related children adolescents group denied liability january cidra facility group cooperating us attorneys similar purported class action filed canada seeking office producing records responsive subpoenas economic damages behalf individuals third party payers addition july group learned us district court governmental entities purchased paxil use patients district massachusetts unsealed complaint brought age group likewise denied liability former employee federal false claims act claiming monetary damages result alleged failure cidra facility comply uk medicines healthcare products regulatory agency gmps manufacture various products mhra completed investigation groups pharmacovigilance reporting obligations relating clinical data group also named two purported consumer fraud class seroxatpaxil children action taken action lawsuits one filed california state court matter thus concluded us district court district puerto rico alleging paxil products manufactured according gmp plaintiffs sought cidra puerto rico manufacturing site economic statutory punitive damages along request following fda inspections october november injunctive relief summer group reached resulted observations possible deficiencies tentative agreement settle matters subject court approval manufacturing practices groups manufacturing facility settlement covers nationwide classes paxil cr consumer cidra puerto rico march fda seized certain lots purchasers third party payers provides claims procedure paxil cr avandamet due manufacturing issues fda class members receive payment splitdefective observations related certain aspects production controls paxil cr tablets process validation laboratory investigations april group reached agreement fda consent decree january group learned writ summons filed consent decree provides independent expert review philadelphia court common pleas group third party manufacturing processes site compliance fda good payers information belief action related alleged manufacturing practice gmp requirements provided paxil cr manufacturing issues cidra group currently consent decree september group provided report gaining information filing relation fda deficiencies identified review setting class litigation corrective plan timetable completiongsk annual report financial statements notes financial statements continued legal proceedings continued wellbutrin sr december january february lawsuits antitrust several purported class actions filed paxilseroxat us district court eastern district pennsylvania paroxetine patent infringement actions brought group behalf direct indirect purchasers group described intellectual property apotex wellbutrin sr complaints allege violations us antitrust certain companies filed antitrust unfair competition laws sham litigation fraud patent office counterclaims group us district court group obtaining enforcing patents covering eastern district pennsylvania wellbutrin sr complaints follow introduction generic competition wellbutrin sr april district based allegations group monopolised appellate court rulings generic manufacturer market paxil bringing allegedly sham patent litigation infringe groups patents parties involved discovery allegedly abusing regulatory procedures listing group filed motion summary judgement patents fda orange book whilst apotex matter remains pending remains discovery stage matters companies resolved secondary wholesaler july rxusa wholesale inc secondary wholesaler november ftc staff advised group filed suit group many pharmaceutical conducting nonpublic investigation determine manufacturers wholesalers us district court group violating section federal trade commission eastern district new york complaint alleges act monopolising attempting monopolise defendants engaged conspiracy refuse supply market paroxetine hydrochloride preventing generic pharmaceutical products rxusa violation federal competition paxil requested group submit certain state antitrust laws groups motion dismiss complaint information connection investigation october remains pending ftc closed investigation basis findings action warranted following public wellbutrin xl reference ftc investigation regarding paxil number outgrowth intellectual property matters discussed governmental private civil actions claims initiated respect wellbutrin xl actions filed usa us matters exception biovail gsk purported classes direct indirect referenced apotex matter resolved purchasers allege unlawful monopolization anti trust violations related enforcement biovails wellbutrin october competition directorate european xl patents filing biovail citizen petitions group commission initiated inspection concerning allegations filed motion dismiss remains pending group abused dominant position marketplace concerning enforcement intellectual property rights litigation flonase surrounding regulatory approvals marketing seroxat purported direct indirect purchaser class actions europe october commission made formal request filed us district court eastern district pennsylvania information group responded request alleging group illegally maintained monopoly power end market flonase charged plaintiffs supracompetitive prices predicate allegations filing january european commission announced inquiry group allegedly sham citizen petitions subsequent certain aspects competition pharmaceutical sector litigation group filed motion dismiss complaints initiated inspections premises number innovator purported classes direct indirect purchasers generic pharmaceutical companies including group discovery also underway commission published preliminary report november based information provided innovator generic pharmaceutical companies report suggests defensive patenting strategies may lead obstacles innovation innovator companies employ measures hinder generics coming onto market anticipated final report issued second quarter group continues cooperate commission investigation gsk annual report financial statements notes financial statements continued legal proceedings continued plaintiffs subsequently amended complaints assert class action limited solely pharmaceutical sales commercial corporate representatives working california asserting claims securities class actions californias wage hour laws september attorneys representing purported class suits seek variety compensatory punitive statutory purchasers glaxosmithkline shares american depositary damages group moved summary judgement dismissing shares ads filed second amended securities class action claims putative class representatives ground complaint group us district court exempt employees court held southern district new york alleging group violated appeals pending united states court appeals us securities laws failure disclose unfavourable clinical ninth circuit cases involving manufacturers virtually data studies paxil misrepresentation remaining factual legal arguments therefore deferred ruling patent protection paxil augmentin violation summary judgement motion stayed activity federal false claims act basis groups recent awp case appellate court rules least one settlement government october judge companies pending cases entered order dismissing complaint upheld us court appeals second circuit march third case filed us district court district matter concluded arizona november seeks establish nationwide collective action behalf entire groups us pharmaceutical november attorneys purporting represent class sales representatives ground representatives purchasers glaxosmithkline shares ads filed exempt employees us fair labor standards amended consolidated complaint group senior act plaintiffs seek double damages overtime allegedly officers us district court southern district new worked groups pharmaceutical sales representatives york alleged group individual defendants three year period violated us securities laws artificially inflated price glaxosmithklines stock misleading investors safety environmental matters avandia amended consolidated complaint also alleges gsk notified potential responsibility relating past several current former senior officers members operations past waste disposal practices certain sites group engaged insider trading motion dismiss primarily usa matters subject complaint filed behalf group individual litigation including proceedings initiated us federal state defendants may district court entered order governments waste disposal site remediation costs tort dismissing case defendants plaintiffs filed appeal actions brought private parties us court appeals second circuit appeal gsk advised may responsible party remains pending approximately sites appear national priority relenza list created comprehensive environmental response may biota holdings limited filed complaint compensation liability act superfund proceedings victorian supreme court australia alleging group seek require operators hazardous waste facilities failed fulfil development promotion production transporters waste sites generators hazardous obligations zanamivir relenza terms licence waste disposed sites clean sites reimburse agreement group biota biota sought substantial government cleanup costs instances gsk damages mediation ordered court july involved alleged generator hazardous waste although dispute settled without admission liability gsk sites gsk involved current former continues sell relenza pursuant licence agreement operator facility although superfund provides defendants jointly severally liable cleanup costs wage hour claims proceedings frequently resolved basis nature december two purported class actions filed quantity waste disposed generator site gsks group behalf entire groups us pharmaceutical sales proportionate liability cleanup costs substantially representatives actions filed transferred determined sites referred us district court central district california initially alleged representatives exempt employees gsks potential liability varies greatly site site california law andor us fair labor standards act cost investigation study remediation sites could consequently entitled overtime pay among things time substantial gsk routinely accrues amounts related share liability mattersgsk annual report financial statements glaxosmithkline plc directors statement responsibilities directors statement responsibilities relation disclosure information auditors companys financial statements directors office date report confirmed directors responsible preparing parent company financial statements remuneration report accordance far aware relevant audit applicable law regulations information companys auditors unaware company law requires directors prepare financial taken steps ought statements financial year law directors taken director make aware prepared parent company financial statements relevant audit information establish companys accordance applicable law united kingdom accounting auditors aware information standards united kingdom generally accepted accounting confirmation given interpreted accordance practice parent company financial statements required provisions section za companies act law give true fair view state affairs company end financial period going concern basis preparing financial statements directors making enquiries directors reasonable required expectation company adequate resources continue select suitable accounting policies apply operational existence foreseeable future reason consistently continue adopt going concern basis preparing financial statements make judgements estimates reasonable prudent combined code state regard parent company financial board considers glaxosmithkline plc applies principles statements applicable uk accounting standards combined code corporate governance financial followed subject material departures disclosed reporting council described corporate governance explained financial statements pages complied provisions except described directors responsible keeping proper accounting records disclose reasonable accuracy time required listing rules financial services financial position company enable ensure authority auditors considered directors statement parent company financial statements comply compliance relation points combined code companies acts also responsible specified review taking reasonable steps safeguard assets company ensuring operation systems internal control hence taking reasonable steps prevention detection fraud irregularities parent company financial statements year ended st december comprising balance sheet year sir christopher gent ended st december supporting notes set chairman pages report rd march responsibilities auditors relation parent company financial statements set independent auditors report financial statements year ended st december included annual report published hard copy printed form made available website directors responsible maintenance integrity annual report companys website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different gsk annual report financial statements glaxosmithkline plc independent auditors report members glaxosmithkline plc audited parent company financial statements basis audit opinion glaxosmithkline plc year ended st december conducted audit accordance international standards comprise company balance sheet uk gaap auditing uk ireland issued auditing practices board related notes parent company financial statements audit includes examination test basis evidence relevant prepared accounting policies set therein amounts disclosures parent company financial also audited information remuneration report statements part remuneration report audited described audited also includes assessment significant estimates reported separately group financial statements judgments made directors preparation parent glaxosmithkline plc year ended st december company financial statements whether accounting policies appropriate companys circumstances consistently respective responsibilities directors auditors applied adequately disclosed directors responsibilities preparing annual report planned performed audit obtain directors remuneration report parent company financial information explanations considered necessary statements accordance applicable law united kingdom order provide us sufficient evidence give reasonable accounting standards united kingdom generally accepted assurance parent company financial statements accounting practice set directors statement part remuneration report audited free responsibilities material misstatement whether caused fraud irregularity error forming opinion also evaluated responsibility audit parent company financial overall adequacy presentation information statements part remuneration report audited parent company financial statements part directors accordance relevant legal regulatory requirements remuneration report audited international standards auditing uk ireland report including opinion prepared opinion companys members body accordance section companies act purpose opinion giving opinion accept assume responsibility parent company financial statements give true fair purpose person report shown view accordance united kingdom generally accepted whose hands may come save expressly agreed accounting practice state companys affairs prior consent writing st december report opinion whether parent company parent company financial statements part financial statements give true fair view whether parent directors remuneration report audited properly company financial statements part remuneration prepared accordance companies act report audited properly prepared accordance companies act also report whether information given report directors consistent opinion information given report directors parent company financial statements consistent parent company financial statements pricewaterhousecoopers llp addition report opinion company chartered accountants registered auditors kept proper accounting records received london information explanations require audit rd march information specified law regarding directors remuneration transactions disclosed read information contained annual report consider whether consistent audited parent company financial statements information comprises chairman ceo summary strategy report directors including unaudited part remuneration report directors statement responsibilities shareholder information consider implications report become aware apparent misstatements material inconsistencies parent company financial statements responsibilities extend informationgsk annual report financial statements glaxosmithkline plc company balance sheet uk gaap st december notes fixed assets investments debtors e cash bank current assets creditors amounts due within one year f net current liabilities net assets capital reserves called share capital g share premium account g reserves h profit loss account h equity shareholders funds approved board rd march sir christopher gent chairman gsk annual report financial statements glaxosmithkline plc notes company balance sheet uk gaap presentation financial statements expenditure description business expenditure recognised respect goods services received glaxosmithkline plc parent company gsk major global supplied accordance contractual terms provision healthcare group engaged creation discovery made obligation exists future liability respect development manufacture marketing pharmaceutical past event amount obligation products including vaccines overthecounter otc medicines reliably estimated healthrelated consumer products investments subsidiary companies preparation financial statements investments subsidiary companies held cost less financial statements prepared going concern provision impairment basis drawn accordance uk generally accepted impairment investments accounting principles uk gaap uk accounting carrying value investments reviewed impairment presentation st december comparative figures indication investment might impaired st december appropriate comparative provision resulting impairment review charged figures reclassified ensure consistent presentation income statement year concerned current year information share based payments permitted companies act profit issuance company subsidiaries grant loss account company presented annual report companys options represents additional capital contributions accounting convention standards company subsidiaries additional investment balance sheet prepared using historical cost subsidiaries results corresponding increase shareholders convention complies applicable uk accounting standards equity additional capital contribution based fair value grant issued allocated underlying grants accounting principles policies vesting period preparation balance sheet conformity generally taxation accepted accounting principles requires management make estimates assumptions affect reported current tax provided amounts expected paid amounts assets liabilities disclosure contingent applying tax rates enacted substantially enacted assets liabilities date balance sheet actual balance sheet date amounts could differ estimates company accounts taxation deferred balance sheet prepared accordance accelerated reason timing differences originated companys accounting policies approved board reversed balance sheet date deferred tax assets described note b recognised extent considered recoverable future taxable profits b accounting policies deferred tax measured average tax rates foreign currency transactions expected apply periods timing differences foreign currency transactions recorded exchange rate expected reverse deferred tax liabilities assets ruling date transaction forward rate hedged discounted forward exchange contract foreign currency assets financial guarantees liabilities translated rates exchange ruling balance liabilities relating guarantees issued company behalf sheet date forward rate subsidiaries held fair value amortised life dividends paid received guarantee dividends paid received included accounts period related dividends actually paid received c operating profit fee relating audit company charged operating profitgsk annual report financial statements glaxosmithkline plc notes company balance sheet uk gaap continued fixed assets shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited capital contribution relating share based payments e debtors amounts due within one year uk corporation tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings f creditors amounts due within one year bank overdraft amounts owed group undertakings creditors company guaranteed debt issued certain subsidiary companies receives annual fee subsidiary year company guaranteed billion debt issued us shelf registration statement subsidiary gsk capital inc aggregate company issued guarantees billion debt instruments amount due subsidiary companies relation guarantee fees recovered life bonds disclosed within debtors see note e gsk annual report financial statements glaxosmithkline plc notes company balance sheet uk gaap continued g share capital share premium account share ordinary shares p premium number share capital authorised st december st december share capital issued fully paid st january issued share option schemes purchased cancelled st december issued share option schemes purchased cancelled st december st december st december number shares issuable outstanding options number unissued shares option st december issued share capital shares held esop trust shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trust disclosed note employee share schemes share capital purchased cancelled includes cancellation million previously acquired treasury shares h reserves profit reserves loss account total st january profit attributable shareholders dividends shareholders ordinary shares purchased cancelled ordinary shares purchased held treasury shares capital contribution relating share based payments st december profit attributable shareholders dividends shareholders ordinary shares purchased cancelled capital contribution relating share based payments st december profit glaxosmithkline plc year million million dividends million million gave retained profit million profit million cost shares purchased cancelled million million cost shares purchased held treasury shares nil million million profit loss account reserve st december stood million million million unrealised milliongsk annual report shareholder information shareholder information section includes financial record financial record presenting historical information prepared accordance quarterly trend ifrs adopted european union also ifrs five year record issued iasb full product development pipeline product development pipeline section also discusses shareholder return form dividends shareholder information share price movements provides information share price dividends shareholders nature trading market annual general meeting share price movements dividends shown investor relations registrar graphs details price movements dividends taxation information shareholders pages glossary terms index share price dividends per share us pence us u ukk hsahraer ep rpicreic e u su asd ard prr ipceri cue sus u ukk idviivdiednednsd ps epre srh sahrea us u dsiv didievinddesn pdes rp aedr asds analysis shareholdings st december number total total number accounts accounts shares shares holding shares totals held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline totals bank new york mellons holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value th february bny nominees limited held ordinary shares representing issued share capital date th february number holders shares usa holdings shares number registered holders adr holdings adr certain shares adr held brokers nominees result number holders record registered holders usa representative number beneficial holders residence beneficial holders gsk annual report shareholder information financial record quarterly trend unaudited analysis group results pharmaceutical sales therapeutic area provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement results major restructuring turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders adjusted earnings per share pence p p p p p diluted earnings per share pence p p p p p calculation results major restructuring described note financial statements presentation financial statementsgsk annual report shareholder information financial record continued quarterly trend unaudited analysis group results pharmaceutical sales therapeutic area provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement results major restructuring turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders adjusted earnings per share pence p p p p p diluted earnings per share pence p p p p p calculation results major restructuring described note financial statements presentation financial statements gsk annual report shareholder information financial record continued quarterly trend pharmaceutical turnover total group q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antivirals hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin altabax oncology emesis hycamtin zofran tykerb vaccines hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix pharmaceutical turnover includes copromotion incomegsk annual report shareholder information financial record continued quarterly trend pharmaceutical turnover usa q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antivirals hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin altabax oncology emesis hycamtin zofran tykerb vaccines hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix pharmaceutical turnover includes copromotion income gsk annual report shareholder information financial record continued quarterly trend pharmaceutical turnover europe q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antivirals hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin altabax oncology emesis hycamtin zofran tykerb vaccines hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix pharmaceutical turnover includes copromotion incomegsk annual report shareholder information financial record continued quarterly trend pharmaceutical turnover rest world q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antivirals hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin altabax oncology emesis hycamtin zofran tykerb vaccines hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix pharmaceutical turnover includes copromotion income gsk annual report shareholder information financial record continued quarterly trend consumer healthcare turnover total group q q q q cer cer cer cer overthecounter medicines panadol franchise smoking cessation tums cold sore franchise breathe right alli oral healthcare aquafresh franchise sensodyne franchise dental care nutritional healthcare lucozade horlicks ribena consumer healthcare turnover usa q q q q cer cer cer cer overthecounter medicines panadol franchise smoking cessation tums cold sore franchise breathe right alli oral healthcare aquafresh franchise sensodyne franchise dental care nutritional healthcare lucozade horlicks ribena gsk annual report shareholder information financial record continued quarterly trend consumer healthcare turnover europe q q q q cer cer cer cer overthecounter medicines panadol franchise smoking cessation tums cold sore franchise breathe right alli oral healthcare aquafresh franchise sensodyne franchise dental care nutritional healthcare lucozade horlicks ribena consumer healthcare turnover rest world q q q q cer cer cer cer overthecounter medicines panadol franchise smoking cessation tums cold sore franchise breathe right alli oral healthcare aquafresh franchise sensodyne franchise dental care nutritional healthcare lucozade horlicks ribena gsk annual report shareholder information financial record continued five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board restated restated restated restated turnover business segment pharmaceuticals consumer healthcare restated restated restated restated pharmaceutical turnover therapeutic area respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis vaccines restated restated restated restated pharmaceutical turnover geographic area usa europe rest world emerging markets japan asia pacific canada rest world pharmaceutical turnover includes copromotion income restated restated restated restated consumer healthcare turnover otc medicines oral healthcare nutritional healthcare gsk annual report shareholder information financial record continued financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share p p p p p diluted earnings per share p p p p p financial results major restructuring turnover operating profit profit taxation profit taxation pence pence adjusted earnings per share p p adjusted diluted earnings per share p p millions millions millions millions millions weighted average number shares issue basic diluted return capital employed return capital employed calculated total profit taxation percentage average capital employed year balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity minority interests total equity gsk annual report shareholder information financial record continued number employees usa europe rest world asia pacific japan middle east africa latin america canada rest world manufacturing selling administration research development number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates day year feb jan dec nov oct sept high low st december federal reserve bank new york ceased publishing noon buying rates bank england pm buying rates used subsequent calculations pm buying rate th february usgsk annual report shareholder information product development pipeline key inlicense alliance relationship third party bla biological license application month first submission maa marketing authorisation application europe month first regulatory approval maa first eu nda new drug application usa approval letter phase evaluation clinical pharmacology usually conducted volunteers al month approvable complete response letter received indicates phase ii determination dose initial evaluation efficacy conducted ultimately approval given subject resolution small number patients outstanding queries phase iii large comparative study compound versus placebo andor established po month eu positive opinion treatment patients establish clinical benefit safety estimated submission dates disclosed within months date chart date represents likely year submission considered reasonably high probability successfully meeting date assuming clinical data meets expected endpoints clinical trials estimated submission dates compound type indication phase maa ndabla biopharmaceuticals monoclonal antibody stroke monoclonal antibody alzheimers disease iboctadekin doxil il immunomodulator topoisomerase ii ovarian cancer inhibitor iboctadekin rituximab il immunomodulator anticd nonhodgkins lymphoma monoclonal antibody monoclonal antibody rheumatoid arthritis ii monoclonal antibody severe asthma ii belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus ii antibody sc mepolizumab antiil monoclonal antibody severe asthma nasal polyposis ii ofatumumab anticd human monoclonal antibody diffuse large b cell lymphoma ii ofatumumab anticd human monoclonal antibody multiple sclerosis ii belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody iv ofatumumab anticd human monoclonal antibody follicular lymphoma iii ofatumumab anticd human monoclonal antibody rheumatoid arthritis iii otelixizumab anticd monoclonal antibody type diabetes iii syncria glucagonlike peptide agonist type diabetes iii bosatria mepolizumab antiil monoclonal antibody hypereosinophilic syndrome submitted ssep ofatumumab anticd human monoclonal antibody refractory chronic lymphocytic leukaemia submitted sfeb sjan cardiovascular metabolic high affinity nicotinic acid receptor hma dyslipidaemia agonist prolyl hydroxylase inhibitor anaemia gastrinreleasing peptide grp receptor agonist type diabetes muopioid receptor inverse agonist obesity sodium dependent glucose transport sglt type diabetes inhibitor sirt activator type diabetes also chronic obstructive pulmonary disease copd oxytocin antagonist threatened preterm labour ii bile acid receptor agonist type diabetes ii sirt activator type diabetes also oncology indications ii losmapimod p kinase inhibitor cardiovascular disease also copd depression ii pazopanib multikinase angiogenesis inhibitor eye drops agerelated macular degeneration also cancer indications ii remogliflozin etabonate sglt inhibitor type diabetes ii remogliflozin etabonate sglt inhibitor type diabetes ii rilapladib lppla inhibitor atherosclerosis ii ronacaleret calcium antagonist osteoporosis fracture healing ii avandamet xr ppar gamma agonist metformin type diabetes extended release iii na avandia simvastatin ppar gamma agonist statin type diabetes iii na darapladib lppla inhibitor atherosclerosis iii arixtra synthetic factor xa inhibitor treatment acute coronary syndrome approved aaug alfeb sep avandia ppar gamma agonist prevention disease progression approved snov ajul volibris endothelin antagonist pulmonary arterial hypertension approved aapr na gsk annual report shareholder information product development pipeline continued estimated submission dates compound type indication phase maa nda infectious diseases plasmodium electron transport chain inhibitor malaria topoisomerase ii inhibitor treatment bacterial infections hiv integrase inhibitor hiv infections novel class antibacterial agent treatment bacterial infections hiv integrase inhibitor hiv infections ii idx nonnucleotide reverse transcriptase inhibitor hiv infections ii sitamaquine aminoquinoline treatment visceral leishmaniasis ii na tafenoquine aminoquinoline plasmodium vivax malaria ii neurosciences ht antagonist depression anxiety nk antagonistssri depression anxiety crf antagonist depression anxiety dopamine antagonist drug dependency dopamine antagonist drug dependency ampa receptor modulator schizophrenia sodium channel blocker bipolar disorder type glycine transport inhibitor schizophrenia muscarinic acetylcholine agonist dementia nknk antagonist schizophrenia purinergic atp receptor antagonist pain orvepitant nk antagonist depression anxiety histamine h antagonist dementia ii glycine antagonist smoking cessation ii crf antagonist depression anxiety ii orexin antagonist sleep disorders ii p kinase inhibitor neuropathic pain ii ht antagonist dementia ii firategrast dual alpha integrin antagonist vla multiple sclerosis ii losmapimod p kinase inhibitor depression also cardiovascular disease copd ii solzira voltagegated calcium channel modulator migraine prophylaxis ii solzira voltagegated calcium channel modulator neuropathic pain ii almorexant orexin antagonist insomnia iii lamictal xr sodium channel inhibitor epilepsy partial generalised tonicclonic seizures oncedaily iii na retigabine neuronal potassium channel opener epilepsy partial seizures iii rosiglitazone xr ppar gamma agonist alzheimers disease iii lunivia nonbenzodiazepine gaba agonist insomnia submitted pooct na solzira voltagegated calcium channel modulator restless legs syndrome submitted ssep jan lamictal xr sodium channel inhibitor epilepsy partial seizures oncedaily approvable na al sep requip modutabxl nonergot dopamine agonist parkinsons disease oncedaily controlled release formulation approved amar ajun treximet ht agonist naproxen migraine fixed dose combination approved na aaprgsk annual report shareholder information product development pipeline continued estimated submission dates compound type indication phase maa nda oncology pololike kinase inhibitor cancer centromereassociated protein e cenpe cancer inhibitor mitogenactivated protein kinase inhibitor cancer mek totrombopag thrombopoietin receptor agonist thrombocytopaenia sirt activator colon haematologic cancers also type diabetes ii mesenchymalepithelial transition factor papillary renal cell carcinoma gastric cancer ii cmet kinase inhibitor head neck squamous cell carcinoma pazopanib multikinase angiogenesis inhibitor nonsmall cell lung cancer ii pazopanib multikinase angiogenesis inhibitor ovarian cancer ii pazopanib multikinase angiogenesis inhibitor metastatic breast cancer ii tyverbtykerb epidermal growth factor receptor egfr dual kinase inhibitor revoladepromacta thrombopoietin receptor agonist oncologyrelated thrombocytopaenia ii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma unresectable disease ii tyverbtykerb egfr dual kinase inhibitor refractory inflammatory breast cancer ii avodart alpha reductase inhibitor reduction risk prostate cancer iii elesclomol oxidative stress inducer metastatic melanoma iii pazopanib multikinase angiogenesis inhibitor sarcoma iii pazopanib multikinase angiogenesis inhibitor inflammatory breast cancer iii tyverbtykerb egfr dual kinase inhibitor revoladepromacta thrombopoietin receptor agonist chronic liver disease induced thrombocytopaenia iii revoladepromacta thrombopoietin receptor agonist hepatitis c induced thrombocytopaenia iii tyverbtykerb egfr dual kinase inhibitor breast cancer adjuvant therapy iii tyverbtykerb egfr dual kinase inhibitor breast cancer first line therapy iii tyverbtykerb egfr dual kinase inhibitor gastric cancer iii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma resectable disease iii duodart avodart alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fixed dose combination submitted sdec alpha blocker pazopanib multikinase angiogenesis inhibitor renal cell cancer also agerelated macular degeneration submitted sfeb sdec zunrisarezonic nk antagonist chemotherapyinduced postoperative nausea vomiting submitted sjul smay hycamtin topoisomerase inhibitor oral small cell lung cancer secondline therapy approved amar aoct revoladepromacta thrombopoietin receptor agonist idiopathic thrombocytopaenic purpura approved sdec anov tyverbtykerb egfr dual kinase inhibitor refractory breast cancer approved ajun amar respiratory immunoinflammation p kinase inhibitor inhaled copd chemokine receptor cxcr antagonist cystic fibrosis copd transient receptor potential vanilloid trpv nonallergic rhinitis antagonist intranasal motilin receptor agonist delayed gastric emptying antiinflammatory macrolide conjugate oral inflammatory bowel disease sirt activator copd also type diabetes longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist pde iv inhibitor inhaled asthma copd ii muscarinic acetylcholine antagonist copd ii glucocorticoid agonist asthma also copd asthma combination ii longacting beta agonist histamine hh dual antagonist oral allergic rhinitis ii novel glucocorticoid agonist inhaled asthma ii longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist muscarinic antagonist beta agonist copd ii histamine hh dual antagonist intranasal allergic rhinitis ii lipoxygenaseactivating protein flap asthma ii inhibitor darotropium muscarinic acetylcholine antagonist copd ii darotropium muscarinic acetylcholine antagonist copd ii longacting beta agonist losmapimod p kinase inhibitor oral copd also cardiovascular disease depression ii entereg peripheral muopioid antagonist post operative ileus approved na amay see note financial statements post balance sheet events gsk annual report shareholder information product development pipeline continued estimated submission dates compound type indication phase maa bla paediatric vaccines mosquirix recombinant malaria prophylaxis ii hibmencytt conjugated neisseria meningitis groups c disease haemophilus iii influenzae type b disease prophylaxis menacwytt conjugated neisseria meningitis groups c w disease prophylaxis iii synflorix conjugated streptococcus pneumoniae diseases prophylaxis infants submitted pojan children kinrix subunit inactivated diphtheria tetanus pertussis poliomyelitis prophylaxis approved ajun booster th dose rotarix live attenuated oral rotavirusinduced gastroenteritis prophylaxis approved afeb aapr vaccines cytomegalovirus recombinant cytomegalovirus infection prophylaxis hiv recombinant hiv infection prophylaxis nthipneumo recombinant streptococcus pneumoniae haemophilus influenzae disease prophylaxis adults pneumoniae adult recombinant conjugated streptococcus pneumoniae disease prophylaxis tuberculosis recombinant tuberculosis prophylaxis ii zoster recombinant herpes zoster prevention ii flu pandemic hn inactivated split monovalent pandemic influenza prophylaxis iii prepandemic quebec new generation flu vaccine inactivated split trivalent seasonal influenza prophylaxis elderly iii simplirix recombinant genital herpes prophylaxis iii boostrix subunit adult booster diphtheria tetanus pertussis approved ajun adec pandemrix flu pandemic hn inactivated split monovalent pandemic influenza prophylaxis approved amay dresden prepandrix hn inactivated split monovalent prepandemic influenza prophylaxis approved amay flu prepandemic dresden cervarix recombinant human papilloma virus infection prophylaxis approved asep aldec antigen specific cancer immunotherapeutic asci wt recombinant treatment acute myelogenous leukaemia magea asci recombinant treatment melanoma iii magea asci recombinant treatment nonsmall cell lung cancer iiigsk annual report shareholder information shareholder information ordinary shares company listed london dividends per ads stock exchange new york stock exchange nyse table sets dividends per ads us dollars form american depositary shares ads details last five years translated us dollars applicable listed debt listed refer note net debt exchange rates share price year us st january high year low year st december increasedecrease dividend calendar table sets middle market closing prices quarter exdividend date record date payment date companys share price increased compares q th february th february th april decrease ftse index year q th april st may th july share price th february q th july st july th october market capitalisation q th november th november th january market capitalisation based shares issue excluding treasury shares glaxosmithkline st december financial reporting calendar billion date gsk fifth largest company publication date market capitalisation ftse index results announcements smithkline beecham plc floating rate unsecured quarter april loan stock quarter july loan stock listed exchange holders may require quarter october smithkline beecham plc redeem loan stock par ie preliminaryquarter january every loan stock held first business day march june annual reportsummary februarymarch september december holders wishing redeem part loan stock complete notice back results announcements loan stock certificate return registrar arrive least results announcements issued london stock exchange days relevant redemption date available news service shortly afterwards issued media made available website sent taxation us securities exchange commission nyse general information concerning uk us tax effects share financial reports ownership set taxation information shareholders gsk publishes annual report shareholder needing dividends full detail report summary document glaxosmithkline pays dividends quarterly continues increase available date publication website summary cash returns shareholders dividend policy dividends sent shareholders shareholders may elect receive remain essential component total shareholder return annual report writing registrars alternatively shareholders gsk committed increasing dividend longterm may elect receive notification email publication details dividends declared amount payment financial reports registering wwwshareviewcouk dates given note financial statements dividends copies previous financial reports available gsks website dividends per share printed copies obtained registrars uk table sets dividends per share last five years gsk response center usa corporate responsibility report year pence late march gsk publish website corporate responsibility report covering performance areas including community investment ethics integrity access medicines rd environment health safety gsk annual report shareholder information shareholder information continued nature trading market annual general meeting following tables set periods indicated high queen elizabeth ii conference centre th may low middle market closing quotations pence shares broad sanctuary westminster london stock exchange high low last reported london swp ee sales prices us dollars ads nyse agm companys principal forum communication pence per share private shareholders addition formal business high low presentation chief executive officer quarter ended st march performance group future development february opportunity questions board chairmen january boards committees take questions matters relating december committees november october investors holding shares nominee service september arrange nominee service appointed corporate quarter ended st december representative proxy respect shareholding order quarter ended th september attend vote meeting quarter ended th june quarter ended st march adr holders wishing attend meeting must obtain proxy quarter ended st december bank new york mellon enable quarter ended th september attend vote business transacted adr holders quarter ended th june may instruct bank new york mellon way quarter ended st march shares represented adr voted year ended st december completing returning voting card provided bank year ended st december accordance instructions given year ended st december documents display memorandum articles association company us dollars per ads documents referred annual report high low available inspection registered office company quarter ended st march february exchange controls limitations january affecting security holders december currently uk laws decrees regulations november restricting import export capital affecting october remittance dividends payments holders september companys shares nonresidents uk quarter ended st december limitations relating nonresidents uk quarter ended th september english law companys memorandum articles quarter ended th june association right holder vote quarter ended st march quarter ended st december respect companys shares quarter ended th september quarter ended th june quarter ended st march year ended st december year ended st december year ended st december th february internet information company including details share price available gsks website wwwgskcom information made available website constitute part annual reportgsk annual report shareholder information shareholder information continued duplicate publications adr programme administrator queries relating receipt duplicate copies gsks adr programme administered publications addressed registrars bny mellon shareowner services po box investor relations pittsburgh pa investor relations may contacted follows wwwbnymelloncomshareowner tel us toll free uk great west road brentford middlesex tw gs tel outside usa tel email shrrelationsbnymelloncom usa administrators also provide global buydirect direct ads one franklin plaza po box philadelphia pa purchasesale dividend reinvestment plan adr holders tel us toll free gsk response center tel outside usa tel us toll free registrar provision details intended companys registrars invitation inducement engage investment activity equiniti advice share dealing obtained stockbroker aspect house spencer road lancing west sussex bn da independent financial adviser wwwshareviewcouk tel inside uk tel outside uk equiniti also provides following services nominee dealing account individual savings account isa glaxosmithkline corporate sponsored nominee shareview service share dealing service dividend reinvestment plan share dealing service shareholders may trade shares either held certificates corporate sponsored nominee internet telephone shareview dealing share dealing service provided equiniti internet deals log wwwshareviewcoukdealing telephone deals call inside uk nominee isa service either wwwshareviewcouk dealing call telephone services available monday friday market trading hours glaxo wellcome smithkline beecham corporate peps share centre limited oxford house oxford road aylesbury bucks hp sz tel gsk annual report shareholder information taxation information shareholders statement based upon uk us tax laws practices us shareholders date report intended general guide following summary certain uk taxation usa federal holders advised consult advisers respect tax income tax considerations may relevant us holder consequences purchase ownership shares shares adr summary applies shareholder adr consequences state local tax laws holds shares adr capital assets citizen resident usa implications current ukus income usa domestic corporation otherwise subject tax convention united states federal income taxation net income basis us holders adr generally treated owners respect shares adr resident uk underlying shares purposes current usauk double uk tax purposes hold shares purposes taxation conventions relating income gains income tax trade profession vocation carried uk convention estate gift taxes estate gift tax convention branch agency purposes us internal revenue code taxation dividends amended code gross amount dividends received without reduction uk shareholders uk withholding tax treated foreign source dividend income us tax purposes eligible dividend received taxation dividends deduction allowed us corporations dividends adr th april rate tax credits reduced one payable us dollars dividends shares payable sterling ninth result compensating reductions rate tax dividends paid pounds sterling included income dividend income increase tax borne uk resident us dollar amount calculated reference exchange rate individual shareholders tax credits however longer repayable day dividends received holder subject certain shareholders tax liability less associated tax credit exceptions shortterm hedged positions individual eligible us holder subject us taxation maximum rate taxation capital gains respect qualified dividends received uk shareholders may liable uk tax gains disposal shareholders advised consult tax advisers shares adr disposals made prior th april confirm eligibility may also entitled indexation relief taper relief sales indexation relief calculated market value shares taxation capital gains st march cost subsequent purchases generally us holders subject uk capital gains tax date purchase indexation relief individual subject us tax capital gains realised sale shareholders ceased th april capital gain taxed disposal shares adr marginal tax rate individual disposals th april estate gift taxes indexation taper relief available capital estate gift tax convention us shareholder gain taxed flat rate rather marginal generally subject uk inheritance tax tax rate individual stamp duty inheritance tax uk stamp duty sdrt subject certain exemptions individual shareholders may liable inheritance tax payable issue transfer shares adr custodian transfer shares adr tax may charged amount depository rate price issued amount value shareholders estate reduced result consideration provided transferred sale value transfer way gift disposal less full transferred consideration market value sdrt would payable transfer adr uk gift disposal subject uk inheritance stamp duty payable transfer adr provided tax us estate gift tax estate gift tax convention instrument transfer executed remains times would generally provide tax paid usa credited outside uk stamp duty transfer adr would tax payable uk payable rate consideration transfer stamp duty sale underlying shares would result liability uk uk stamp duty stamp duty reserve tax sdrt subject stamp duty case may sdrt rate certain exemptions payable purchase shares rate purchase pricegsk annual report glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates combined code guidelines required listing rules financial services authority address principal aspects corporate governance company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties nonequity minority interest preference shares issued subsidiary outside parties preference shares shares issued varying dividend rates treated outside interests profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid shareholders funds shareholders equity share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding excluding treasury shares statement recognised income expense statement comprehensive income subsidiary entity glaxosmithkline holds majority shareholding andor exercises control treasury share treasury stock turnover revenue gsk annual report index performance overview intellectual property accounting principles policies interest rate risk management acquisitions disposals internal control framework adjustments reconciling profit tax operating cash flows inventories annual general meeting investments associates joint ventures annual remuneration investor relations registrar assets held sale key accounting judgements estimates associates joint ventures key performance indicators board legal proceedings business review major restructuring programmes cash cash equivalents movements equity chairman ceo summary nature trading market combined code net debt commitments new accounting requirements committee reports nonexecutive director terms conditions fees competition nonexecutive directors remuneration consolidated balance sheet notes financial statements consolidated cash flow statement operating profit consolidated income statement intangible assets consolidated statement recognised income expense investments consumer healthcare noncurrent assets contingent liabilities noncurrent liabilities corporate executive team operating income corporate governance provisions critical accounting policies outlook dialogue shareholders pensions postemployment benefits directors senior management performance overview directors senior management remuneration pharmaceutical turnover directors interests post balance sheet events directors interests contracts presentation financial statements directors statement responsibilities principal group companies dividends product development pipeline donations eu political organisations eu products political expenditure property plant equipment earnings per share quarterly trend economy reconciliation net cash flow movement net debt employee costs regulation employee share schemes related party transactions employees remuneration policy environment health safety remuneration report exchange rates report directors executive director terms conditions remuneration research development finance costs responsibility finance income risk factors financial instruments related disclosures segment information financial position resources share capital control financial record share capital share premium account financial review share options financial review share price dividends financial statements glaxosmithkline plc prepared shareholder information uk gaap strategy financial trends ratios taxation five year record taxation information shareholders foreign exchange management total equity global manufacturing supply trade payables glossary terms trade receivables goodwill trademarks governance policy treasury operations improving access medicines us law regulation incentive plans world economy independent auditors report world market responsibility want work way reflects values head office registered office expectations stakeholders ethical glaxosmithkline plc great west road social environmental considerations integral brentford middlesex tw gs business decision making also central united kingdom achieving challenging inspiring mission tel improving lives people worldwide registered number find approach corporate printed uk paper used responsibility production document made post consumer waste wwwgskcomresponsibility pulp bleached using totally chlorine free process